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ABSTRACT
DEVELOPMENT OF IMPROVED ACELLULAR PERTUSSIS VACCINES THROUGH
INCLUSION OF THE RTX ANTIGEN OR INDUCTION OF MUCOSAL IMMUNITY
Dylan T. Boehm
Pertussis is a human respiratory disease, primarily caused by the Gram-negative
pathogen Bordetella pertussis. The infection is most severe and can be life-threatening
in young children and infants where it manifests as a series of paroxysmal coughs. The
disease is more commonly known as whooping cough, due to the whoop omitted during
a massive inspiratory effort to bring air back into the lungs. Pertussis is a toxin-mediated
disease that persists due to an early release of toxins that allow that bacteria to evade
the cells of the innate immune response. The inhibition of the host response continues
as toxin activity disrupts the signaling generating an adaptive immune response.
Fortunately, two generations of vaccines have been developed to combat the spread of
the highly contagious disease. The whole-cell pertussis (wP) vaccine was implemented
in the 1950s and was successful in controlling cases. However, due to adverse side
effects associated with the immunization, wP vaccines were replaced with acellular
protein (aP) vaccines absorbed to an alum adjuvant. The second generation aP
vaccines induced an immune response capable of neutralizing key virulence factors
contained in the vaccine, thereby controlling the symptoms of the disease.
Unfortunately, there has been a re-emergence of pertussis incidence in countries using
the aP vaccines. Included in this resurgence is an increased number of adolescents and
adults with unrecognized pertussis, leading to the potential of adult and adolescent
reservoirs of the infection. We reasoned that a pertussis vaccine capable of inducing
sterilizing immunity, rather than controlling the symptoms, would decrease the spread of
pertussis. In this work, we propose two directions towards this goal. The first was
through the neutralization of a key virulence factor not included in any current vaccine
formulations, adenylate cyclase toxin (ACT). This was accomplished through the
optimization of a mouse immunization and challenge model. In initial experiments using
a neutrophil reporter mouse, NeCre luc, we visualized the spatiotemporal localization of
neutrophils after B. pertussis challenge in wP or aP immunized mice with a vaccine
dose known to be protective. In these experiments wP immunized mice elicited an
exaggerated immune response, that persisted after clearance of the pathogen, raising
concerns to the relevance of the high vaccine dose in characterizing the immune
response. In subsequent experiments, we addressed these concerns, by titrating the
concentration of a Diphtheria-Tetanus-acellular Pertussis (DTaP) subunit vaccine to a
dose that did not induce a protective response in a murine model. In defining a suboptimal protective dose for mice, the additive effects of potential antigens could be
evaluated, that were previously masked by the higher concentrations of vaccine. This
model was confirmed through the addition of an ACT toxoid, RTX. The inclusion of RTX
into a DTaP vaccine produced an antibody response that neutralized the toxin in vitro,
and upon challenge with B. pertussis reduced the bacterial burden compared to mice
only receiving the DTaP vaccine. We continued in the direction of promoting a vaccine-

induced immune response capable of clearing B. pertussis from the respiratory tract in
future experiments. We hypothesized that early neutralization of the bacterial toxins
through the generation of a mucosal immune response in the respiratory tract would
increase the clearance of the pathogen. This was tested using a mucosal, intranasally
(IN) administered DTaP vaccine. Administration of DTaP through the IN route induced a
B. pertussis-specific systemic IgG response, and mucosal IgA response, capable of
neutralizing the toxins at the site of infection. Furthermore, IN vaccinated mice reduced
the bacterial burden to the same levels of intraperitoneal immunized mice. The work
completed in this dissertation demonstrates the protective effects of the antigen RTX
when incorporated into a current DTaP vaccine. We then altered the route of
administration to an intranasal delivered vaccine, demonstrating the effectiveness of
inducing a local mucosal response against B. pertussis infection. Together these
findings establish a foundation for potential vaccine strategies to suppress the toxinmediated dysregulation of the host response and lead to the more efficient clearance of
B. pertussis from the respiratory tract.
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Chapter 1 - Introduction
Disease Overview
Pertussis is an exclusively human pathogen that exists in all populations worldwide. In
the pre-vaccine era, the number of cases often exceeded 200,000 annually in the
United States, peaking at more than 250,000 in 1934 1. The infection occurs in three
stages: catarrhal, paroxysmal, and convalescent. In the catarrhal stage, symptoms can
include a mild cough, rhinorrhea and lacrimation; similar to other upper respiratory
infections

2,3.

Over time the cough worsens in frequency and intensity as the disease

reaches the paroxysmal phase, normally ranging from 2-8 weeks 3. The paroxysmal
phase is defined by repeated coughing fits lasting 5-10 coughs per minute, known as a
paroxysm. Following a paroxysm, an individual performs a massive inspiratory effort to
refill the lungs with air resulting in the classic whoop 4. The coughing fits are associated
with production of high amounts of mucus and are commonly followed by post-tussive
emesis5. Additional symptoms can include elevated white blood cells counts
(lymphocytosis or leukocytosis), bronchopneumonia, and hypoxia. In the most severe
cases these symptoms can be fatal and from 2000 - 2016 0.1% of cases resulted in
fatalities, 88.8% of which occurred in infants 6. The transition to the convalescent phase
occurs over several weeks or months and is associated with a reduction in severity of
paroxysms and other symptoms 7.
Pertussis is a highly contagious respiratory disease that is spread through aerosolized
B. pertussis, a dispersal method capable of infecting surrounding individuals8.
Household contact studies have shown that transmission between family members is
common and capable of causing mild or asymptomatic infections in adults. One study
found that 46% of asymptomatic household contacts had antibody titers to B. pertussis
9.

An aerosolized dispersal coupled with an incubation period between 7-10 days leads

to a contagious disease capable of infecting multiple individuals

10.

So much so, that

pertussis still occurs in cyclical epidemics every 2-5 years; as it did in the pre-vaccine
era 6. Pertussis surveillance data shows that in United States cases rose from 1,010 in
1976, to a peak of 48,000 cases in 2012 (Figure 1) 1. The increase of pertussis cases is
also occurring in other countries that have adopted acellular vaccines such as the
1

United Kingdom and Australia

11,

suggesting the cyclical pattern of pertussis epidemics

is unchanged by modern vaccines.

Figure 1: Incidence of clinical B. pertussis cases in the United States from 19222017. Data reported from CDC.
History of B. pertussis vaccination and the increase in B. pertussis incidence
In 1906, Jules Bordet and Octave Gengou were the first scientists to isolate the bacteria
B. pertussis from an individual. Prior to the isolation of the bacteria, a disease with the
same characteristics of Pertussis had been described since the middle ages 12. The first
documented outbreak occurred in Paris during 1578

12.

Until the 1930s there was still a

debate as to whether B. pertussis was the causative agent of Pertussis, due to repeated
failed attempts to culture the bacteria from a coughing patient

13.

Before the 1950s, the

World Health Organization (WHO) estimates that nearly half of all children that came
into contact with B. pertussis would develop symptomatic pertussis

14.

The widespread

implementation of a killed whole-cell pertussis (wP) vaccine drastically reduced the
incidence and mortality of pertussis, to the point that in 1975, it was proposed as a
candidate for eradication

15.

However, beginning in the 1980s, the number of cases

began to increase in countries with high vaccine coverage

14.

Around this time concerns

arose regarding the reactogenicity of wP vaccines. In the late 1970s a landmark study
examined the reactogenicity of whole-cell pertussis vaccine combined with diphtheria
2

and tetanus toxoids (DTP) compared to diphtheria and tetanus toxoids alone (DT)

16.

The authors determined a correlation with redness, pain, and swelling at the injection
site; as well as fever, and persistent crying when compared to DT immunization alone.
In the early years of DTP vaccination there were reports of serious neurologic events
and in some cases death 17. Understandably, this condition of “vaccine encephalopathy”
arose as a major concern against pertussis immunization. As a result of these concerns,
neurologic symptoms following pertussis immunization were extensively studied. Initial
findings suggested that a correlation existed; however, these experiments lacked proper
control groups, and multiple conditions could explain the neurological symptoms. A welldesigned study, the National Childhood Encephalopathy Study, concluded there was no
correlation between encephalopathy and pertussis immunization, and that cases of
vaccine encephalopathy were the first seizures of infantile epilepsy

18.

In the following

years DTP formulations were altered to be safer; however, in some cases, immunization
was not as effective and resulted in some countries stopping DTP immunizations all
together 19. These inconsistencies in wP formulations and public concern pushed for the
development of safer pertussis vaccines composed of acellular proteins with DT toxoids
(DTaP) 5. It is important to note that, wP pertussis vaccines are still widely used today,
especially in low- to middle-income countries; where they are effective at controlling the
number of cases.
The first DTaP vaccines were developed in Japan by Sato and colleagues; which
consisted mainly of filamentous hemagglutinin (FHA), a membrane-bound adhesin of B.
pertussis, with lower amounts of chemically detoxified pertussis toxin (PT), over time
other adhesins were included, fimbriae (Fim) proteins and pertactin (PRN)

20.

As

development of DTaP vaccines continued the amount of PT was increased equal to the
concentration of FHA

21.

This generated a more specific immune response capable of

neutralizing key virulence factors of B. pertussis while reducing fever, and local
inflammatory reactions seen with wP immunizations. At the time, the Sato vaccines
were the needed solution because they demonstrated low toxicity in mice, but were
protective, generating high serum titers to antigens. When DTaP vaccines were moved
to humans they were less reactogenic than wP immunizations, but still induced a robust
antibody response

22.

Evidence from household-contact studies and a decrease in
3

pertussis surveillance further supported the success of these DTaP vaccines, leading
other countries, including the US to pursue DTaP vaccines 23.
A key difference between the development of wP vaccines and DTaP vaccines was the
method used for testing vaccine efficacy. After early inconsistencies in wP preparation,
which resulted in ineffective vaccines, a validation method was developed to confirm lot
validation 5. Pearl Kendrick and others developed the mouse potency test in the mid1940s that enabled the prediction of wP vaccine efficacy

24.

Briefly, this used an

intraperitoneal injection of a test vaccine and a standard vaccine into young mice; then
mice were challenged with 105 of live B. pertussis through intracerebral inoculation 14 to
17 days after the immunization. Vaccine-induced protection was determined by survival
of the mouse. Vaccine potency was assessed as international units, determined by
comparing mouse survival following different lots of wPs compared to survival following
a standard vaccine. The problem was that DTaP vaccine-induced protection could not
be fully validated using Kendrick’s mouse potency test, as DTaP immunizations did not
protect against lethality in the intracerebral challenge

25.

To address this, a modified

Kendrick test was developed to assess vaccine potency of DTaP immunizations 26. This
protocol extended the time between immunization and challenge allowing for the
generation of an antibody response

26,27.

This led to the validity of DTaP vaccines to be

determined from antibody titers against the individual antigens composed in a particular
vaccine. As opposed, to the survival of mice following intracerebral challenge in wP
validation tests. However, evidence now suggests that IgG antibody titers are not a true
correlate of protection against pertussis

28.

As a result, Guiso et al. developed an

intranasal mouse challenge model, where B. pertussis was capable of colonizing the
lung. This protocol led to the validity of DTaP vaccines based on serological titers and
clearance of the pathogen from the lower-respiratory system of mice 25.
In the United States vaccine coverage of DTaP has remained high and as of 2016
93.7% of children aged 19 – 35 months have received ≥3 doses

29.

Nevertheless, a

WHO review concluded that the United States, along with Australia, England, Wales
and Portugal are experiencing a pertussis resurgence based on increased morbidity
and hospitalizations

14.

The increase in incidence of pertussis cases suggests that
4

current DTaP vaccines do not offer complete protection against B. pertussis. Multiple
hypotheses have been proposed explaining the resurgence of incidence of pertussis
including shortcomings of DTaP vaccines, vaccine-driven evolution, and increased
surveillance of pertussis cases.
Waning DTaP Vaccine
Evidence that DTaP vaccine efficacy waned earlier than wP first arose in the early
2000s

30.

The mechanisms of protection between DTaP and wP vaccines will be

explored at length later in this chapter. Presently, human data exists suggesting
differences in the long-term protection from individuals immunized with either wP or
DTaP vaccines, suggesting that wP vaccines offer longer protection

31.

Studies in the

US and Australia examining cohorts of children receiving either wP or DTaP priming
immunizations, followed by DTaP booster immunizations have allowed for the study of
the different responses

31.

A study comparing protection up to 2 years post–booster

immunization found higher IgG titers, memory B-cell numbers, and T-cell cytokine
responses in DTaP primed individuals compared to wP primed children shortly after
booster immunization

32.

At 2 years post-boost DTaP primed children IgG titers

remained higher, but only a Th1 cellular response was observed in wP primed children
32.

Another study used a similar experimental design; however, they examined

protection in wP primed children two years later than they did in DTaP primed children
33.

Their findings suggested that even with an additional 2 years post-boost wP primed

children exhibited a higher cytokine response, and more CD4 and CD8 T cell
proliferation to B. pertussis antigens

33.

A large case-control study in northern California

found that DTaP protection waned unexpectedly fast following the fifth dose of DTaP

34.

A parallel study also, found that after the fifth dose of DTaP the odds of acquiring
pertussis increased on average 42% each year

35.

This trend continued as the same

group compared pertussis rates among adolescents who received the Tdap booster,
which consists of a lower concentration of vaccine antigens with the addition of Fim
antigen. These studies found that Tdap effectiveness dropped from 69% the first year
after vaccination to an alarming 9% after 4 years

36.

Predictably, a study found that

individuals who only received DTaP immunizations compared to those who received the
wP vaccine schedule were at greater risk of contracting pertussis
5

37.

Together these

data clearly demonstrate the waning of protection provided by DTaP vaccines following
a completed vaccine schedule.
Asymptomatic Transmission
Recently, data has emerged suggesting asymptomatic transmission in humans based
on five areas of research

38.

First, it is known that subclinical levels of pertussis exist in

countries such as the United States and the United Kingdom1,14. Secondly, household
contact is a well-documented mode of transmission of pertussis

5,9,23.

However, based

on compiled data from household contact studies a symptomatic individual was only
identified as the source of infection in 42% of cases

11.

Third, the process termed

“cocooning” an infant (vaccinating those that will have early contact with the infant), has
not been found to increase protection among infants

39,40.

Fourth, is the unexpected

high number of cases in infants, given the high vaccination rate in countries such as the
United States

41.

Lastly, is the persistence of the cyclical epidemics of pertussis similar

to the pre-vaccine era 14.
Up to this point, human data suggesting asymptomatic infection is only correlative;
however, in the non-human primate model it has been shown that asymptomatic
transmission following DTaP immunization can occur

42.

Warfel et al., demonstrate that

while convalescent or wP vaccine-induced protection inhibited colonization by B.
pertussis and blocked transmission to an unprotected animal, DTaP immunized
baboons were colonized and transmitted the infection

42.

It is then conceivable to think

that the correlations stated above by Althouse and Scarpino

38

may be occurring in

humans, and asymptomatic infection could be accounting for the resurgence of
pertussis in countries with strictly DTaP immunization schedules.
Vaccine-driven evolution of B. pertussis
B. pertussis is often described as an organism with limited genetic variability, although
recent data has revealed substantial variation in circulating strains across different
countries

43,44.

Weigand et al. find that this variation occurs mostly in genes that encode

for immunogenic proteins, such as ptxA, fimH, genes encoding for PT and FHA,
respectively

45.

Furthermore, these strains quickly spread through the population,

leading researchers to conclude that these mutations may be a result of vaccine-driven
6

selection 44,46. Sealey et al., note the increased mutation rate in antigen-encoding genes
found in various DTaP vaccines, and further mention that the frequency of the mutations
has increased since the widespread incorporation of DTaP vaccines

47.

Perhaps the

most recognized mutation is the rise of PRN deficient stains, which have spread at
alarming rates across the United States and Europe

48,49.

In the United States a 2015

study, found that of 753 clinical isolates, 85% were PRN-deficient, a staggering statistic
when PRN is considered a major immunogen in current vaccine formulations 50.
Increased Surveillance and Diagnosis
As mentioned earlier, cyclical outbreaks of pertussis continue to occur. In the prevaccine era, these outbreaks were associated with high fatalities, and this was common
in low and high-income countries

11,14.

Today, these high fatality outbreaks continue to

occur mainly in low-income countries without established infant immunization programs.
In these countries, positive diagnosis occur from observation of classical pertussis
clinical symptoms 51. However, the resurgence of pertussis cases has been observed in
high-income countries with well-established vaccine programs. In these countries,
cases of pertussis are now diagnosed using quantitative real-time (RT)-PCR using
insertion sequences allowing for the identification of Bordetella species, such as IS481,
IS1001 and IS1002

52.

PCR diagnosis was first implemented for pertussis testing in the

late 1980s and early 1990s and has since become the standard in developed countries
52,53.

It must be considered that the increased sensitivity of pertussis diagnosis is playing

a role in increased pertussis case incidence. When the WHO assessed the reemergence of pertussis they did not support a global increase in pertussis cases due to
the increasing global population and increased diagnosis sensitivity

14.

However, taking

these factors into consideration they did determine a pertussis resurgence in the United
States and other developed countries 14.
Together these proposed hypotheses are supported by evidence that suggests that the
switch to DTaP immunizations is playing a role in the resurgence of pertussis. A
proposed strategy to circumvent for this resurgence of cases is a vaccine capable of
inducing a Th1/Th17 mediated immune response more similar to wP vaccines. The
rationale behind this strategy is that priming with a more pro-inflammatory vaccine will
7

lead to the generation of an immune response more similar to the natural infection of B.
pertussis. The hope being, that this response extends the duration of protection and
leads to clearance of the pathogen from the respiratory tract.
Pathogenesis of B. pertussis
Much of the work performed in understanding the pathogenesis has been performed
using animal models of B. pertussis infection. B. pertussis colonizes the respiratory tract
and much of the work has focused on the establishment of colonization following
inhalation of the bacteria. Aerosolized B. pertussis is transmitted through respiratory
droplets

54.

The bacteria attach to cilia, expressed on respiratory airway epithelial cells,

through bacterial adhesins, such as Fim and FHA 55.
Once in the in the host, a currently unknown natural signal activates the sensor kinase
(BvgS), of the bvgAS locus, a two-component regulatory system responsible for many
of the virulence factors of B. pertussis. The activation of the histidine kinase BvgS and
the phosphorylation of the response regulator BvgA results in the transcriptional
regulation of BvgAS regulated genes, known as the Bvg+ phase

55.

Virulence factors

activated in the Bvg+ phase are known as vags (virulence-activated genes) and include
ptx (PT), cya (adenylate cyclase toxin), bteA, (type III secretion system), fha (FHA), fim2
and fim3 (Fim); and have been classically considered essential for infection

56–59.

After

the establishment of infection B. pertussis produces bacterial toxins that either enter the
bloodstream or effect surrounding cells.
Pertussis toxin
Pertussis toxin (PT) is an AB5 toxin, that is exclusively expressed by B. pertussis. In
earlier stages of the infection, PT plays a role in adherence to ciliated respiratory cells
60.

In later stages, PT inhibits chemotaxis of phagocytic cells to the site of inflammation,

where it is believed to play a critical role in the clinical symptoms of pertussis

61.

PT

binds to glycoproteins on the cell surface of a wide variety of host cells, and the entire
holotoxin is phagocytosed. In the endoplasmic reticulum, the S1 subunit is released into
the cytoplasm, where it catalyzes ADP-ribosylation of Gi proteins, holding them in their
inactive state

62–64.

This results in 1) cytoplasmic increases of cyclic adenosine

monophoshate (cAMP), and 2) a dysregulation of Gi protein-coupled signaling
8

pathways; PT is specifically known to inhibit macrophage and neutrophil recruitment to
the site of infection

65,66.

In early studies by Morse and associates, PT was termed,

leukocytosis-inducing factor (LPF), where they determined LPF was responsible for the
increase in leukocytosis and lymphocytosis following intravenous administration of the
toxin

67.

It was not until the work of Margaret Pittman demonstrated that LPF was an

essential toxin for the pathogenesis of B. pertussis was the toxin referred to as PT 5,68. It
has been shown in numerous studies that neutralization of PT alone results in vaccineinduced protection. Therefore, detoxified toxin is included in all acellular vaccines

60,69–

72.

Figure 2: Pathogenesis of B. pertussis.

1) Aerosolized B. pertussis contained in expelled droplets is inhaled by individual. 2) Infection is initiated
by adherence of bacteria to cilia, present on airway epithelial cells by bacteria adhesins; FHA, PRN, and
Fim. 3) Activation of BvgAS phosphorelay, leads to expression of vags critical for infection, such as PT
and ACT. 4) Secretion of PT and ACT dysregulate the innate immune response. PT suppresses systemic
signaling of Gi protein-coupled signaling pathways utilized by chemokine receptors, resulting in
leukocytosis. ACT acts locally at the site of infection, through catalytic activity of adenylate cyclase
domain and hemolysin activity of RTX domain on APCs. The immunomodulatory activity of PT, ACT along
with other produced by B. pertussis allow for evasion of the innate immune response and persistence of
infection.
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Adenylate cyclase toxin
Adenylate cyclase toxin (ACT, CyaA) is a large 177kDa monomeric protein, that
consists of five regions: 1) N-terminal adenylate cyclase domain (AC), 2) a central
hydrophobic domain, 3) a modification region responsible for acylation of the protein, 4),
a repeat in toxin (RTX) hemolysin binding domain, and 5) a C-terminal secretion signal
61,73–76

. ACT is secreted through a type I secretion system, through a channel formed

by the CyaBDE proteins

77.

Following secretion, ACT is modified by acylation at sites

K860 and K983.
This process is essential for toxin activity and it has been shown that acylation
enhances binding to complement receptor 3 (CR3, αMβ integrin, CD11b/CD18)78. A
recent hypothesis proposes that FHA may play a role in the delivery of ACT by binding
to newly secreted ACT; thereby, retaining the toxin on the surface of bacteria

79.

This

hypothesis is supported by findings that suggest delivery of ACT requires a close
association of live bacteria with target host cells

80.

Additionally, activation of the toxin

also requires calcium, which binds in the RTX motifs of the binding domain, forming
beta rolls

81.

Upon, this activation the RTX region can then bind CR3, leading to the

penetration of host cell membrane by the hydrophobic region of ACT

82.

the translocation of the AC domain into the cytoplasm of the host cell

This allows for
83.

Calmodulin

present in the cytoplasm of the host cell increases the catalytic activity of ACT, which
drastically increases cellular cAMP to supraphysiological levels

84.

The increases in

cAMP caused by AC activity of ACT has been shown to inhibit activation of antigenpresenting cells (APCs), as well as induce apoptosis

84–86.

Thus, ACT, along with PT

has significant immunomodulatory properties, leading to the classification of these two
toxins as the two most important virulence factors of B. pertussis pathogenesis

61.

Despite the immunomodulatory properties of ACT, it has yet to be included in newer
generation pertussis vaccines. Limited studies have evaluated ACT as a potential
antigen. Guiso et al. demonstrated purified ACT was protective in a murine intranasal
challenge against B. pertussis

87.

Furthermore, the same group demonstrated anti-ACT

antibodies were capable of neutralizing ACT and inhibiting ACT activity on neutrophils
88.

These studies yielded encouraging results; however, after the widespread
10

incorporation of DTaP into vaccine schedules progress on Pertussis vaccine research
had slowed. Yet, ACT remains a strong antigen candidate for future pertussis vaccine
development.
Adhesin factors of B. pertussis
FHA is a large, 232-kDa adhesin produced by all Bordetella spp. Studies suggest that
the protein has multiple binding sites, which facilitate binding of B. pertussis to
monocytes, macrophages, ciliated respiratory cells, and nonciliated epithelial cells

89–91.

FHA has been shown to be a strong immunogen and serum antibodies to FHA have
been found in patients following natural infection and after immunization

92.

Due to the

protein’s immunogenicity and role in attachment, it is considered a major virulence
factor and included in most DTaP vaccines.
Another group of antigens included in current 5-component DTaP formulations is the
Fim proteins. Fim proteins are filamentous, polymeric cell surface proteins, that bind
host cells. They are also expressed during the Bvg+ growth phase, and like other vags
have been shown to play a critical role in B. pertussis pathogenesis and adhesion to
host cells

93.

In vivo studies using Fim-negative strains have demonstrated reduced

growth in the trachea and nasopharynx of mice
vitro

95.

94,

and reduced bacterial adherence in

Two serotypes of fimbriae are most commonly observed in clinical isolates,

Fim2 and Fim3, and are expressed in a serotype-specific manner

96.

It has been

demonstrated that Fim proteins are involved in bacterial agglutination, and included in
current DTaP formulations as agglutinogens 97.
The continued research of B. pertussis pathogenesis has driven antigen selection for
current acellular vaccines. As the field pushes for the development of the next
generation of pertussis vaccines there is evidence that other virulence factors of B.
pertussis have the potential for inclusion into new vaccines.
Immunity to B. pertussis
Pertussis cases are most severe in infants and can even be fatal. However, the majority
of individuals are able to clear the infection. Studies using animal models have
suggested that cells of the innate immune response are able to control the early
infection in naïve animals

98.

The innate immune response generated following
11

challenge with B. pertussis has been shown to consists of antimicrobial peptides,
components of the complement system, and effector cells such as macrophages,
neutrophils, natural killer cells, and dendritic cells

99.

However, complete clearance

requires the development of an adaptive, B. pertussis-specific response. Immune
subversion of the innate immune response and persistence of B. pertussis infection are
capable of delaying the generation of an adaptive immune response, suggesting that
the interface between the innate and adaptive immune responses is crucial to
controlling infection.
In the natural immune response, adherent bacteria colonize the respiratory epithelium.
B. pertussis virulence factors act as pathogen-associated molecular patterns (PAMPS)
such as: lipooligosacharide (LOS), ACT, FHA, PT. These PAMPS bind pattern
recognition receptors present on mucosal epithelial cells, macrophages and dendritic
cells (DCs) leading to a cascade of pro-inflammatory responses

100,101.

Cytokines such

as: interleukin-6 (IL-6), interleukin-1 β (IL-1β), interleukin-12 (IL-12), tumor necrosis
factor alpha (TNF-α) and interleukin-17 (IL-17) have been shown to be produced early
in B. pertussis infection and lead to recruitment of macrophages, neutrophils, DCs, and
natural killer T cells to the respiratory tract 69,98,102–104.
Macrophages are long-lived phagocytic cells capable of residing in the tissue. Thus,
they are one of the first cell types that play a role in recognition of B. pertussis. In animal
studies it has been shown that upon challenge with B. pertussis a large percentage of
the bacteria are cleared early in infection, suggesting that macrophages have a role in
clearance of the pathogen

65,105.

Studies in the mouse model have highlighted the role

of macrophages in early B. pertussis infection, by showing that depletion of airway
macrophages enhanced the infection

65.

It was previously mentioned that macrophages

are susceptible to toxins, PT and ACT. There is evidence that some B. pertussis
survives phagocytosis and can persist in macrophages. This suggests that
dysregulation caused by bacterial toxins could lead to an intracellular niche and
persistent infection

106–108.

Thus, there is potential that neutralization of both toxins

would be a beneficial property of future pertussis vaccines.
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Neutrophils have been shown to have an interesting role in the clearance of B.
pertussis. In the mouse model following natural infection by the bacteria, neutrophils
were shown to not play an essential role in bacterial clearance

109.

However, when

bacteria are opsonized, neutrophils do play a significant role in bacterial clearance

109.

Furthermore, the formation of neutrophil extracellular traps (NETs) has been observed
following infection with B. pertussis

110.

Like macrophages, neutrophils as well are

affected by B. pertussis toxins through inhibition of chemotaxis, phagocytosis, NET
formation from ADP-ribosylation and cAMP accumulation

111.

The role of neutrophils in

pertussis has not been fully explored and provides an interesting avenue for future
research.
Adaptive immune response
The generation of an adaptive immune response is necessary for complete protection
against B. pertussis. DCs from the infected respiratory tract migrate to lymph nodes to
present antigen to naïve T cells. The lungs of naïve adult mice do not contain high
numbers of T cells; however, following infection of B. pertussis T cells are recruited to
the lung which correlates with bacterial clearance from the tissue

101.

A critical role of

CD4+ T cells in pertussis immunity was shown using athymic nu/nu mice, as challenge
resulted in persistent infection or death

112.

Adoptive transfer of convalescent splenic T

cells into these athymic mice cleared the infection. Conversely, similar experiments
using transfer of B. pertussis-specific CD8+ T cells to sublethally irradiated BALB/c mice
did not result in clearance of infection, suggesting cellular responses mediated by CD4+
T cells play an important role in immunity to B. pertussis

112.

In particular, CD4+ T cells

from infected mice produce IFN-γ and IL-17, and not Th2 associated cytokines

113.

Furthermore, IFN-γ -/- mice have a significantly reduced ability to clear the pathogen, and
lethal disseminating B. pertussis infections have also been observed

113,114.

Studies

using IL-17A -/- mice, also reached similar findings, determining greater bacterial burden,
and decreased neutrophil concentrations in the lungs of infected knockout mice
compared to WT mice

115.

Data from baboons infected with B. pertussis correlate with

data from mouse model as both models generate Th1 and Th17 immune responses
following infection and colonization of B. pertussis 116. Taken together, data from mouse
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and baboon models demonstrate that the natural infection of B. pertussis is cleared
through the induction of a mixed Th1 and Th17 immune response116.
Mucosal immune response
B. pertussis is strictly a pathogen of the respiratory system. In humans all but the most
severe cases occur in the upper respiratory tract 5. In the mouse model, B. pertussis
infection also remains in the respiratory tract and only in immunocompromised models
or neonatal mice has dissemination into other organs been documented

114,117.

Yet

today, all commercially available pertussis vaccines are given parenterally and have not
been observed to induce local immune responses in the respiratory system. Therefore,
it seems that this under-explored avenue of immunity could play an important role
against B. pertussis. Findings from the non-human primate pertussis model have
strengthened this possibility. As mentioned early, Warfel et al., demonstrate DTaP
immunization in baboons did not inhibit transmission of B. pertussis to another animal
118.

While wP immunization inhibited transmission, B. pertussis colonization persisted

for more than 19 days. Only in baboons that had been previously challenged with B.
pertussis and convalescent at the time of challenge, was colonization inhibited. In
another study by the same group, a strong IL-17 response was measured in
nasopharyngeal wash fluid following B. pertussis infection

116.

Upon, re-challenge of

convalescent baboons Th-17 associated cytokines were increased early in infection.
The strength of the baboon work comes from relevance to B. pertussis pathogenesis in
humans. However, non-human primate models are unobtainable for most researchers.
Mice share similar T cell responses to humans and through the mouse model protection
from the mucosal immune response can be currently addressed.
Immunoglobulin A in the respiratory tract
The induction of a mucosal immune response is associated with production of IgA
antibody. In the mucosal surfaces IgA is the predominate isotype, where it exists in the
dimeric form as secretory IgA (SIgA). Mucosal IgAs are known to block adhesion of
bacteria and neutralize toxins, and serum IgA can facilitate receptor-mediated
phagocytosis in other bacterial respiratory infections

119.

In a study using IgA-/- mice, it

was shown that upon challenge with B. pertussis infected mice did not exhibit a
14

statistically different bacterial burden compared to WT

120.

More so, upon secondary

challenge there was still no difference, suggesting that IgA did not play a critical role in
protection in a natural infection or a primed response. Interestingly, IgA antibodies did
appear to play a significant role in protection against, the closely related, Bordetella
bronchiseptica clearance in the upper-respiratory tract; however, not in the lowerrespiratory tract

120.

The authors do state that this finding may be due to B. pertussis

infecting human hosts, while B. bronchiseptica effects mainly other mammals. However,
recent data has determined contradicting findings

121.

SIgA antibodies are transported

across the mucosa through the polymeric Ig receptor. Using a mouse model deficient in
this receptor, the specific role of SIgA in the respiratory tract was determined in the
aforementioned study. Solans et. al. found that following intranasal administration of a
live-attenuated B. pertussis vaccine, BPZE1, that in SIgA-deficient mice protection was
strongly diminished compared to WT mice

121.

Additionally, the authors demonstrate

that IL-17 plays a critical role in the production of nasal SIgA following BPZE1
immunization, as IL17-/- mice produced only background levels of the antibody.
Furthermore, in these mice the vaccine did not inhibit colonization. In human data,
infection has been shown to be correlated with B. pertussis-specific IgA in the nasal
secretions of infected patients 122. It was found that these antibodies were detected at 23 weeks after infection, but the response is reduced to low levels around 6 months. A
possible protective role of human IgA was shown in vitro where anti-B. pertussis IgA
antibodies from serum and nasal washes of convalescent individuals were shown to
inhibit adherence of B. pertussis to human respiratory cells 123.
Local cellular mucosal immune response
In the pathogenesis of B. pertussis, the first cells to encounter the pathogen are those of
the lung-resident innate immune cells. The process of antigen-presentation via
macrophages and DCs to naïve T cells in the draining lymph nodes is well understood,
as described earlier. The role of Th1 and Th17 immune responses to B. pertussis are
also well described though, most of this data comes from peripheral T cells

114,115,124.

It

has been shown that T cells from the lung and those from the spleen respond differently
to bacterial antigens, and suggests a compartmentalization between T cells of periphery
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and those of the lung 125. More recently, it has been shown that lung CD4+ specific to B.
pertussis do still secrete IFN-γ and/or IL-17 112,126.
The group of Kingston Mills has identified a portion of the CD4+ T cells secreting IFN-γ
and IL-17 are from a population known as tissue-resident memory T cells (TRM)

127.

These cells exhibit classical memory T cell effector markers, CD44+ and CD62L-, along
with expression of surface markers associated with tissue retention CD69+ and/or
CD103+

127,128.

An innovative method was used to confirm that these TRM cells are

indeed not circulating and retained in tissue. An anti-CD45 labeled-antibody was
administered intravenously prior to euthanasia, thus labeling cells that were circulating
as CD45+, while cells retained in the tissue would not be labeled. Then using another
anti-CD45 labeled-antibody with a different fluorophore, cells were labeled in single-cell
suspension along with other markers, TRM cells that were negative for the first anti-CD45
antibody, and positive for the second were classified as cells that were resident in the
tissue

127.

In the study described above, these TRM cells provide a protective role

following the secondary infection of a mouse previously infected with B. pertussis.
Additionally, these studies were repeated and found that these cells persisted in the
lung tissue for several months following the initial infection, and then expanded after rechallenge. The finding that these mucosal resident TRM are capable of secreting IL-17
and IFN-γ, suggest that this population may play a critical role in recruitment of
phagocytes during the secondary immune response. More evidence suggesting a
critical role was shown when migration of CD4+ T cells was chemically inhibited during
secondary challenge with B. pertussis, and the infection was still cleared due to the
presence of TRMs in the lung, this was also shown using adoptive transfer with similar
findings

127.

The findings described in this section provide strong evidence that the

generation of a local mucosal immune response plays a role in the clearance of B.
pertussis following previous challenge. However, the generation of a mucosal immune
response has not been observed following parenteral immunization with DTaP vaccines
129.
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Pertussis vaccine-mediated immunity
It is clear that widespread use of wP vaccines was effective. By the 1970s the average
yearly rate of pertussis cases in the United States dropped to <1 per 100,000
population, compared to 157 cases per 100,000 population in the 1950s130. These
vaccines, still used today, are composed of killed whole B. pertussis organisms. As, a
result the vaccines consist of numerous potential antigens and adjuvants, creating a
highly immunogenic vaccine. However, this creates a degree of reactogenicity, mostly
attributed to the presence of LOS

131.

It has been discussed that the adverse effects of

wPs caused the switch in vaccine schedules to DTaP vaccines, and that following the
change pertussis cases are re-emerging. Following the resurgence of pertussis, work
has focused on understanding the differences in the vaccine-induced immune response
following DTaP or wP immunization. While, it is known that DTaP-induced protection
wanes significantly each year, initially strong IgG serum titers are observed

132.

A recent

study demonstrated DTaP-induced IgG levels remain higher than individuals immunized
by wP until 6 years of age; however, wP protection persists longer

133.

Data

characterizing the T cell responses in children following DTaP or wP priming suggests
greater differences between the immunizations. Children receiving DTaP demonstrated
Th2 responses, while children receiving wP preferentially induce Th1 cells

134,135.

Interestingly, current data suggests that the T cell responses induced by initial vaccine
priming are imprinted. Data from human patients suggests that Tdap booster
immunizations do not alter the T cell responses or IgG antibody subtypes induced by
wP, as these patients still produce the response elicited by the wP vaccine 133,136.
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Table 1: Immune response to B. pertussis following previous infection or vaccination.

Summary of current literature in mice, baboons, and humans. Figure adapted from Wilk et al.11, Kapil
and Merkel 102, and Brummelman et al. 101.

The vaccine-induced responses following challenge with B. pertussis have been well
characterized in mouse models. The response to B. pertussis in a wP immunized
mouse mirrors the response to natural infection. A strong pro-inflammatory response is
elicited in response to infection, resulting in enhanced bactericidal activity of
macrophages and neutrophils

102,124,137.

In mice, the IgG profile following wP

immunization is made up primarily of IgG2a/c, as well as IgA, and IgG1 antibodies,
suggesting a Th1 response, whereas the IgG antibody isotype IgG2a/c (depending on
18

mouse strain)

105,115.

This pro-inflammatory response has been shown to be dependent

upon IFN-γ, as is natural infection, wP-primed IFN-γ-/- mice could not clear a challenge
with B. pertussis

115,138.

Similarly, IL-17 has been shown to be induced following wP-

induced protection, and clearance of B. pertussis was delayed in IL-17-/- compared to
WT mice, although mice did clear the infection eventually 115. Recent work by Wilk et al.
has demonstrated a novel finding suggesting that clearance of B. pertussis from the
nasal cavity is dependent upon IL-17, as the TRM population was not detected in IL-17-/mice, nor could they clear the infection in the nasal cavity

129.

Interestingly, the TRM

population and more so bacterial clearance in the nasal cavity only occurred following
natural infection with B. pertussis or with intraperitoneal wP immunized mice. Clearance
from the nasal cavity and the TRM population were not found following challenge of
DTaP or Tdap primed mice.
DTaP on the other hand consists of high doses of 3-5 B. pertussis antigens mainly: PT,
PRN, FHA, Fim2 and Fim3. Thus, DTaP immunizations induce a more specific
response that is capable of neutralizing the symptoms of the disease; however, it does
not inhibit colonization or transmission

118.

In mice, DTaP induces a predominantly IgG1

driven humoral immune response. It is known that in mice DTaP induces a Th2
response, but also a Th17 mediated response. This was further shown through the
finding that DTaP immunized IL-4-/- mice were fully protected from infection, and the
protection was mediated through IL-17. The Th17 response is known to be induced by
aluminum used as an adjuvant. The induction of a Th17 response has not been shown
to occur in humans or non-human primates and is specific to mice

101,115,118.

Although a

Th17 immune response is observed in DTaP immunized mice, it is not sufficient to
induce the TRM population that was induced with wP immunization, which may play a
role in the duration of memory between the vaccine-induced responses. It is clear that
DTaP-vaccine induced immunity has various shortcomings including narrow specificity,
different Th-cell subtype response, and different memory T cell populations.
The goal of this body of work was to better understand and improve upon the current
DTaP vaccine-induced immune response. The development of DTaP vaccines occurred
at a time when an answer to the reactogenic wP vaccines was desperately needed.
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Thus, the development process occurred quickly, the duration and type of immune
response elicited were not designed to be tested in the safety and efficacy trials. We
aimed to characterize the DTaP vaccine-induced response through a mouse model
capable of addressing vaccine efficacy beyond production of B. pertussis-specific IgG
antibodies. In chapter 2, we characterize the neutrophil response to B. pertussis
following immunization and challenge. Using, a neutrophil reporter mouse line, NeCre
luc we observed the drastic neutrophil response following challenge of a wP-primed
mouse, compared to DTaP protection and even natural infection. We used RNAseq
analysis to observe transcriptional changes between the vaccinated groups to further
characterize pro-inflammatory response. The work in chapter 3, discusses the titration
of DTaP immunization dose to a relevant immunization dose for murine studies. In this
chapter, we aimed to determine a sub-optimal vaccine dose. Defining this dose would
enable us to determine effects of potential antigens. Furthermore, we implemented an
antigen of a key virulence factor of B. pertussis, ACT. The antigen (RTX) induced a
strong serum IgG response that was capable of neutralizing the toxin in vitro. Inclusion
of the antigen resulted in increased bacterial clearance and a reduction in the proinflammatory response following B. pertussis infection. Data from non-human primates
and mice studies suggest that the lack of clearance of B. pertussis from the upperrespiratory in DTaP protected mice was a shortcoming of the vaccine. In chapter 4, we
address the mucosal immune response by characterizing DTaP vaccine-induced
immunity when the vaccine was administered intranasally. In this work we determined
that intranasal immunization with DTaP can generate a local mucosal immune
response. When the vaccine was administered with a Th17 promoting adjuvant we
detected a local IL-17 response at the site of infection and production of IgA in the
respiratory tract. In chapter 5, the implications of these works in the generation of future
pertussis vaccines are discussed. The current state of pertussis vaccine research is at a
crossroads due to the uncertainty of which vaccine avenue to pursue, this work
establishes a safe, intranasal vaccine with parameters that could be used to establish
protection in mice and non-human primates.
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Abstract
Bordetella pertussis

(B. pertussis) is the causative agent of pertussis (whooping

cough). Since the 1990s, pertussis has re-emerged in the United States despite an
estimated 95% vaccine coverage. Our goal was to characterize neutrophil responses
and gene expression profiles of murine lungs in the context of vaccination and B.
pertussis challenge. We utilized a bioluminescent neutrophil mouse model (NECre luc)
to track neutrophil recruitment. NECre luc mice were immunized with whole cell vaccine
(WCV), acellular vaccine (ACV), or a truncated adenylate cyclase toxoid (RTX) vaccine.
Neutrophil recruitment was measured in live mice across time and corroborated by flow
cytometry and other data. WCV immunized mice showed signs of neutrophilia in
response to B. pertussis challenge. Mice immunized with either ACV or WCV cleared
the challenge infection; however immunization with RTX alone was not protective. RNA
sequencing revealed distinctive gene expression profiles for each immunization group.
We observed an increase in expression of genes associated with responses to
infection, and changes in expression of distinct genes in each vaccine group, providing
a complex view of the immune response to B. pertussis infection in mice. This study
suggests that combination of immunological analysis with transcriptomic profiling can
facilitate discovery of pre-clinical correlates of protection for vaccine development.
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Introduction
Pertussis is a human disease primarily caused by a respiratory infection of the Gramnegative pathogen Bordetella pertussis (B. pertussis). The hallmark of pertussis is a
distinctive whooping cough. What is surprising about pertussis is that the cause of the
cough has never been elucidated, which highlights the fact that there are many underresearched aspects of this disease. Aerosolized B. pertussis bacterium are inhaled and
adhere to airway respiratory epithelial cells through bacterial adhesins such as
filamentous hemagglutinin (FHA), fimbriae and pertactin1. After colonization B. pertussis
express multiple toxins including pertussis toxin (PT) and adenylate cyclase toxin
(ACT). B. pertussis releases PT, which dysregulates the immune response through
ADP-ribosylation of the G-protein α-subunit of cytokine receptors present on a range of
leukocytes2–5 . The secretion of PT has long range effects, ACT is thought to act locally
on host cells by converting ATP into supraphysiological levels of cAMP, further
dysregulating the host immune response6.
In the 1940s, an effective whole cell vaccine (WCV) was developed and as a result,
basic research efforts on B. pertussis decreased. The WCVs were highly reactogenic
and caused prolonged and unusual crying after administration, hyporesponsivness, and
febrile convulsions

7–9.

These issues led to the development of acellular vaccines

(ACV), known today as DTaP/Tdap (hereafter referred to as ACV). The ACVs utilize an
alum adjuvant and induce a Th2 response to several key virulence factors such as PT,
FHA, fimbriae, and pertactin depending on vaccine formulations. Whereas the ACV
induces a Th2 response in human and mice, WCV immunization and B. pertussis
infection promote a Th1/Th17-type response10–14. Since the replacement of the WCV
with the ACVs there has been a remarkable increase in the number of cases in the US,
with the number of reported cases in 2012 equaling that of 1954. Multiple factors
potentially played a role in the return of pertussis in the US. It has been documented
that the Th2 response induced by ACV immunization may be inferior to the Th1/Th17
response directed by the WCV15. Additionally, ACV protection wanes significantly as
early as one year after vaccination, and by 4 years after vaccination vaccine
effectiveness is only 9%16. Furthermore, in a non-human primate model it has been
shown that ACV immunized baboons challenged with B. pertussis are capable of
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carrying the infection and transmitting aerosolized B. pertussis to naïve baboons17.
Additionally, the findings of an epidemiological study suggest that asymptomatic
transmission of pertussis is indeed occurring in the human population, and has a role in
the increase of pertussis incidents18. These recent findings demonstrate the
shortcomings of the ACV. Utilizing new technologies that were not available during the
developments of the WCV or ACVs we can further investigate differences between
WCV and ACV protection. Adenylate cyclase toxin (ACT) is an essential virulence factor
of B. pertussis and a known protective antigen19–21. ACT contains two main domains:
adenylate cyclase and the Repeats-in-Toxin (RTX). In the absence of the AC domain,
the protein is non-toxic and referred to simply as RTX22. In a previous study, sera from
mice immunized with RTX contained antibodies capable of neutralizing ACT. ACT
antigens are not included in any commercial formulations of ACVs and many have
proposed that its inclusion could improve protection6.
Neutrophils play a role in both the innate and adaptive arms of the immune
system. Following B. pertussis infection of a naïve mouse, neutrophils reach peak
recruitment between 5 and 7 days after challenge23,24. This occurs after the bacterial
burden has begun to decrease. Subsequent studies have determined that neutrophil
depletion prior to B. pertussis infection in naïve mice does not increase bacterial
burden. However, when immunized mice are challenged with B. pertussis following
depletion of neutrophils the B. pertussis bacterial burden increase, demonstrating a
protective role of neutrophils in immunized mice25. As previously mentioned, B.
pertussis toxins PT and ACT both affect neutrophils and their recruitment6,26–28. These
toxins contribute to a significant rise in the number of circulating white blood cells and in
severe cases leukocytosis is linked to fatality1. Leukocytosis was first described in
pertussis patients as early as the 1890s29,30. In the 1960’s, Stephen Morse observed
leukocytosis following WCV immunization31, which he hypothesized was caused by PT,
then known as leukocytosis-inducing factor32. Therefore, it can be conceived that the
toxin associated effects on neutrophils would be neutralized following ideal B. pertussis
immunization, and this raises the question of where and when neutrophils are recruited
in an ACV or WCV protected mouse?
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In this study, we utilized in vivo imaging systems (IVIS) to characterize the
neutrophil responses to B. pertussis challenge in mice vaccinated with ACV or WCV.
We implemented NECre luc mice, a luminescent neutrophil reporter mouse strain,
previously used in a Bacillus anthracis infection model to track neutrophil recruitment
following B. pertussis challenge33. To do so, we: 1) validated the NECre luc mouse as a
model for tracking neutrophil recruitment in response to B. pertussis infection, 2) tracked
the spatiotemporal localization of neutrophils in response to B. pertussis challenge in
ACV and WCV vaccinated mice, and 3) and characterized vaccine-associated gene
expression profiles of the infected lungs from each group using RNA sequencing. The
NeCRE luc mouse33 was used to measure the presence and relative quantities of
neutrophils in live mice during B. pertussis challenge. We then corroborated our findings
with flow cytometry analysis to quantify neutrophils in the blood and airway of naïve and
immunized mice. WCV immunization resulted in robust neutrophil recruitment and
clearance of B. pertussis, but also resulted in morbidity of the NeCre luc mice. RNAseq
analysis was performed on the lungs of naïve or immunized mice at both early and late
time-points after challenge with B. pertussis. We observed specific gene signatures for
each vaccine, and we also identified gene expression profiles that had not been
associated with B. pertussis or immunization. Neutrophil specific gene expression
corroborated our cellular analysis of the respiratory tract demonstrating increased
expression of neutrophil specific genes in WCV immunized mice. Furthermore, we
determined the T-helper cell gene expression profiles of lung transcriptomes and
corroborated the activation of Th1 specific gene expression to increased levels of Th1associated cytokine production in the lungs of WCV immunized mice. Utilizing the depth
of data generated through RNAseq, we could classify specific B cell clonotypes present
in the lung of each immunization group. This technique allowed for analysis of the
diversity and frequency of the immunoglobulin repertoire of immunized groups. We
hypothesize that these approaches can continue to be applied to other pathogen to host
interactions

to

characterize

the

underpinnings

immunological responses.
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Results
ACV and WCV immunization of NECre luc mice results in clearance of B.
pertussis, however WCV immunized mice experience increased morbidity and
mortality.
To characterize the effects of vaccination on neutrophil recruitment, NECre luc mice
were immunized with the vaccines as indicated in Supplementary Table S1, and then
boosted with the same vaccine 21 days later by intraperitoneal injection. We then
compared the neutrophil recruitment in naïve, ACV, WCV, and RTX-only vaccinated
NECre luc mice during B. pertussis challenge. At day 35 post initial immunization,
NECre luc mic were challenged with virulent B. pertussis strain UT25 (Fig. 1) by
intranasal instillation. A challenge dose of 2 x 107 CFUs B. pertussis does not typically
cause morbidity in immunocompetent mice such as CD-1 or C57B6/J (data not shown).
We originally planned to euthanize 4 mice per group on each experimental day (1, 2, 4,
and 9). However, 2 of 13 naïve challenged NECre luc mice were euthanized at day 2
due to morbidity (Fig. 2). At day 6, we observed additional unexpectedly morbidity in the
WCV group, which required euthanasia of all remaining WCV immunized NECre luc
mice (Fig. 2). Conversely, no morbidity was observed in the ACV and RTX immunized
mice 9 days post B. pertussis challenge (Fig. 2). We were surprised to observe
morbidity in the WCV immunized mice. Upon determining viable bacterial burden from
lung, trachea, and nasal lavage, we observed clearance of B. pertussis to our limits of
detection in both ACV and WCV immunized mice compared to naïve infection (Fig.
3abc). Taken together, these data suggested that morbidity of the WCV immunized
mice was not fully attributed to bacterial burden. Additionally, we determined that
vaccination with RTX resulted in 100 percent survival out to 9 days post-challenge (pc),
while bacterial burden were similar to naïve infected mice, suggesting that RTX
immunization did not improve bacterial clearance (Fig. 3abc).
Analysis of serological responses of immunized mice.
As expected, the ACV immunized mice were protected against challenge as they rapidly
cleared the B. pertussis challenge dose (Fig. 3abc). WCV immunized mice cleared B.
pertussis, but this response was delayed compared to the ACV mice. To determine the
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efficacy of immunization on antibody production, we performed serology analysis. PT is
a common antigen of both the ACV and WCV and we observed a significantly higher
concentration of anti-PT in the ACV mice compared to the WCV (Fig. 3d). Immunization
of NECre mice with RTX with alum adjuvant resulted in high anti-RTX antibody titers
(Fig. 3e) despite the fact that we did not see increased clearance due to RTX
immunization. In another study, we immunized CD1 mice with RTX and alum adjuvant
and we also saw no clearance of B. pertussis compared to non-vaccinated mice (data
not shown). Our data suggest that, while immunization with RTX induces antibody
production, it is not sufficient to protect mice from B. pertussis infection as a single,
antigen vaccine.
Spatiotemporal IVIS imaging of neutrophils in naïve and vaccinated NECre luc
mice.
Neutrophil accumulation in NECre luc mice were visualized on days 1, 2, 4, 6
and 9 post-challenge. Mice were IP injected with the high sensitivity luciferin CycLuc133
before imaging. A Lumina II IVIS (Xenogen) was used to capture luciferase-driven
neutrophil luminescence at indicated time-points (Fig. 4 and Supplementary Fig. 1).
Luminescent signal of the whole body (Fig. 4d) or nasal cavity (Fig. 4e) of vaccinated
mice was then compared to signal from naïve, non-infected mice and calculated as fold
change. At day 1 post-challenge, we detected significantly higher luminescence in naïve
challenged mice compared to naïve non-challenged mice, suggesting that there is a
higher neutrophil accumulation in challenged mice. Furthermore, whole body
luminescence in WCV immunized and challenged mice was significantly higher than the
whole body luminescence of naïve, ACV and RTX B. pertussis challenged mice at day 1
(Fig. 4d). In general, luminescence signals of all groups decreased across days 2 and 4.
However, in the WCV group at day 6, we detected an increase in signal in the nasal
cavity (71-fold) and the whole body (47-fold) compared to naïve not challenged mice
(Fig. 4de). Due to variability between animals, this increase was not significant
compared to other groups. At this point WCV immunized mice were morbid and
required euthanasia. Taken together this data suggests that WCV immunization prior to
challenge resulted in increased neutrophil accumulation compared to other vaccination
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groups. We next aimed to corroborate our IVIS luminescence data with flow cytometry
analysis of respiratory tissues.
Validation of neutrophil infiltration in respiratory tissue by flow cytometry
Luminescent signal of luciferase-expressing cells correlates with the localization of
neutrophils in NECre luc mice33. To confirm this, we measured the relative number of
neutrophils by performing flow cytometry analysis on respiratory tissue following IVIS
imaging. Single cell suspensions from lung tissue or nasal lavage were labelled with
antibodies recognizing cell surface markers. We defined neutrophils as CD11b+GR-1+
live cells (Supplementary Fig. 2). Similar to the IVIS data, all B. pertussis challenged
groups had significantly higher neutrophil percentages in nasal lavage compared to
naïve non-challenged mice (Fig. 4f). At day 1 post B. pertussis challenge, WCV
immunized mice had a significantly higher percentage of neutrophils than ACV
immunized mice in nasal lavage. The percentages of neutrophils decreased from day 1
to day 2 in all vaccinated groups, as well as the naïve group. At day 4, WCV immunized
mice exhibited higher levels of neutrophils than those observed at day 2 (Fig. 4g).
Correlating with the nasal lavage, WCV mice exhibited significantly higher percentages
of neutrophils in the lungs than ACV mice. Lung neutrophils at day 4 were not
statistically significant between any of the groups. However, by day 6 there was a 53%
increase in lung neutrophils compared to day 4 in the WCV group, which directly
correlates with the increased luminescence signals measured by IVIS imaging (Fig. 4g).
WCV immunized NECre luc mice induce a more robust Th1 immune response
compared to ACV immunized mice.
It has been previously documented that upon B. pertussis challenge, WCV immunized
mice elicit a Th1/Th17 immune response, similar to a naïve infection while ACV
immunized mice generate primarily a Th2 response10–12,34. We hypothesized that similar
responses are triggered by WCV and ACV in the NECre luc model. To test this
hypothesis, we determined the cytokine profiles in lungs of immunized and challenged
mice using electrochemiluminescent sandwich immunoassays. The Th1 response was
determined by increased levels of IFN-γ, IL-12p70, IL-1β and TNF-α (Fig. 5ab), while
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the Th17 response was qualified by increased IL-17A and IL-6 (Fig. 5cde). Th2
responses were associated to increased levels in IL-4 and IL-5.
As expected, we observed an increased Th1 response in the WCV vaccinated NECre
luc mice compared to the ACV group. We also observed an increase in the Th1
response in naive challenged mice compared to non-challenged mice or the ACV group.
Interestingly, the highest levels of IL-17 were observed in WCV NECre luc mice (Fig.
5c). The levels of Th2-associated cytokines, IL-4 and IL5 were similar between the
WCV and ACV groups. (Supplementary Fig. 3). The lung cytokine profile from NECre
luc mice immunized with RTX resembled a profile of naïve B. pertussis challenged mice
with the exception of IL-6, which was lower in the RTX group. Taken together these
data from the NECre luc mouse model corroborates previous findings by displaying a
strong Th1/Th17 response in response to B. pertussis in WCV vaccinated mice.
Characterizing the gene expression profiles of the lungs of immunized and naïve
mice after B. pertussis challenge
Current and past B. pertussis immune response studies have focused on a limited set of
known immunological responses to B. pertussis challenge such as: bacterial burden,
antibody response, recruitment of phagocytes, cytokine profiles, and others

35,36.

Whooping cough is a toxin-mediated disease, due mainly to the activity of pertussis and
adenylate cyclase toxins. These toxins are released and affect a wide array of host
cells4,25. It is therefore conceivable that B. pertussis infection would have a broader
effect on the respiratory tissue beyond the induction of predictable immune response
factors. To address this, we employed RNA sequencing (RNAseq) to observe the effect
of B. pertussis challenge on the lungs of immunized and naïve NECre luc mice at a
transcriptomic level. This allowed us to characterize the transcriptome response to
infection and vaccine-induced responses. We hypothesized that regardless of the
vaccine administered, we would identify a set of genes differentially regulated in all
challenged mice. Additionally, we sought to discern the unique gene expression profiles
in response to challenge in each immunized group.
To perform RNAseq analysis, lungs from NECre luc mice were harvested at an early
time-point (day 1) following B. pertussis challenge and at a late time-point (day 6 or 9).
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RNA from the lungs of the mice was isolated. Libraries were prepared and sequenced
on the Illumina HiSeq 1500 platform. To characterize transcriptional responses to B.
pertussis challenge in naïve or vaccine mice (ACV, WCV, RTX), we compared the
challenged samples to control mice that were not immunized nor challenged. Based on
this, we expected to determine both the immunological (innate and adaptive) and the
non-immunological responses to B. pertussis challenge. We determined the
differentially expressed genes (DEGs) for both early (day 1) and late (day 6 or 9
depending on group) time-points. The total numbers of differentially regulated genes are
shown in Fig. 6ac. Overall, there were more differentially genes at the later time-point
than early after challenge (Fig. 6ac). At day 1 post-challenge, the WCV group had the
most genes activated (Fig. 6a, Supplementary Fig. 5). Of the genes that were
upregulated at day 1 in the WCV, 29.7% were not found upregulated in the other groups
(464 of 1,560). At the late time-points, there were more common upregulated genes and
only 14.1% of the genes were unique to the WCV. We found that 12.6% of unique
upregulated genes (196) were common to all groups either challenged with B. pertussis
following immunization or naïve challenge, suggesting that these genes were common
to infection (Fig. 6b). At the later time-point, 19.8% of unique upregulated genes (867 of
6,595) were shared by the WCV, ACV, RTX groups, while this number was much lower
at the early time point (8.5% of DEGs, 133 of 1,560) (Fig. 6bd). Cumulatively, this data
suggests that: 1) WCV vaccination induces a more diverse early response to B.
pertussis challenge due to the higher number of unique genes compared to other
groups, and 2) at the later time-point all vaccinated groups have a more similar lung
transcriptome.
Ingenuity Pathway Analysis (IPA) was performed to determine enrichment analyses of
gene expression signatures in the context of each immunization. Using IPA Knowledgebased enrichment analysis, statistically significant genes were grouped into disease and
function categories. A system of genes was considered enriched based on Fisher’s
exact test on the ratio of represented genes. At the early time-point we, observed that
the largest changes were associated with genes involved in immune cell trafficking of
the WCV group (Fig 7a). Genes with the highest fold changes within this system were
associated with activation and migration of leukocytes (Fig. 7b). Additionally, we
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observed significant enrichment of genes associated with the humoral and cellmediated immune responses (Fig. 7b). Pertussis toxin affects multiple aspects of the
cardiovascular system such as blood pressure, leukocyte migration, etc7,37,38. In both
naïve and immunized mice, we observed gene expression signatures related to
cardiovascular diseases (Fig. 7ab). ACV immunization results in high amounts of antiPT antibodies (Fig. 4d), and we observed fewer genes significantly altered in the ACV
immunized mice, suggesting positive effects of anti-PT antibodies on neutralization of
toxin activity. At the late time-point, immune cell trafficking gene expression seemed to
decrease in naïve, ACV, and RTX groups; however, the expression of these genes was
still high in the WCV group. As expected, immune-related gene signatures dominated
the responses to B. pertussis infection. However, thousands of genes significantly
dysregulated due to infection at both time-points were not related to immune response
or were not sufficiently characterized to be assigned a function. Analysis of the lung
transcriptomes corroborated the findings of flow cytometry and cytokine profile
analyses, further supporting that there is an increase in leukocyte activity in the
respiratory tissue of WCV immunized mice compared to ACV or RTX immunized mice
following B. pertussis challenge.
Analysis of neutrophil-specific gene signatures
Since we observed that neutrophils accumulate in the lung of WCV immunized NECre
luc mice, we chose to delve further into the changes in expression of genes associated
with neutrophil activity. To compare the neutrophil response between the groups, we
selected genes with GO terms associated with neutrophil migration and activation and
plotted the relative fold changes for this subset of genes for each immunization group
(Fig. 8). The expression levels of these genes from either the naïve challenged, or
immunized and challenged groups was compared to naïve, not infected control mice
(Fig. 8).
Cxcl2 is a chemokine produced by monocytes and neutrophils at sites of infection39.
Previously it has been shown that convalescent mice previously challenged with B.
pertussis express lower amounts of cxcl2 when re-challenged with B. pertussis than
naïve mice40. This suggests that the adaptive responses in these mice negate the need
43

for the innate production of Cxcl2. Supporting this hypothesis, we observed the highest
expression levels of Cxcl2 in naïve and RTX immunized mice, which had similar
bacterial burdens (Fig. 7bd and Fig. 8be). The induction of Cxcl2 expression was lower
in ACV vaccinated mice than naïve mice (Fig. 8ac). The expression of Cxcl2 also
increased in the WCV mice, but remained high at the late time-point (Fig. 8b). Our
serological analysis indicated that WCV immunization only induced minimal anti-PT
production, whereas ACV induced high amounts of anti-PT (Fig. 3d). PT has been
shown to induce production of Cxcl2 in TY10 cerebral endothelial cells which further
suggests a causal relationship between non-neutralized PT and Cxcl2 production41.
All of the groups showed increases in a number of other C-X-C and C-C family
chemokines (cxcl3, cxcl1, ccl3, ccl4, ccl6, and ccl17). Cxcl1 gene expression was
increased at day 1 in all groups compared to the non-infected control (Fig. 8). We also
observed an increase in IL-23 expression in the WCV group (Fig. 7b), which might be
associated with the IL-17 cytokine response measured in the WCV lung tissue. Tumor
necrosis factor (tnf) gene expression was increased in WCV, RTX, and ACV mice
compared to non-infected mice. However, Tnf expression levels decreased in ACV mice
and were lower than those observed in uninfected mice at day 9 (Supplementary Fig.
4). Ross et al. demonstrated that IL-17A promotes production of CXCL1 during B.
pertussis challenge10. In our cytokine analysis, only the WCV mice had sufficient IL-17
to be detected in the lung homogenates (Fig. 5c). Taken together these data suggest
that although we did not observe high IL-17A gene expression in the transcriptome or in
the IL-17 cytokine analysis, there could still be sufficient IL-17A in the Naïve, ACV, and
RTX challenged mice that could account for the increased Cxcl1 gene expression.
We observed that S100a9 and S100a8 were highly upregulated in WCV and RTX
groups (Fig. 7 and Fig. 8b). S100a9 is a major calcium-binding protein of neutrophils,
which forms a heterodimer with S100a8, and promotes polymerization of microtubules.
Interestingly, S100a8/a9 is produced mainly by neutrophils and high plasma levels of
S100a8/a9 correlate with higher blood neutrophil blood levels in heathy human adults42.
S100a8/a9 promotes transendothial phagocyte migration by promoting tubulin
polymerization43. Additionally, monocytes isolated from human patients with cardiac
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injury have been found to be particularly responsive to S100a8/a9 and secrete
increased amounts of TNF-α and IL-644. S100a8/a9 can induce neutrophil chemotaxis
and adherence, but PT can block this function of S100a8/a945. These data suggest that
PT induction of leukocytosis may be related to the role of S100a8/a9 in leukocyte
recruitment. S100a8/a9 expression was lowest in the ACV mice which had the highest
amount of serum anti-PT.
Overall the WCV mice had higher expression of more neutrophil genes than any of the
other groups (Fig. 7). Expression of these neutrophil signatures did not return to
uninfected levels. These observations corroborates IVIS (Fig. 4de) and flow cytometry
analyses (Fig. 4fg). Neutrophil gene expression in ACV mice was dynamic and returned
to levels lower than uninfected mice by day 9. ACV mice did not have detectable B.
pertussis in their lungs at day 9, indicating that the initial challenge does had been
cleared (Fig. 3). ACV and WCV signatures were the most dissimilar, while the RTX and
naïve mice transcriptome profiles were the most similar (Fig. 7). This correlates with the
fact that RTX mice still have detectable B. pertussis in their nares, trachea and lungs at
day 9 at levels similar to those observed in non-vaccinated mice. These data confirm
our neutrophil observations but also enhance our analysis of the neutrophil dynamic in
the context of vaccination status and B. pertussis challenge.
B cell gene expression signatures in relation to immunization status.
It has been established that B cells are required for the clearance of B. pertussis in mice
and that ACV immunization protects through neutralizing antibodies46,47. To further
investigate antibody production between WCV and ACV immunized mice, we aimed to
determine the diversity of B cell clone expansion between vaccinated and nonvaccinated challenged mice. Using MiXCR software, the same illumina sequenced
reads mentioned above were analyzed specifically for immunoglobulin profiling48.
Individual B cell clones were identified by B cell receptor sequence and clonal
expansion was accessed by immunoglobulin diversity and frequency between the
vaccinated and challenged, naïve challenged, and non-challenged control groups. At
the early time-point day 1 post-challenge, immunoglobulin diversity and frequency of B
cells depicted a close relation between the ACV and RTX vaccination groups, as also
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did WCV and naïve challenged mice (Supplementary Fig. 6a). This response shifted by
the late time-point (days 6 or 9), when we observed that WCV and ACV groups were
more similar. Using this approach, we were able to determine the individual variable and
joining segments abundance, and the frequency of which a particular was found. Not
surprisingly, we observed the highest degree of diversity at the late time-point. WCV
and ACV were the most similar due to a higher number and abundance of clonotypes
(Supplementary Fig. 6b). We focused our analysis on the diversity of the third
complementarity-determining region (CDR3) of the heavy Ig chain, because this region
has been shown to be necessary for antigen specificity49. The highest abundant CDR3
region sequence, NQHLFW, was present only in the WCV immunized mice, while the
other 10 highest CDR3 regions were shared across vaccine groups at the early and late
time-points (Supplementary Table 6 and Supplementary Table 7). Together this data
suggests that clones generated from acellular based vaccines (ACT and RTX) are more
closely related because they are generated to a limited number of antigens. However,
by the late time-point, proliferation of specific B cell clones generated from WCV has
created the same diversity seen in the ACV clones. The B cell clonotype analysis
suggests that we can aim to further understand these populations in the future, but we
will need to increase our sequencing depth by directly isolating the cell populations from
the immunized mice instead of analyzing the full lung tissue. It may also be interesting
to probe the T cell receptor clonotypes using the same method.
Discussion
In this study, we compared the innate and adaptive immune responses of immunized
NECre luc mice vaccinated with ACV or WCV vaccines, to mice immunized with a
truncated ACT toxin absorbed to alum (RTX), or non-vaccinated naïve mice following
challenge with B. pertussis. ACV and WCV immunized mice cleared B. pertussis
challenge but distinctive immune responses were observed. We also determined that
the RTX antigen alone was not protective as a single antigen vaccine with alum
adjuvant in NeCre luc mice. We utilized IVIS imaging to track the recruitment of
neutrophils to the respiratory tract of challenged mice from days 1 to 9 post-challenge.
The data obtained illustrated a dramatic increase in the amount of neutrophils recruited
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to the lungs and nasal cavity of WCV immunized mice compared to ACV immunized
mice when followed by B. pertussis challenge. These data were also supported by flow
cytometry and cytokine analysis. Furthermore, by performing RNA sequencing on the
lung transcriptome during infection in vaccinated or naïve mice, we described unique
gene expression profiles depending on the vaccination status of the mice. We also used
RNA sequencing to begin to describe the immunoglobulin diversity induced by each
vaccine.
Upon initial B. pertussis challenge, we observed activation of neutrophil associated
genes in all groups, however it was only in the WCV immunized mice that we saw
increased neutrophil genes expression still elevated at the late time-point. Neutrophilia
and elevated neutrophil related genes expression at the late time-point, when bacterial
numbers in the airways are greatly reduced, indicates either over activation of neutrophil
“chemokine storm,” or possibly a lack of neutralization of bacterial toxins. Multiple
studies suggest that PT is responsible for neutrophilia and leukocytosis following B.
pertussis infection13,32,50,51. Immunization with the ACV induced 1,146-fold more anti-PT
antibody production than WCV immunization at day 2 (Fig. 3d). It is possible that the
low levels of anti-PT production in WCV mice resulted in insufficient neutralization of
PT, resulting in exacerbated neutrophilia. Surprisingly, the highest neutrophil
accumulation was determined at day 6 post-challenge when bacterial levels were
similar to those of ACV protected mice (Fig. 3). These findings suggest that while WCV
immunization is protective at clearing infection in NECre luc mice, it also induced severe
neutrophilia. Interestingly, the neutrophil response in WCV mice decreased at days 2
and 4 but highly increased at day 6 (Fig. 4). At day 2, we observed a significant
increase in IL-17 in the lungs of WCV mice (Fig. 5c) that could result from the increased
IL-17 expression in these mice. Stephen Morse observed dose-dependent leukocytosis
in mice following vaccination with killed B. pertussis31. In this study, NECre luc mice
were immunized with 1/5th the human dose of WCV. We now realize that this dose is
likely well above the proportional weight of a mouse compared to a human. It is possible
that this high vaccine dose induced the hyper leukocytosis, similar to the dosedependent increase that Morse observed. It is known that hyperleukocytosis is
associated with death in infant cases, and that PT is responsible for inducing
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leukocytosis1,7,52. Furthermore, mice and baboons infected with B. pertussis and then
treated with anti-PT antibodies had lower levels of leukocytosis compared to noninfected controls50. An epidemiological study found that in unvaccinated individuals with
pertussis, 72% of patients experienced leukocytosis53. In this study, we observed that
WCV immunized NECre luc mice experienced neutrophilia and morbidity, which
highlights the potential issues of using WCVs. It would be interesting to determine the
relationship of neutrophilia and WCV immunization in epidemiological past studies but
we have not been successful in identifying a study that specifically looked at
neutrophilia because studies most note general leukocytosis.
In NECre luc mice, the ACV was clearly more protective and less detrimental to the
mice than the WCV. Truncated and full-length ACT purified from B. pertussis culture
has been shown to be a protective antigen21. Wang et al. described the RTX region of
ACT as highly immunogenic and easily purified as a recombinant protein22. We have
observed that immunization of CD1 mice with RTX and alum adjuvant results in high
anti-RTX titers (data not shown). Here, we immunized NECreluc mice with RTX and
alum, but no protection was observed (Fig. 3abc). The previous studies were performed
with strain 18323 and the antigen was directly isolated from B. pertussis21,54. It is now
known that strain 18323, is an outlier compared to most other global B. pertussis strains
and Guiso et a21l. noted that strain 18323 produces less PT than the Tohama I type
strain. From our work, we know that UT25 produces more PT and ACT than Tohama I
(data not shown). It is possible that due to the increased PT levels produced by UT25,
vaccination with RTX was not sufficient to block colonization and proliferation in vivo.
Although RTX immunization did not result in clearance of B. pertussis from NECre luc
mice, we did observe a reduction in the pro-inflammatory cytokine IL-6 in the RTX group
compared to not vaccinated and WCV vaccinated and challenged mice (Fig. 5e). PT
and ACT have both been shown to induce the production of IL-6 in human cell lines55,56.
The anti-ACT antibodies generated by RTX vaccination may play a role in reducing the
levels of IL-6 due to reducing the activity of ACT. We hypothesize that it is necessary to
neutralize both PT and ACT to provide optimal protection and in future studies, we will
test RTX as an antigen in a multivalent ACV containing PT antigen.
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Using standard immunological analyses, we observed typical Th2 and Th1/17
responses in ACV and WCV immunized mice respectively. B. pertussis utilizes PT and
ACT to facilitate survival in the host and most studies about the PT/ACT specific effects
have been perform on cell cultures in vitro. Microarray analysis has been used to profile
the lung transcriptome of mice challenged with B. pertussis40,57. Here, we sought to use
RNAseq to investigate the overall gene expression profiles of the murine lung in
response to B. pertussis challenge. Analysis of the lung transcriptome 1 day after B.
pertussis challenged exhibited a distinct profile in mice vaccinated with WCV compared
to ACV, RTX, or naïve infected mice. This response was consistent with our WCV
cytokine

profile

demonstrating a

strong pro-inflammatory response.

Similarly,

transcriptome data from others during early B. pertussis infection noted an increase in
chemokines such as Cxcl2, Cxcl10, Cxcl3, Ccl3, Cxcl1, and Ccl457,58. In Raeven et al,
convalescent mice previously infected with B. pertussis exhibited higher expression of
these chemokines compared to naïve mice, similar to our whole cell transcriptome
where these chemokines are consistently higher than the naïve mice (Fig. 7 and Fig. 8).
We observed the highest expression of these chemokines in the naïve and RTX mice
groups, where these groups had a similar gene profile of genes belonging to the
immune cell trafficking and cardiovascular disease annotations (Fig. 7). These findings,
along with higher bacterial burden (Fig. 3) suggest that RTX-alum immunization does
not provide sufficient protection.
Our overall transcriptomic profiling revealed thousands of significant gene expression
changes (Fig. 6). After analyzing the neutrophil (Fig. 8), and innate gene changes
(Supplementary Fig. 4), we then sought to specifically characterize B cell clone
diversity. The RNAseq reads were re-processed with the MiXCR algorithm and we
analyzed the abundance and diversity of VDJ clonotypes (Supplementary Fig 5).
Besides the T cell response differences of the ACV and WCV (Th2 v. Th1/Th17)
another significant difference between these two vaccines is the number of antigens.
ACVs have 3-5 antigens (PT, FHA, PRN, FIM2/3) but the WCV hypothetically has
~3,000 antigens. In light of this, it would be logical to hypothesize that the WCV would
induce a vast antibody repertoire as measured by many VDJ clonotypes. However, we
observed a greater diversity and abundance in the ACV group compared to the WCV at
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both early and late time-points (Supplementary Fig. S6). It is important to point out that
this analysis was performed on total lung RNA. If we were to isolate B cells and
sequence deeper we would expect to more thoroughly characterize the repertoire.
These data are interesting but we do not know which clone types result in functional
antibodies that protect against B. pertussis. Further analysis is required to bridge the
gap between clonotypes and functional/protective antibodies.
Using NeCRE luc mice, we performed tracking neutrophil recruitment during a B.
pertussis respiratory infection. These data demonstrate how analysis of cellular
responses through in vivo imaging can be used to provide a quantitative parameter
throughout a study. This model can be applied to other bacterial infection models or
cancer tumor progression models where following the same mouse throughout a study
would be beneficial. In this study, we also added next generation sequencing
technology to expand upon the immunological findings. RNAseq analysis can be further
employed to understand key cell populations and how they are impacted by both
immunization and B. pertussis challenge. Our current goal is to continue to refine the
murine challenge models with new technological approaches in order to facilitate
formulation of new pertussis vaccines. The findings of this study suggest that by
integrating RNAseq analysis with classic immunological techniques, it is possible to
illuminate novel intricacies of vaccine induced immunity to B. pertussis.
Methods
Bacteria and culture conditions
B. pertussis strain UT25 (UT25Sm1) were cultured on Bordet-Gengou (BG) agar (1906)
supplemented with 15% defibrinated sheep blood (Hemostat Laboratories) for 48 h at
36°C59. B. pertussis was then transferred from BG plates to three flasks of 12 ml of
modified Stainer-Scholte liquid medium (SSM)60. SSM cultures were not supplemented
with cyclodextrin (Heptakis(2,6-di-O-methyl)-β-cyclodextrin). SSM cultures were grown
for ~22 h at 36°C with shaking at 180 rpm until the OD600 reached 0.5 on a 1 cm path
width spectrophotometer (Beckman Coulter DU 530). The cultures were then diluted to
1 x 109/ ml with SSM.
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Mouse Strains
All mouse strains used were bred in a specific pathogen-free experimental conditions
within the Office of Laboratory Animal Resources vivarium at West Virginia University.
Mice were aged 8 – 12 weeks, male and female sex mice were equally assigned to all
vaccination groups. 129-Elanetm1(cre)Roes/H mice (Medical Research Council, London,
UK) were crossed with FVB.129S6(B6)-Gt(ROSA)26Sortm1(luc)kael/J mice (Jackson
labs; 0051225) resulting in NECre luc progeny. NECre luc mice were injected with
CycLuc 1 lucferin (EMD Millipore, Darmstadt, Germany) and confirmed to be
luminescent using Xenogen Lumina II61. Upon intraperitoneal injection of a luciferase
substrate (luciferin), neutrophils emit luminescence that is detectable using a high
sensitivity live animal imaging system (Xenogen IVIS Lumina II).
Vaccines used in study and administration
All vaccines were formulated into 200 µl doses with the antigen content described
below. 100 µl of INFANRIX (GSK) human vaccine (DTaP) which is 1/5 human dose of
the vaccine, was mixed in 100 µl of PBS. The NIBSC WHO standard Bordetella
pertussis

whole-cell vaccine (NIBSC code 94/532) was received lyphophilzed and

reconstituted in 1ml of PBS. At this concentration one human dose is 100 µl therefore,
20 µl was mixed with 180 µl of PBS, which is 1/5 of the human dose (66 µg of total
protein). A truncated ACT protein (RTX) was purified as previously described

22

5.6 ug

of RTX was combined with 100 µl alum adjuvant (Alhydrogel®, InvivoGen)
corresponding to 1 mg of aluminum hydroxide. All immunizations occurred by
intraperitoneal injection. Unvaccinated mice received 200 µl of sterile PBS.
Vaccination and Challenge with Bordetella pertussis
NECre luc mice were bred to ages ranging from (8-12 weeks). Mice were vaccinated at
day 0, and then boosted 21 days later. Thirty-five days post initial vaccination, B.
pertussis UT25 was grown as described above, and provided as a challenge dose at 2 x
107 CFU in 20 µl. Mice were anesthetized by intraperitoneal injection of 200 µl of
ketamine (6.7 mg/ml) and xylazine (1.3 mg/ml) in 0.9% saline. Two 10 µl doses of
bacteria were administered through nasal inhalation into each nostril of the mouse. Mice
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from each of the groups were challenged WCV (8), ACV (8), RTX (6), and naïve control
(PBS injection) (5).
Collection of murine samples and determination of bacterial burden
On days 1,2,4,6, and 9 pc, mice were euthanized by intraperitoneal injection of
pentobarbital and dissected in a biosafety cabinet under BSL-2 conditions. Blood was
collected by cardiac puncture, serum was separated by centrifugation through a BD
Microtainer SST blood collector (BD), or blood for complete blood cell counts were
collected in BD Microtainer Tubes with K2EDTA (BD). Trachea and lungs were
removed, placed in 1 ml PBS, and then homogenized. Trachea tissue was
homogenized by a Brinkman Homogenizer (Polytron), while lung tissue was dissociated
using a Dounce homogenizer (Kimble Chase). To determine viable B. pertussis in the
nares, 1 ml of PBS was flushed through the nares and collected. In order to determine
bacterial burden 100 µl of homogenate or nasal lavage was serial diluted in sterile PBS.
Four 10 µl aliquots of each serial dilutions were plated on BG containing streptomycin
(100 µg/ml) to ensure only UT25 B. pertussis grew on the plates. After 72 h at 36°C
colony forming units (CFUs) were counted and the bacterial burden per tissue was
calculated. Due to the serial dilutions plated our limit of detection was 103 CFUs per ml
or organ. CFUs from experimental groups at each time-point were compared to the
naive (PBS injected) and challenged group by a two-tailed unpaired t test using the
software package Prism 7 (GraphPad, La Jolla, CA). All experiments were performed in
accordance with the National Institutes of Health Guide for the Care and Use of
Laboratory Animals. All murine infection experiments were performed per protocols
approved by the West Virginia University Institutional Animal Care and Use Committee
(protocol number Damron 14-1211).
IVIS imaging
NECre luc mice received 83 mg/kg of CycLuc1 luciferin by IP injection (100 µl). Five
minutes after injection mice were anesthetized with 3% isoflurane, mixed with oxygen
from the XGI-8 gas anesthesia system supplied with a Xenogen IVIS Lumina II.
Luminescent signals were acquired during a five-minute exposure. Acquisition was
performed using Living Image 2.5 software (Xenogen). Images were acquired with a
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binning of 4. Following imaging, mice were either euthanized for dissection and
extraction of tissue samples or returned to the vivarium. Luminescence was determined
by quantification of photons emitted per second generated in each region of interest
(ROI): whole mouse image or nasal cavity. The background of each image was
subtracted from the ROI, background photons were defined by the average of two ROIs
away from the mouse, for the same image. Data was expressed as relative fold change
between target ROIs from experimental groups to an average of ROIs from control mice
that were not vaccinated or challenged. Group comparisons were analyzed by one-way
analysis of variance (ANOVA) followed by a Tukey’s multiple-comparison test using
Prism 7.
Preparation of tissue and flow cytometry analysis
Blood, lung, and cells isolated from nasal lavage were analyzed by flow cytometry. A
100 µl sample was removed from lung homogenate of all samples and filtered through a
70 µm cell strainer, then centrifuged at 1000 x g for 5 mins to pellet cells. Supernatant
was removed, and RBC lysis buffer (BD Pharm lysis) added incubated at 37ᵒC for 2 min,
then pelleted using the same centrifugation conditions. Cells were resuspended in 500
µl of PBS + 1% FBS, 100µl was aliquoted for antibody staining. After cardiac puncture
blood was placed in EDTA containing tube (BD Bioscience), RBC were lysed using
Pharmlyse (BD Biosciences) with a 15 min room temperature incubation and then
prepared in a similar manner to other tissues. All cell suspension samples were
incubated on ice in PBS and 1% FBS for blocking. Antibodies against specific cell
surface markers: PE-conjugated GR-1 (BD, 553128) Alexa Fluor 700-conjugated
CD11b (Biolegend, 101222) were added to cell suspensions and incubated in the dark
for 1 h at 4ᵒC. Lung, blood, and nasal wash suspensions were pelleted, and
resuspended in PBS prior to analysis. Samples were read using LSR Fortessa (BD),
and analyzed using FlowJo v10 (FlowJo, LLC). PMNs were classified as CD11b+Gr-1+
single, live cells.
Cytokine Quantification
Lung homogenates were pelleted by centrifugation and then supernatant was collected
and stored at -80ᵒC until analysis. Concentration of cytokines in the lungs of vaccinated
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and challenged mice were determined by quantitative sandwich immunoassays, Meso
Scale Discovery (Rockville, MD) V-PLEX Proinflammatory Panel (K15048G-1) and
Mouse IL-17 Ultra-Sensitive kits (K152ATC-1), following manufacturer’s instructions.
Data was analyzed by one-way ANOVA, with a Tukey’s multiple-comparison test for
each time-point.
Serology
Vaccinated and challenged mouse serological responses to RTX, and PT were
determined by qualitative ELISA. High-binding 96-well ELISA plates were coated
overnight at 4ᵒC with 50 µl of purified RTX or Pt in PBS at a concentration of 1 µg/mL.
Purified B. pertussis antigens, were obtained from Dr. Jennifer Maynard. Serum
samples from NVNC, PBS, ACV, and WCV serum titers were analyzed for PT, as the
RTX group had no PT in vaccine. Samples from NVNC, PBS, WCV, and RTX were
analyzed for serum antibody titers to RTX, as ACV would not be expected to have RTX
titers because no RTX was included in vaccine. Plates were then washed with PBS +
1% Tween 20 (PBS-T), then blocked with 5% milk in PBS-T for 1 hour at room
temperature. Sera were diluted to a concentration in the linear dose range for each
antigen. Plates were incubated for 2 h at 37⁰C with serial diluted serum samples from
vaccinated groups. Following 3 PBS-T washes, 1:4000 goat anti-mouse IgG-AP
(Southern Biotech), secondary antibody was added and incubated 1 h at 37⁰C. Plates
were washed, then developed for 30 min with 100 µl p-nitrophenyl phosphate.
Colorimetric signal was measured using Spectramax i3 (Molecular Devices) at 450nm.
An average of blanks was subtracted from all absorbances and used as a baseline
detection limit. The minimum detection limit above the baseline was analyzed by oneway ANOVA, with a Tukey’s multiple-comparison test for each time-point using Prism 7.
Isolation of Lung RNA, illumina library preparation, and sequencing
Lung RNA was prepared similar to previously reported62 with the following
modifications. The freshly isolated NECre luc mice lungs were homogenized and RNA
was prepared immediately using RNeasy purification kit (Qiagen). Each lung was
placed in 1 ml of sterile PBS and then 2 ml of TE lysozyme (1mg/ml) was added and
allowed to incubate for 10 min on ice. 2 ml of RLT buffer was added and incubated for
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another 10 min on ice. The homogenate was then pushed through a syringe needle.
The homogenates were pelleted by centrifugation at 20,800g (max speed microfuge) for
10 min. The supernatant was extracted and then 2.8ml of 100% EtOH was added to
each tube. This supernatant of each mouse sample was then disturbed to four RNeasy
tubes for RNA isolation. The RNA was eluted and pooled into one sample per mouse.
The resulting RNA was quantified on a Qubit 3.0 (ThermoFisher) with the high intensity
assay kit. Next, the RNA integrity was assessed using Agilent BioAnalyzer RNA Pico
chip. All samples were then submitted Ribo-zero rRNA depletion (illumina) and
reassessed for RNA integrity. rRNA depleted mRNA samples were then fragmented
and prepared into libraries using illumina ScriptSeq Complete Gold (Epidemiology).
Libraries were checked for quality control with KAPA qPCR QC assay (KAPA
Biosystems). The libraries (33 total) were then sequenced on an illumina HiSeq at the
Marshall University Genomics Core facility on 2 lanes of 2x50B. pertussis. Sequencing
data were deposited to the Sequence Read Archive (SRA) and are available under the
reference number SRA587785, BioProject number PPJNA394758.
RNAseq bioinformatics analyses
The reads were analyzed using the software CLC Genomics workbench 9.5. Mus
musculus genome was downloaded from NCBI (version GRCm38.78). Reads were
mapped against the genome using the following settings for mapping: mismatch cost =
2, insertion cost = 3, deletion cost = 3, length fraction = 0.8, similarity fraction = 0.8.
RPKM values were generated using default parameters for CLC Genomics. On average
~20 million reads were obtained for each sample and with stringent parameters ~73%
mapped to the murine genome with our mapping parameters. Fold changes in gene
expression and statistical analyses were performed using an Extraction of Differential
Gene Expression (EDGE) test p value. Expression data for each gene was considered
significant if the p value was less than 0.05. Venn diagrams were generated using
Venny 2.163. Fold-change of gene expression data was plotted relative to nonchallenged control groups at each time-point. Supplementary Table 8 contains the
exported gene expression analysis worksheets and statistical analyses. Gene list were
created using GO terms acquired though AmiGO 2 database including neutrophil
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(CL:000075), neutrophil activation (GO:0042119), neutrophil migration (GO:1990266),
innate immune response (GO: 0045087), T-helper 1 type immune response
(GO:0042088), type 2 immune response (GO:0042092), and T-helper 17 type immune
response (GO:0072538)64.
Pathway Enrichment Analysis
Ingenuity Pathway Analysis (Qiagen) was utilized to map lung transcriptomes to
biological and disease functions. Lung transcriptomes were loaded to IPA, and
comparative analyses were performed at early and late time-points. Gene expression
fold-changes were mapped to higher-order disease and function defined by the IPA
knowledge base, and a gene enrichment analysis was performed on early and late timepoints. A Fisher Exact T-test was used to determine statistically significant (p < 0.05) pvalues of the functions that made up the higher-order disease category and represented
as a range of p-values. The relative fold-change of these identified genes was
determined, and the 10 highest fold-changes were represented as heat maps.

Immunoglobulin and T-cell receptor profiling
B cell clones were identified using MiXCR software (MiLabratory), capable of generating
quantitated clonotypes of immunoglobulins48. The same paired-end Illumina sequenced
reads mentioned above were merged using concatenation, then imported into MiXCR
software. Merged reads were aligned to each other to generate clonotypes of based on
VDJ segment regions of unique immunoglobins specific to each sample. Clone data for
each sample was grouped based on vaccine received, and time-point. Clonotypes from
each sample were then separated into T and B cells, based on T-cell receptor or B-cell
receptor specific sequences. Prepared data files were then imported into VDJtools
(MiLabratory), for data representation according to established protocol65. Briefly, data
was represented to show V-J diversity, and quantify unique clonotypes using
dendrograms and chord diagrams.
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Figures
Figure 1: Experimental workflow for vaccination, B. pertussis challenge, sample
acquisition, and analysis of this study.
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Figure 1: Experimental workflow for vaccination, B. pertussis challenge, sample
acquisition, and analysis of this study. Schematic diagram of experimental design
showing vaccination schedule, immunization groups, B. pertussis challenge,
euthanasia, sampling, and analysis method on days 1,2,4, 6, and 9 days pc in NECre
luc mouse model. Mice were initially vaccinated and then given a booster dose of the
same vaccine at day 21. A challenge dose of 2 x 107 viable bacteria was administered
by intranasal inhalation at day 35. IVIS imaging of neutrophils was monitored throughout
study. The overall numbers of mice per group are indicated. At time-points shown
bacterial burden, complete blood cell counts, lung cytokine profiles, lung and nasal
wash neutrophil cells, serum antibody titers, and lung transcriptome were determined.
To characterize the effects of vaccination, the vaccinated groups were compared to a
group of not vaccinated and not challenged controls.
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Figure 2: Kaplan- Meier survival curves of NECre luc mice according to
immunization group.
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Figure 2: Kaplan- Meier survival curves of NECre luc mice according to
immunization group. The survival percentage of remaining NECre luc mice (prior to
scheduled euthanasia) immunized with WCV, ACV, RTX, and B. pertussis challenged,
or not vaccinated and challenged with B. pertussis. Log-rank (Mantel-Cox) test: ***p<
0.0005. In Fig. 1 the time-points where mice were euthanized for analysis are indicated.
In this survival curve, we are only showing the mice became morbid throughout the
study timeframe.
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Figure 3: Bacterial burden in respiratory tissue and serological responses to B.
pertussis challenge of immunized and naïve NECre luc mice.

Figure 3: Bacterial burden in respiratory tissue and serological responses to B.
pertussis challenge of immunized and naïve NECre luc mice. Mice were vaccinated
with PBS control vehicle, WCV, ACV, or RTX then B. pertussis challenged. At days
1,2,4,6 and 9 pc the bacterial burdens were determined by culturing of (A) nasal lavage,
homogenates of (B) trachea and (C) lung on BG agar. The dashed line at 1000 CFUs
represents the lower limit of detection, due to plating. Data in each group were
compared to PBS control using an unpaired two-tailed t-test. Significant differences are
not indicated on the graphs for clarity (Supplementary Table 2 indicates all statistics
performed).
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Figure 4: IVIS imaging and flow cytometric analysis of naïve and immunized
NECre luc mice post challenge with B. pertussis.

Figure 4: IVIS imaging and flow cytometric analysis of naïve and immunized
NECre luc mice post challenge with B. pertussis. IVIS imaging of luminescent
neutrophils in anesthetized mice following luciferin injection. (A) Representative images
of naïve, not B. pertussis challenged NECre luc mice. (B) Representative images of
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PBS control, WCV, ACV, and RTX immunized and B. pertussis challenged NECre luc
mice at day 1 pc and (C) day 6 pc (D and E). Luminescence was measured on Xenogen
IVIS Lumina II. Relative luminescence levels quantified by fold change of emitted
photons/second of NECre luc mice following B. pertussis challenge (N=3-5) compared
to average luminescence of naïve, not challenged NECre luc mice (N=5). Neutrophil
luminescence of (D) whole animal signal and (E) nasal cavity was determined at days
1,2,4,6, and 9 pc. (f) Quantification of the percentage of live, single cells classified as
neutrophils (GR-1+CD11b+) detected in nasal lavage (f) and lung homogenate (g).
Significant differences are not indicated on the graphs for clarity, but are included in
Supplementary Table 3.
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Figure 5: Analysis of cytokine profiles from lungs of naïve and immunized NECre
luc mice post challenge with B. pertussis.
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Figure 5: Analysis of cytokine profiles from lungs of naïve and immunized NECre
luc mice post challenge with B. pertussis. Th1 associated cytokines from the
supernatant of lung homogenates were analyzed at days 1,2,4 and 9 pc. Cytokines (a)
IFN-γ, (b) IL-12p70, (c) IL-17, (d) IL-6, (e) IL-1β, (f) TNF-α were quantified using
electrochemiluminescence immunoassays. Significant differences are not indicated on
the graphs for clarity but, are included in Supplementary Table 4. ND: Sample not
determine, #: data above upper limits of detection.
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Figure 6: Lung transcriptome profile of vaccinated and challenged NECre luc
mice.

Figure 6: Lung transcriptome profile of vaccinated and challenged NECre luc
mice. RNA sequencing was performed on total RNA from homogenized lung on days 1
(Early) or 6/9 (Late) following challenge with B. pertussis. (a) The total number of
statically differentiated genes found in lung transcriptome at early (a) or late (c) timepoints. Statistically differentiated genes were categorized as those that were activated
or repressed. Venn diagram of statistically differentiated genes either unique or
common to vaccinated or naïve groups at early (b) or late (d) time-points.
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Figure 7: Enrichment analysis and relative fold-changes of genes upregulated
following B. pertussis challenge.

Figure 7: Enrichment analysis and relative fold-changes of genes upregulated
following B. pertussis challenge. Early (day 1)(a), and late (day 9)(b) IPA
comparative analysis of lung transcriptomes from vaccinated and non66

vaccinated/challenged groups was performed, gene enrichment p-values are
represented in –log scale. P-value was calculated by IPA software based on the number
of genes found in a certain data set to the total number of genes associated to a
particular function in the IPA knowledge base. Threshold indicates the significance
(p<0.05, Fisher’s exact t-test) Black-PBS, Blue – WCV, Yellow-ACV, Red – RTX.
Relative fold changes of ten highest genes associated with a particular function
annotation present in either of the experimental groups.
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Fig. 8: Differentiated genes associated with neutrophil recruitment at early and
late time-points following B. pertussis challenge.

Fig. 8: Differentiated genes associated with neutrophil recruitment at early and
late time-points following B. pertussis challenge. Gene expression profiles are
shown for (a) Naïve, (b) WCV, (c) ACV, and (d) RTX immunized and challenged mice.
Blue and gold bars indicate the fold change compared to control non-challenge nonvaccinated mice at early and late time-points, respectively. Genes shown are the 25
genes with the highest variance across all groups between early and late time-point.
Genes were ranked based on variance in fold change across groups for the early and
late time-points, separately.

68

Supplemental Information
Characterizing the innate and adaptive responses of immunized mice to
Bordetella pertussis infection using in vivo imaging and transcriptomic analyses
Dylan T. Boehma, Melinda E. Varneya, Ting Y. Wonga, Evan S. Nowaka, Emel SenKilica, Jesse Halla, Shelby D. Bradforda, Katherine DeRoosa, Justin Beverea, Matthew
Epperlya, Jennifer A. Maynardb, Erik L. Hewlettc, Mariette Barbiera, and F. Heath
Damrona*

a

Department of Microbiology, Immunology, and Cell Biology, West Virginia University,
Morgantown, WV, USA
b

Department of Chemical Engineering, University of Texas at Austin, Austin, TX 78712,
USA
c

Department of Medicine, Division of Infectious Diseases and International Health,
University of Virginia, Charlottesville, Virginia, USA

69

Supplementary Fig. 1: IVIS imaging of naïve and immunized NECre luc mice post
challenge with Bp as image was acquired from Xenogen IVIS Lumina II.

Supplementary Fig. 1: IVIS imaging of naïve and immunized NECre luc mice post
challenge with Bp as image was acquired from Xenogen IVIS Lumina II. Images at
day (a) 1, (b) 2, (c) 4, and (d) 6 – WCV or 9 – Control (Non-vaccinated/ no challenge),
PBS, and ACV. Relative luminescence was quantified based on region of interest
luminescence in these non-adjusted images.

70

Supplementary Table 1. Compositions of vaccines of this study

Vaccine component*
Pertussis Toxoid***
Filamentous Hemagglutinin
Pertactin
RTX
Aluminum hydroxide
Other antigens/adjuvants

aP (1/5

th

Vaccine groups
human dose)
wP**
RTX + alum

5
5
1.6
0
125
0

0.4
3.5
0.3
0.2
0
62

0
0
0
10
1 (mg)
0

*All masses of antigens or adjuvant are indicated in μg
** This estimate is based on the number of peptides identified for each antigen in the
wP. The percentage is then used to estimate the potential mass based on the fact that
the wP dose used in this study contained 66 μg of total protein.
*** For total pertussis toxin, the sum of PtxA,B,C,D peptides was combined.
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Supplementary Table 2. Statistical analysis from Figure 3abc.
Day 1
ACV
Trachrea WCV
RTX
Nasal ACV
Lavage

Day 2
0.0524 WCV
0.059
0.0729
0.0984 ACV
WCV

Day 4
0.0341

0.0764 ACV
0.0209 WCV

Unpaired two-tailed T tests to PBS challenged group
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0.0567
0.0567

Supplementary Table 3: Relevant statistical differences in relative fold changes
of neutrophil luminescence of Bp challenged mice.
Luminescence was analyzed by one-way ANOVA with a Tukey’s multiple comparison
test at each time point.
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Supplementary Fig. 2: Representative images and gating strategy for neutrophils
from lung and nasal lavage tissues.
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Supplementary Fig. 2: Representative images and gating strategy for neutrophils
from lung and nasal lavage tissues. Neutrophils were gated as live, single cells (data
not shown), quadrants demonstrate positively labeled cells determined by single marker
flow cytometry controls. Region of interest shows neutrophil population (Gr-1+CD11b+).
(a) Lung and (b) nasal lavage representatives.
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Supplementary Fig. 3: Analysis of Treg and Th2 associated cytokines from lungs
of naïve and immunized NECre luc mice post challenge with B. pertussis

Supplementary Fig. 3: Analysis of Treg and Th2 associated cytokines from lungs
of naïve and immunized NECre luc mice post challenge with B. pertussis.
Cytokines were analyzed at days 1, 2, 4 and 9 pc, then quantified using
electrochemiluminescence immunoassays. (a) Cytokines IL-10 and IL-5 associated with
Treg immune response. (b) Cytokines IL-2 and IL-4 associated with a Th2 immune
response. ND: Sample not determined.
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Supplementary Table 4: Relevant statistical differences between cytokine
production in lungs of immunized and Bp challenged NECre luc mice.
Samples were analyzed by one-way ANOVA with a Tukey’s multiple comparison test at
each time point.
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Supplemental Fig. 4: Volcano plot analysis of differentiated genes at early and
late time-points of immunized or naïve mice following challenge.

Supplemental Figure 4: Volcano plot analysis of differentiated genes at early and
late time-points of immunized or naïve mice following challenge. Upregulated
genes are represented in red, repressed gens are in blue. Relative fold change was
calculated compared to not infected control mice.
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Supplementary Fig. 5: Gene expression profiles of T helper cell immune
responses at early time point.

Supplementary Fig. 5: Gene expression profiles of T helper cell immune
responses at early time point. Differentiated genes associated with (a) Th1, (b) Th2,
and (c) Th17 immune responses. Fold changes are relative to NVNC mice. Genes
represented are significantly different in at least one group, genes were sorted based on
variance of fold change among the experimental groups.
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Supplementary Fig. 6: Repertoire of B cell clones identified from experimental
groups at late time point.

Supplemental Fig. 6: Repertoire of B cell clones identified from experimental
groups at late time point. (a) Relativeness of immunoglobulin profiles between
vaccinated and challenged, challenged, or non-challenged groups at late time point. (b)
Immunoglobulin diversity and frequency of non-challenged control, experimental groups
at late time points. Chord diagrams are used to visualize variable – joining segment
diversity. Outer arcs demonstrate overall count of a particular variable (upper portion of
chord diagram) or joining segment (lower portion of chord diagram) in each group. Inner
ribbons represent the linked segments of a clonotype, while the thickness of the ribbon
signifies frequency of the clonotype.
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Abstract
Bordetella pertussis

(B. pertussis) is the primary causative agent of pertussis

(whooping cough), which is a respiratory infection that leads to a violent cough and can
be fatal in infants. There is a need to develop more effective vaccines because of the
resurgence of cases of pertussis in the US since the switch from the whole cell
pertussis vaccines (wP) to the acellular pertussis vaccines (aP; DTaP/Tdap). Adenylate
Cyclase Toxin (ACT) is a major virulence factor of B. pertussis that is: 1) required for
establishment of infection, 2) an effective immunogen, 3) a protective antigen. The Cterminal Repeats-In-Toxin domain (RTX) of ACT is sufficient to induce production of
toxin neutralizing antibodies. In this study, we characterized the effectiveness of
vaccines containing the RTX antigen against experimental murine infection with B.
pertussis. RTX was not protective as a single-antigen vaccine against B. pertussis
challenge, and adding RTX to 1/5th human dose of aP vaccine did not enhance
protection. Since the doses of aP used in murine studies are not proportionate to
mouse/human body masses, we titrated the aP vaccine from 1/20th to 1/160th of the
human dose. Mice receiving 1/80th human aP dose had bacterial burden comparable to
naïve controls. Adding RTX antigen to the 1/80th aP base resulted in enhanced bacterial
clearance. Inclusion of RTX induced: production of antibodies recognizing RTX,
enhanced production of anti-PT, decreased secretion of pro-inflammatory cytokines
such as IL-6, and decreased recruitment of total macrophages in the lung. This study
shows that adding RTX antigen to an appropriate dose of aP vaccine can enhance
protection against B. pertussis challenge in mice.
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Introduction
Whooping cough is a disease caused by an upper respiratory tract infection that is
primarily caused by the Gram-negative pathogen, Bordetella pertussis (B. pertussis)
and several other Bordetellae. These infections, commonly referred to as pertussis, can
be fatal in infants, but can also cause significant suffering in children, adolescents, and
adults. Fortunately, two generations of vaccines have been developed and have greatly
reduced the incidence of pertussis in the US and worldwide. Killed whole cell vaccines
(wP) were first reported in 1933 1. With the development of the Kendrick test in 1947,
wPs were standardized leading to an increase in vaccine efficacy such 80% of those
immunized developed long-term immunity to pertussis 2. Use of the wP resulted in
drastic reduction of the incidence of whooping cough in the second half of the twentieth
century. However, in the 1990s, due to reactogenicity and public concern, wPs were
replaced with acellular vaccines (aP; DTaP; Tdap) containing 3-5 pertussis protein
antigens and alum adjuvant 3. Since the introduction of aPs, increases in pertussis
cases throughout the US and Europe have been observed and a number of reasons
have been postulated to explain their lack of complete efficacy of the aPs 4.
One of the major issues with the aPs is that their efficacy wanes each year after
administration

5,6.

Recent data from the non-human primate model of pertussis

demonstrates that while the aPs prevent the paroxysmal whooping cough, they do not
protect from colonization and transmission 7. In light of the increased incidence and our
appreciation of the lack of efficacy of the aP, there is a need to develop another
generation of vaccines with improved efficacy and duration of protection. Various
approaches have been considered for the development of the new generation of
pertussis vaccines, including: 1) addition of new antigens to the current aPs, 2)
repolarization of the host Th-2 response triggered by alum-adjuvanted aPs to a Th-1/Th17 response by changing the adjuvant and adding new antigens, or 3) re-introduction of
wPs (live attenuated or killed) either as primary immunization or as a re-polarizing
booster.
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B. pertussis expresses pertussis toxin (PT) and adenylate cyclase toxin (ACT) to
facilitate infection and impair the host immune response in a variety of ways. Detoxified
PT antigens are included in all commercial aPs. When the aP was developed, ACT was
recognized as an essential virulence factor, but as of the late 1980s, ACT had not been
extensively evaluated as protective antigen and was not available in purified form. It
was therefore not included in aP formulations. The cyaA gene encodes ACT, a soluble
toxin of 1,706 amino acids 8, comprised of an adenylate cyclase (AC) domain and a
Repeats in Toxin (RTX) domain 9. The RTX domain is responsible for the hemolytic
activity of ACT

10.

The cyclase domain can be delivered to eukaryotic cells where it

catalyzes ATP into supraphysiological concentrations of cAMP, which impairs many cell
functions and leads to cell death 9. B. pertussis requires ACT to establish lethal infection
in neonatal mice

11,

where the toxin targets macrophages, neutrophils, dendritic cells,

and other integrin αMβ2 expressing cells 9. ACT has both adenylate cyclase and
hemolytic activities and its hemolytic activity is required for B. pertussis penetration into
the lung parenchyma

12.

Underscoring its role in disease, AC enzyme activity has been

detected in airway samples from a non-human primate model of pertussis infection
and humans

13,

and convalescent humans have antibodies against ACT

Furthermore, adenylate cyclase activity can be detected in wPs

16

13,

14,15.

and in our own mass

spectral analysis we have confirmed the presence of ACT in wP vaccines
(unpublished).
In light of the role of ACT in virulence and the fact that B. pertussis infection induces
production of anti-ACT antibodies, ACT has been evaluated as a protective antigen in
pre-clinical murine immunization/challenge models. Before aPs replaced wPs in the US
and Europe, Guiso et al. demonstrated that a polypeptide consisting of the AC domain
purified from B. pertussis was a protective antigen in mice

17.

The same group

demonstrated that full length toxin purified from B. pertussis was protective (16).
Subsequent studies showed that recombinant ACT was also a protective antigen

18,19

and an adjuvant 20. While immunization with ACT results in toxin neutralizing antibodies,
the presence of these antibodies do not correlate directly with protection. However,
antibodies that recognize the C-terminal domain (RTX) are protective
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19.

These studies

were further supported by evidence that the hemolytic domain only antigen (RTX) was
protective in mice against sub-lethal and lethal challenge with B. pertussis

19.

In all of

the aforementioned studies, ACT antigens were evaluated as single antigen
formulations without any of the aP antigens. Cheung et al. observed that inclusion of
enzymatically inactive recombinant ACT enhanced protection of the aP

21,

and that

unlike previous single antigen studies, neither active nor enzymatically inactive ACT
protected alone 21. The study also showed that inclusion of ACT in the aP skewed the Thelper cell responses from a humoral Th2 response to a more cell-mediated Th1
response 21.
Multiple studies have demonstrated the protective capacity of ACT 8. In order to
determine the appropriate form of ACT for use in a human vaccine, it is necessary to
identify a protective toxoid form that would be readily purified for mass production.
Genetic mutation of the ACT coding sequence results in an enzymatically inactive
form/molecule that is protective in mice

21.

However, the use of a full length ACT would

be problematic to for use in human vaccines due to: 1) the susceptibility of the toxin to
proteolytic degradation

22

and 2) overexpression of ACT leads to formation of inclusion

bodies in the E. coli cytoplasm

23-25.

A recent study confirmed that ACT is prone to

aggregation and proteolysis 9. Wang et al. characterized a recombinant RTX antigen
that was 1) readily purified, 2) immunodominant, and 3) elicited neutralizing antibody
production

26.

While these results are very promising, it is essential to determine the

efficacy of recombinant RTX antigen in pre-clinical models of pertussis, both alone and
in combination with aP. It is likely that a new aP vaccine would still include PT, FHA,
and FIM antigens. Our objective was to investigate the RTX antigen with the standard
aP antigens as a multivalent formulation. In this present study, inclusion of the RTX
antigen into an aP formulation was evaluated with a murine immunization and challenge
model. We observed that immunization with RTX alone was not protective and
furthermore when either RTX or full length ACT was added to the 1/5th human dose, no
significant enhancement of protection occurred. The use of high amounts of the human
aP in mice (such as 1/4th, 1/5th, or 1/10th human dose) relates back to doses intended
for commercial vaccine lot validation. It is known that as little as 1/50th human dose of
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aP is protective in mice

27.

We hypothesized that identification of the minimal protective

and maximal non-protective aP doses would allow us to investigate enhancement of
protection by inclusion of new antigens, thereby refining this evaluation platform. By
performing a vaccine titration study using two-fold dilutions, we were able to identify
1/80th human dose of aP as a minimal protective dose. When the RTX antigen was
added into the 1/80th human dose, improved bacterial clearance was observed.
Inclusion of RTX antigen also enhanced antibody production to PT demonstrating the
adjuvant capacity of RTX. The enhanced protection correlated with 1) decreased proinflammatory cytokine production, 2) decreased blood and lung neutrophils, and 3)
decreased macrophages in the lung. This study begins to redefine murine immunization
and B. pertussis challenge model for evaluation of pertussis vaccines and sheds light on
the positive effects of including RTX as an antigen in the acellular vaccines.
Materials and Methods
ACT and RTX antigen expression and purification
ACT and RTX antigens were expressed and purified as previously described

9.

Following purification, antigens were stripped of endotoxin with Dextoxi-GelTM Endotoxin
Removing Gel (Thermo Scientific, 20399) and Zeba Spin columns (Thermo Scientific,
89896). Endotoxin purity was quantified with Pierce® LAL Chromogenic Endotoxin
Quantitation Kit (Thermo Scientific, 88282).
Composition of vaccines used in study and administration
The INFANRIX (GSK) human vaccine (diphtheria, tetanus, and pertussis) was the aP
used in this study. For the purpose of vaccinating mice, 1/5th of the human dose was
used (100 μl). To test ACT as an additional antigen, full length ACT or RTX-ACT were
purified as previously described 9. Equimolar amounts of full length ACT (10 μg) or RTX
(5.6 μg) were used for vaccination. Vaccine compositions are shown in Table S1. Alum
and MPLA were obtained from InvivoGen. The National Institute for Biological
Standards and Control WHO standard whole cell pertussis vaccine (NIBSC code
94/532) was used as the wP. One ampule of NIBSC wP contains 40 IU (10 human
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doses). For murine vaccination, the whole ampule was diluted in 1 ml of sterile PBS and
20 μl (1/5th of the human dose, 66 μg of total protein) were used. The NIBSC wP
standard used in this study has been used in other studies as a wP vaccine

28.

The

NIBSC wP does not contain alum adjuvant, whereas commercial wP vaccine contain
alum to induce antibody production to the Diptheria and Tetanus toxoids. The adjuvant
alum was only added to single antigen vaccines (Table S1). INFANRIX is formulated
with alum, thus we did not include additional alum for aP titration and aP
supplementation with RTX. Unvaccinated mice received 200 μl of sterile phosphate
buffered saline (PBS) as vehicle control. Prior to administration, aP, aP-ACT, aP-RTX,
and wP doses were all diluted into a final volume of 200 μl with sterile PBS and
administered by intraperitoneal injection.
B. pertussis strains and growth conditions
B. pertussis strain UT25 (UT25Sm1)
(Remel)

30

29

was cultured on Bordet Gengou (BG) agar

supplemented with 15% de-fibrinated sheep blood (Hemostat Laboratories)

for 48 h at 36 °C. Bacteria were transferred from BG plates to a flask with 20 ml of
modified Stainer-Scholte liquid medium (SSM)

31.

SSM cultures were not supplemented

with cyclodextrin (heptakis). B. pertussis cultures in SSM were grown for ~22 h at 36°C
with shaking at 180 rpm at which time the OD600 was ~0.6.
Vaccination and challenge with B. pertussis
Four week old CD-1 (outbred; strain code 022) mice were obtained from Charles River.
Mice were vaccinated at 5 weeks of age with the vaccines described (Table S1), and
then boosted with the same vaccines 21 days later. Thirty-eight days post initial
vaccination, B. pertussis UT25 was grown as described above, and cultures were
diluted to provide a challenge dose of 2 x 107 colony forming units (CFU) in 20 μl. Mice
were anesthetized by intraperitoneal injection of 200 μl of ketamine (6.7 mg/ml) and
xylazine (1.3 mg/ml) in 0.9 % saline. Mice received 20 μl total challenge dose by
pipetting 10 μl directly into each nostril of the mouse. Four to eight mice per group were
challenged, and at 1, 3, and 8 days post infection, mice were euthanized. Blood was
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collected by cardiac puncture and serum was separated by centrifugation through a BD
Microtainer blood collector and stored at -80°C until analysis. Trachea and lungs were
removed and separately homogenized with Dounce homogenizers for determination of
bacterial burden in each tissue. To determine the number of B. pertussis in the nares, 1
ml of PBS was flushed through the nares and collected. Serial dilutions in PBS were
plated on BG containing streptomycin (100 μg/ml) to ensure that only UT25 B. pertussis
were cultured. All murine infection experiments were performed according to protocols
approved by the West Virginia University Animal Care and Use Committee (protocol
number 14-1211.10).
Cytokine analysis
Lung homogenates were pelleted by centrifugation and the supernatants were collected
and stored at -80°C until analysis. The concentration of cytokines in the lungs and
serum of vaccinated and challenged mice was determined by Raybiotech Mouse
Inflammation Array C1 (AAM-INF-1-8) following the manufacturer’s instructions. A total
of 100 μl of lung homogenate supernatants or serum were pooled from 4 mice for each
analysis. Quantitative analysis of the concentration of cytokines in the lungs mice was
determined Meso Scale Discovery V-PLEX Proinflammatory Panel (K15048G-1) or
Mouse IL-17 Ultra-Sensitive kits (K152ATC-1) per the manufacturer’s instructions.
Adenylate cyclase toxin neutralization assay
ACT is, through a combination of mechanisms, cytotoxic for J774A.1 (ATCC® TIB-67™)
macrophage-like cells and protection against this effect is the basis for the toxin
neutralization assay

32.

J774A.1 cells were cultured in Dulbecco’s modified Eagle’s

medium with 25 mM glucose (Gibco). J774A.1 cells (30,000 in 90 μl) were seeded in
each well of a 96-well plate and allowed to attach overnight. ACT was incubated with
serum samples for 10 min with mixing at 4°C, and added to the cells at a final ACT
concentration of 80 ng/ml. Cells were then incubated at 37°C for 2 h. The number of
viable cells was determined using the CCK8 assay (Dojindo Laboratories), which
measures reduction of WST-8, a water-soluble tetrazolium salt, by dehydrogenases in
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viable cells. Percent viable cells was determined for ACT alone and for serum + ACT
compared to control cells by the following equation [(treatment - media without cells) /
(control - media without cells)] × 100.
Preparation of flow cytometry samples and analysis
Blood, lung, and cells isolated from nasal lavage or lung were analyzed by flow
cytometry. A 100 µl sample was removed from lung homogenate of all samples and
filtered through a 70 µm cell strainer, then centrifuged at 1,000 x g for 5 min to pellet
cells. Supernatant was removed, Pharmlyse red blood cell (RBC) lysis buffer (BD
Biosciences) was added, and samples were incubated at 37°C for 2 min before being
pelleted by centrifugation at 1,000 x g for 5 min. Cells were finally re-suspended in PBS
+ 1% Fetal Bovine Serum (FBS). To prepare blood samples for flow cytometry, blood
collected by cardiac puncture was placed in ethylenediaminetetraacetic acid (EDTA)
containing tube (BD Biosciences) and RBC were lysed using Pharmlyse with a 15 min
room temperature incubation. Cells were then pelleted by centrifugation at 1,000 x g for
5 min and re-suspended in PBS + 1% FBS. Cells isolated by nasal lavage are in a
single cell suspension by nature, thus only required centrifugation at 1,000 x g for 5 min
to concentrate samples. All cell suspension samples were incubated on ice in PBS and
1% FBS for blocking for 15 min. Antibodies against specific cell surface markers were
added to cell suspensions and incubated in the dark for 1 h at 4°C: PE-conjugated GR-1
(BD, 553128), Alexa Fluor 700-conjugated CD-11b (Biolegend, 101222), PerCP/Cy5.5conjugated F4/80 (Biolegend, 123128). Lung, blood, and nasal lavage suspensions
were pelleted and resuspended in PBS prior to analysis. Samples were read using an
LSR Fortessa (BD) flow cytometer, and analyzed using the software FlowJo v10
(FlowJo, LLC). Neutrophils and macrophages were classified as CD-11b+Gr-1+ single,
live cells or CD-11b+F4/80+ single, live cells, respectively.
Serological analysis of B. pertussis specific antibodies
Vaccinated and challenged mouse serological responses to RTX
Biologicals),

filamentous

hemagglutinin
95

(FHA;

Enzo

Life

26,

PT (LIST

Sciences),

and

lipooligosaccharide (LOS; LIST Biologicals) were determined by enzyme-linked
immunosorbent assays (ELISA). High-binding 96-well ELISA plates were coated
overnight at 4°C with 50 µl of purified RTX, PT, FHA in PBS at a concentration of 1
µg/mL or LOS at 5 μg/ml. IgG2a monoclonal m1B733 (anti-PT) and IgG2a monoclonal
M1H5

26

(anti-RTX) were obtained from Dr. Jennifer Maynard. To measure FHA or LOS

responses, polyclonal murine anti-FHA (Cat #JNIH-11, NIBSC) or murine IgG3
monoclonal antibody D26E (Thermo Scientific) were used, respectively. Plates were
washed with PBS + 1% Tween 20 (PBS-T), then blocked with 5% milk in PBS-T for 2 hr
at 37°C. Sera were diluted to a concentration in the linear detection range for each
antigen. Plates were incubated for 2 hr at 37°C with serially diluted serum samples from
vaccinated groups. Following 3 PBS-T washes, goat anti-mouse IgG secondary
antibody conjugated to alkaline phosphatase (AP) (Southern Biotech) was diluted at
1:2,000 in blocking buffer and added to each well, and incubated 1 h at 37°C. Antibody
standards were prepared from anti-PT, anti-FHA, anti-LOS, anti-RTX by 2-fold dilutions
from 100 µg/mL. Plates were washed, then developed for 30 min with 100 µl pnitrophenyl phosphate. Colorimetric signal was determined by measuring sample
absorbance at 450nm using Spectramax i3 (Molecular Devices). Serum antibody
concentration was calculated by plotting absorbance values of samples to absorbance
of known concentrations of control antibodies. Values were plotted using a logarithmic
scale, and fit to a four-parameter equation. Relative EC50 was determined by fitting the
absorbance values of half of the maximal response to the four-parameter equation.
Dilution of EC50 was determined by plotting the calculated antibody sample
concentrations to sample dilution factors and fit to a four-parameter logistic curve

34.

Dilutions were accounted for by multiplying antibody concentration by dilution factor.
Statistical Analysis
Experiments in this study were performed with a minimum of four biological replicates.
Data were statistically analyzed with GraphPad Prizm 7. Comparisons between single
groups were performed using unpaired two-tailed t-tests and comparisons between
multiple groups were performed using one-way ANOVA with a Tukey test for multiple
comparisons.
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Heat map modeling and visualization of the effects of immunization on correlates
of protection
A master file containing all of the data collected during this project was compiled and
linear regressions were performed for each variable measured in response to
vaccination and challenge (Matlab, Mathworks) to identify variables that correlate with
overall protection against B. pertussis challenge. A subset of those variables were then
extracted and used to plot visual representations of the overall correlates of protection.
For each variable, modulations were calculated as the difference between the averaged
responses of the non-challenged / non-vaccinated mice, and the averaged response of
the mice in each experimental group. To establish a colorimetric scale, green was set
as equal to the non-challenged / non-vaccinated mice, red was used for the maximal
relative increase for that variable, and blue was used for the minimal relative value for
that variable.
Results
Immunization with RTX alone does not enhance clearance of B. pertussis in CD-1
mice.
ACT plays a key role in the pathogenesis of B. pertussis and many studies have shown
that both native and recombinant ACTs can be adjuvants and/or antigens for protection
against pertussis in murine challenge studies

17-20,35-39.

In this study, we aimed to

systematically evaluate the RTX antigen (toxoid version of ACT) for inclusion into the
acellular pertussis vaccine. Wang et al. previously described that recombinant RTX
antigen was immunogenic and readily purified, making it an attractive candidate for
further evaluation. In our previous study using NECre luc mice (transgenic strain
specifically used for tracking neutrophils in live mice

40),

we did not observe protection

when mice were immunized with RTX + alum adjuvant but we did observe the presence
of antibodies that recognize RTX antigens via ELISA (manuscript in review). Here, we
immunized outbred CD-1 mice with the RTX antigen (Table S1) formulated with alum,
which is a Th2 adjuvant, or monophosphoryl lipid A, (MPLA) which is a TLR4 agonist
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that induces Th1 responses. CD-1 mice were immunized intraperitoneally with PBS
vehicle control (naïve) or 1/5th human dose of aP as a positive control for protection.
Twenty one days later the mice were boosted with the same vaccines. Two weeks after
boost, each of these groups of mice were challenged with 2 x 107 CFU of B. pertussis
strain UT25 by intranasal administration. When this challenge dose of B. pertussis is
intranasally administered to anesthetized mice, 26% of the initial dose is recoverable
from the lung at 30 min post challenge and only 5% (106 CFU) is recoverable at 4 h post
challenge (data not shown). These data suggest that many of the B. pertussis that were
instilled by intranasal administration are killed by innate immune responses during the
early stages of infection. However, this dose is sufficient to establish respiratory
infection, as 4 x 106 CFU can be recovered in the airways 24 hr post challenge in naïve
(PBS control immunized) CD-1 mice (Fig. 1A).
At one and three days post B. pertussis challenge, we enumerated the viable bacteria in
the lungs, nares and trachea of naïve, aP, RTX+alum, and RTX+MPLA immunized CD1 mice (Fig. 1A and Fig. S1). The aP immunized mice had 99.75% less B. pertussis at
day 1 post challenge than naïve mice (Fig. 1A), and by day 3, the bacterial load was at
or below our detection limit of 100 CFUs. However, mice immunized with RTX+alum or
RTX+MPLA, were not significantly protected as they contained the same amount of
viable B. pertussis as naïve mice (Fig. 1A and Fig. S1AB). Interestingly, ELISAs were
performed to measure anti-ACT antibodies and showed that mice vaccinated with RTX
in combination with alum or MPLA induced detectable levels of antibodies in sera and
lung homogenates (data not shown).
Vaccination with wP, aP, aP+RTX, and or aP+ACT protect against B. pertussis
challenge. We hypothesized that inclusion of RTX into a standard acellular formulation
would enhance protection against B. pertussis challenge in mice. To test this
hypothesis, we compared aP and wP to aP supplemented with ACT or RTX in a murine
vaccination challenge study. CD-1 mice were immunized as indicated in Table S1 and
boosted three weeks post initial vaccination. At day 38 post initial vaccination, the mice
were challenged with the B. pertussis strain UT25. At 1, 3, and 8 days post challenge,
mice were euthanized for determination of bacterial burden and collection of tissues and
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samples for analysis. Naïve mice harbored similar amounts of B. pertussis in the lungs
(Fig.1B), trachea and nares (Fig. S1CD) as those observed previously (Fig. 1A). wP and
aP-vaccinated mice had significantly lower bacterial loads in the airways than nonvaccinated mice, and aP mice had the lowest bacterial burden at day 1 and 3. By day 8,
all wP or aP immunized mice had cleared the infection to our detection limit. (Fig. 1B).
Overall these data show that in CD-1 mice with UT25 as challenge strain, the 1/5th
human dose of aP is protective and that at that dose, adding RTX or ACT does not
enhance bacterial clearance.
Serological analysis of naïve, wP, aP, aP+ACT, and aP+RTX immunized mice.
ELISAs were performed and we observed that alum and MPLA formulated RTX or ACT
vaccines, induced antibodies that recognize ACT (data not shown). Additionally, 1/5th
aP supplemented with either RTX or ACT also induced detectable antibody production.
Surprisingly, we did not observe any antibodies that would recognize ACT in the wP
immunized mice (data not shown). The lack of anti-ACT in wP immunized mice is likely
due to the fact that when we analyze the wP with shotgun proteomics, we only observe
4 peptides of ACT per 1,000 total peptides in the whole cell vaccine, which shows ACT
makes up a minor amount of the total protein content (data not shown).
AC toxin neutralizing capacity of serum antibodies.
Due to the lack of noticeable effects on the rate of clearance of B. pertussis, it was
unclear that those antibodies influenced clearance of B. pertussis in the mouse. ACT
has potent toxic effects against CD-11b/CD-18-expressing phagocytes, such as
macrophages or neutrophils

41-43.

To determine the functional capacity of the serum

antibodies induced via immunization, we utilized the AC toxin neutralization assay with
J774A.1 cells

32.

Only sera obtained from mice vaccinated with aP+ACT or aP+RTX

were able to neutralize the toxicity of ACT in J774A.1 macrophages (Fig. 1C). We did
not observe detectable anti-ACT antibodies in the serum from wP mice, and this serum
did not neutralize ACT in vitro (Fig. 1C). The AC toxin neutralization data suggest that
immunization with RTX can induce production of antibodies that can neutralize the AC
toxin in vitro.
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Identification of the optimal aP murine dose to determine synergy between aP
and RTX. Our data and previous published studies

9

show that RTX is immunogenic

and could contribute to protection against B. pertussis when used as an antigen.
However, we hypothesized that the dose of aP used (1/5th human) in these studies is
too high to observe synergy between the aP and RTX. Therefore, we sought to define a
physiologically appropriate aP dose, for the mouse, that could be used to evaluate the
effects of inclusion of new antigens into the aP. Guiso et al. demonstrated that 1 full
human dose of DTaP was most protective (SmithKline Beecham Biologicals) 44 and that
1/4th and 1/10th of the human dose were protective yet required more time to result in
sterilizing immunity compared to a full human dose. Alvarez et al.

45

used 1/5th human

dose and supplemented with an iron regulated protein, AfuA (BP1605) and observed
modest improvement in bacteria clearance compared to 1/5th human DTaP
(INFANRIX®; GSK). In other recent studies, 1/50th human human DTaP (INFANRIX®;
GSK) was partially protective in BALB/c mice challenged with B3 lineage strain B1917
27,46.

These two studies encouraged us to determine if lowering the aP dose could allow

us to detect measurable improvements in bacterial clearance when additional antigens
improve the vaccine.
CD-1 mice were immunized mice with aP doses of 1/20, 1/40, 1/80, and 1/160th human
dose (Table S2) to titrate the vaccine and identify both the effective or non-effective
doses. These mice were challenged with B. pertussis, and viable bacteria in the lungs,
trachea, and nasal lavage were determined at 1 and 3 days post challenge (Fig. 2). At
day 1 post challenge, the 1/20th aP group had the least bacterial burden and at day 3,
both the 1/20th and 1/40th were near our detection limit (Fig. 2AB) in the lungs. A similar
trend was observed in the trachea and nasal washes (Fig. 2CDEF). However, the 1/80th
aP group had 3.5 log more viable B. pertussis in the lungs than the 1/40th aP group,
suggesting 1/80th was below the aP dose for maximum protection in CD-1 mice (Fig.
2B). The non-effective dose for trachea seemed to be higher than 1/160th (Fig. 2CD),
whereas the non-effective dose for the nasal lavage was 1/160th (Fig. 2EF). Based on
these data, we selected the 1/40th (minimal effective dose) and the 1/80th (maximal noneffective dose) to supplement with AC toxoid antigen (RTX).
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We hypothesized that neutralization of ACT in vivo would enhance bacterial clearance
and that inclusion of RTX would improve the protection provided by the 1/80th dose as
demonstrated by decreasing viable bacteria in the lung. Testing the inclusion of RTX in
the 1/40th dose would allow for evaluation of other subtler variables such as cytokines
production, phagocyte recruitment, and serology. CD-1 mice were therefore immunized
with either 1/40th or 1/80th dose aP supplemented with RTX antigen (Table S2).
Inclusion of RTX into the 1/40th aP did not affect the bacterial burden at day 3 in the
lungs (Fig. 2B) compared to 1/40th aP alone, as we predicted. When RTX was added to
1/80th aP, we saw a significant decrease in viable bacteria in the lungs at day 3 (Fig.
2B). In light of this observation, it was necessary to measure other metrics in addition to
viable bacteria to further support this finding.
In the trachea and nasal lavage, we observed the similar inverse relationship between
bacterial burden and decreasing vaccine concentration as in the lungs. In the trachea,
there was minimal improvement of bacterial clearance with inclusion of RTX to the
1/40th or 1/80th base aP. In the nares, adding RTX to 1/40th aP decreased the bacterial
burden at day 1 but this difference was not significant (p = 0.29), and no differences
were observed at day 3. Overall, these data highlight the need to consider the location
of B. pertussis in the host in respect to vaccine efficacy in a challenge trial and also the
utility of identifying sub-effective murine vaccine doses to determine if there are effects
of adding new antigens into a formulation.
Serological analysis of antibodies recognizing PT and RTX antigens.
In our aP immunization titration strategy, we expected that as the aP dose decreased,
the concentration of anti-PT in the serum of immunized and challenged mice would also
decrease. Given that mice immunized with 1/40th aP had minimal bacterial burden in all
respiratory tract locations (Fig. 2), we hypothesized that 1/40th aP would induce
production of high concentrations of anti-PT antibodies in serum. We also hypothesized
that inclusion of the RTX antigen into the 1/40th dose would result in production of
significant amount of anti-RTX antibodies. As expected, immunization with RTX in both
1/40th and 1/80th aP doses induced production of antibodies that recognize the RTX
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antigen (Fig. 3AB). Surprisingly, there was very little difference between the amounts of
detectable anti-RTX in 1/40th and 1/80th despite the fact that there was 50% less alum
adjuvant in 1/80th compared to 1/40th. We also observed that as we decreased PT
antigen and alum adjuvant by diluting the vaccine, less anti-PT was produced in
response to B. pertussis challenge (Fig.3CD). At day 1 we saw a dose response curve
for anti-PT respective of the aP dose (Fig. 3C). Anti-PT decreased as would be
expected since PT antigen and alum adjuvant are decreasing respective to the vaccine
dose.
The addition of RTX into the 1/40th and 1/80th doses significantly increased antibody
production to PT compared to same dilution of aP alone (p = 0.045 and p = 0.0039,
respectively) at day 1 post challenge. Yet these levels of anti-PT drastically decreased
at day 3 post challenge (Fig. 3D). This was a puzzling observation. There are several
possibilities to explain this phenomenon. These ELISAs are from serum samples and it
is possible that the high amounts of anti-PT have left the serum and are in the lung or
upper respiratory tract closer to where the pathogens are infecting. The second
possibility is that neutralization of ACT in vivo could decrease antibody production,
which is less required due to bacterial clearance. More kinetics studies should be
performed on these dual antigen considerations, especially with antigens like PT and
RTX which both are classified as immunogens due to their adjuvant properties.
Analysis of cytokine secretion as a function of aP immunization and inclusion of
RTX antigen.
Due to the fact that including RTX into the 1/80th aP dose helps lower the bacterial
burden in the lungs, we then characterized lung cytokine profiles to better understand
the type of immune signaling factors released during infection and their association with
bacterial clearance. To do so, we measured cytokines in lung homogenate of
vaccinated and naïve mice at 1 and 3 days post-challenge. IL-6 is one of the most
important cytokines involved in the immune response to B. pertussis. Respiratory
epithelial cells and macrophages have increased IL-6 mRNA and protein in response to
B. pertussis in vitro

47,48

and C57BL/6 mice have high IL-6 secretion in response to B.
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pertussis infection

48.

Specifically, ACT has been shown to induce IL-6 expression

49.

Furthermore, IL-6 knockout mice have increased B. pertussis burden in the respiratory
tract compared to wild type mice due to decreased recruitment of leukocytes

48.

Based

on these studies and our preliminary cytokine data (Fig. S2), we anticipated that as we
titrated the aP dose down, we would observe increased IL-6 correlating with the
increased bacterial burden (Fig. 4AB). If antibodies against RTX can neutralize ACT in
vivo, we expected to observe decreased IL-6 levels in RTX vaccinated mice. Our data
confirmed this idea at day 1, but at day 3 post challenge, RTX did not affect IL-6
secretion in the 1/80th vaccine dilution group (Fig. 4B).
IL-6 is related to induction of Th17 responses, and in the case of B. pertussis infection,
PT facilitates induction of IL-17 production typically around 7 days post B. pertussis
challenge

50.

At day 1, there were no statistically significant changes were observed in

IL-17 across the groups. However, at day 3, as the aP dose decreased, IL-17 was
slightly increased until it was significantly different at 1/160th human dose (Fig. 4D). It
was surprising to observe that naïve infected mice did not have significantly more IL-17
than mice vaccinated with the 1/160th dose. We interpret these data to mean that: 1) 1
and 3 days are early for IL-17 responses to B. pertussis as we saw biological variability
within the groups and 2) these diluted vaccines are likely capable of eliciting PTneutralizing antibodies. We did not observe any effect on IL-17 concentrations due to
including RTX into either the 1/40th or 1/80th (Fig. 4CD).
B. pertussis challenge of mice induces interferon gamma (IFN-γ) expression, which is
necessary for clearance of B. pertussis from mice

51.

Furthermore, IFN-γ receptor

deficient mice challenged with B. pertussis display atypical disease leading to
dissemination of B. pertussis and death of the mice within several weeks

52.

Since aP

immunization results in Th2 polarization, we expected that as the aP vaccine was
titrated to less effective doses, we would see an increase in IFN-γ induced by the
natural Th1 response to B. pertussis infection

53.

At day 1, the 1/40th aP and the 1/80th

aP displayed similar IFN-γ levels in the lung. However, when RTX was added to the
1/80th we observed a striking reduction of IFN-γ at day 1 only. It is also interesting to
note that naïve infected mice had lower IFN-γ than 1/40th, 1/80th, or 1/160th aP groups at
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day 1 (Fig. 4E), yet high IFN-γ was observed in the naïve infected mice at day 3 (Fig.
4F).
IL-1β mediates clearance of B. pertussis and resolution of inflammation in mice 54. IL-1β
deficient mice have high amounts of IL-17 that are observed at 7 days post challenge
and high IFN-γ at 14 days post challenge

54.

We wondered if neutralization of ACT in

vivo would alter IL-1β production in the lungs of the mice. All challenged mice had very
similar IL-1β levels at day 1 (Fig. 4G) and the levels of IL-1β were lowest in the 1/20th
aP group at day 3. Addition of RTX did not significantly decrease IL-1β which suggests
IL-1β may be induced independently of ACT activity or bacterial burden.
We measured other cytokines such as IL-5, TNF-α, KC Gro, IL-12p70, IL-10, IL-2, and
IL-4, in the lung homogenates of the vaccine groups (Fig. S3 and S4). Vaccination with
aP+RTX resulted in lower IL-5 at day 1 in both 1/40th and 1/80th groups, yet these
groups returned to base aP IL-5 levels at day 5 (Fig. S4). IL-2 followed a similar trend
as IL-5 (Fig. S4). We observed that Th1 related responses such as IFN-γ were
decreased by the addition of RTX to the aP.
Neutrophil infiltration kinetics are not affected by inclusion of RTX into the aP.
Pertussis is characterized by an increase in the number of circulating white blood cells.
This phenomenon known as leukocytosis can lead to lung hypertension and death in
the most severe cases. ACT targets the CR3 receptor expressed on many cell types
including neutrophils 55. Based on this, we hypothesize that neutralization of ACT in vivo
would alter neutrophil kinetics and recruitment profiles in the blood and airway.
Andreasen and Carbonetti reported that in naïve mice, neutrophils did not play a role in
clearance of B. pertussis from the airway 50,56. On the other hand, neutrophils played an
essential role in immune mice in the same study. Another study showed: 1) that PT
inhibited recruitment of neutrophils to the lung and neutrophils played a role in antibody
directed clearance of B. pertussis by the Fcγ receptor

57.

As the dose of the aP

decreased, we observed an increase in lung and blood neutrophils by the 1/160th
neutrophil percentages were similar to those of naïve B. pertussis challenged mice. It is
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likely that as the aP dose decreased, there was less PT neutralization due to a
decrease in anti-PT titers. Lung neutrophil populations of mice immunized with inclusion
of RTX into the 1/40th and 1/80th doses were significantly reduced (p = 0.0142 and p =
0.008, respectively) compared to mice immunized with aP only at the same doses (Fig.
5C); however, by day 3, this reduction was no longer significant because neutrophil
levels had returned to levels observed in non-challenged mice (Fig. 5D). We observed
lower circulating neutrophil populations in the blood at both days when RTX was
included compared to aP only doses (Fig. 5F) (1/40th: p = 0.018, 1/80th: p = 0.071).
Collectively, these data suggest that inclusion of RTX into the aP vaccine impacts the
neutrophil populations in the respiratory tissues and circulating neutrophils in the blood.
Decreased macrophages in the respiratory tract due to inclusion of RTX into the
aP.
Macrophages are a primary target of ACT and are readily killed by the toxin

41,43.

We

hypothesized that as ACT is neutralized in vivo, that there would be an increase in
macrophages due to their increased survival. However, our data did not support that
hypothesis, and instead we saw that both RTX supplemented aP groups had lower
macrophages in the nasal lavage at day 1 compared to aP only. Inclusion of RTX
decreased the overall numbers of macrophages in both the 1/40th and 1/80th base aP
groups (Fig. 6AB). At day 3, we observed that mice vaccinated with 1/40th , 1/80th and
1/160th aP showed increasing amounts of macrophages compared to naïve and naïve
challenged mice. As observed for other parameters measured, this effect might be due
to an induction of a naïve Th1 response due to insufficient aP driven Th2 as a result of
our decrease in aP dose.
Visualizing and modeling the relationships between: antibodies against B.
pertussis toxins, pro-inflammatory signals, phagocytes, and clearance of B.
pertussis from the murine respiratory tract.
The Kendrick test was used to establish units of efficacy for whole cell vaccines in mice
to estimate the dose to be used in humans 2. The murine intranasal infection model was
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then developed to validate aP vaccines

44,58.

Since the introduction Tdap, numerous

pre-clinical studies have been performed to evaluate new antigens or adjuvants to
improve aPs. However, we argue that there is a need for standardization of the murine
evaluation platform to facilitate the development of these formulations, and transition to
other models such as the baboon. In this study, we titrated DTaP and found a dose
(1/80th human) that was partially protective with the B. pertussis strain (UT25) and the
challenge dose of 2x107 CFU that were used. It is clear that decreases in bacterial
burden are indicative of protection; however, we aimed to visually represent all the data
collected to support our conclusions. For this comparison, we represented the increases
and decreases for each variable relative to the no vaccine / no challenge group using a
64 color scheme (Fig. 7). If the relative units increases, the color changes to red, or if it
decreases then the value is represented in blue. We then plotted the average values
per each immunization group (1/20-1/160th) in relation to the RTX supplemented
groups. As one visually compares 1/80th to 1/80th+RTX at day 1 or 3, it is apparent that
adding RTX relatively decreases all values towards the green or no relative change,
which we interpret as overall protection. It is also important to note that values at day 1
are relatively higher than day 3 and this relates to the fact that the total amount of
bacteria are decreasing. The amount of anti-PT or anti-RTX is shown in black to grey to
white color scale (Fig. 7). There is a clear correlation with amount of anti-PT and overall
protection. In addition, it is interesting to see that inclusion of RTX enhanced the anti-PT
levels in the aP+RTX groups. Overall, variables associated with inflammation such as
cytokines or phagocytes tend to return to green or naïve non-infected levels in mice
vaccinated with aP+RTX. We only observed five relatively large decreases (indicated in
blue). The 1/20th aP group had relatively lower KC/GRO which could be associated with
the anti-inflammatory Th2 response due to the high amount of alum in the immunized
mice. We also saw a relative decrease in number of macrophages present in the nasal
wash at day 3 in the naïve group. This decrease could be attributed to high amounts of
PT and ACT secreted during infection which could be impairing normal macrophage
recruitment in the airway. We also saw large relative decreases in macrophages in the
RTX supplemented 1/40th and 1/80th groups at day 3 and reasons for these changes
were described above. Combining these data allow us to consider the overall
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inflammatory response in relation to the vaccination status, to further demonstrate the
effects of including RTX into aP formulations, and to begin to establish a multi-variable
approach to determining efficacy of experimental vaccines in the mouse.
Discussion
There is a resurgence of whooping cough that coincides with the switch to the use of aP
vaccines. In this study, we aimed to accomplish two goals. First, we sought to define an
aP vaccine dose, or doses, that allow the evaluation of synergy between the current aP
and potential new antigens. The second goal was to evaluate RTX as an antigen for
inclusion in acellular pertussis vaccines in the murine challenge model. As a result of
these studies, we now better appreciate the need to continue to refine the
methodologies of improving aP vaccines.
We initiated this study by evaluating the efficacy of ACT and RTX as single vaccine
antigens. Immunization with ACT or RTX alone did not induce significant protection in
CD-1 mice with the UT25 B. pertussis challenge strain (Fig. 1). The AC domain of ACT
was first described as a protective antigen by Guiso et al

17.

In that study, the antigen

preparation that was used consisted of two polypeptides of 43 and 45 kDa. We now
know that these polypeptides corresponded to the AC domain of ACT. In those studies,
BALB/c mice were vaccinated twice with AC polypeptide absorbed on aluminum
hydroxide adjuvant and it was observed that 80% of the AC-vaccinated mice survived B.
pertussis challenge with strain 18323

17.

The aforementioned study was then further

supported by a subsequent study by the same group that showed the protective
capacity of the AC domain and full length recombinant ACT protein

35.

Several more

studies showed that: 1) CyaC acylation of ACT was required for the protective activity 18
and 2) that the C-terminal domain was also required for protection with recombinant
ACT. Full length recombinant ACT was protective when 15 µg of antigen were mixed
and absorbed with 250 µg of alum 19. We used less antigen and adjuvant than Betsou et
al. (either 10 µg of ACT or 5.6 µg of RTX with 125 µg of alum) and we did not observe
protection in CD-1 mice (Fig. 1A), and the use of the MPLA adjuvant did not improve
bacterial clearance compared to alum. An apparent difference between our study and
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that of Betsou et al. is that strain 18323 was used, which has been suggested to be an
outlier compared to most other global B. pertussis strains. Guiso et al. noted that strain
18323 produces less PT than the Tohama I type strain

35.

From our own studies, we

know that UT25 produces more PT and ACT than Tohama I (data not shown). This
information highlights the importance of the challenge strain. Another caveat of our
study is that Betsou et al. absorbed the ACT antigen to alum, which we did not with
RTX. It is possible that absorbing RTX to the aP could further enhance the synergistic
protection observed in this study when RTX was combined with the alum-containing aP.
Another key aspect to consider is the potential endotoxin contamination in recombinant
ACT preparations. Villarino et al. used recombinant ACT but did not observe the same
bacterial clearance as Betsou et al. 19. ACT used by Cheung et al. was highly purified of
endotoxin

21,

as was the RTX that we used in this study 9. It is possible that endotoxin

levels in ACT preparations may influence the overall protection afforded by such
antigens as they may induce a more Th1-biased response.
Several of the aforementioned studies indicated that single antigen vaccines containing
ACT were protective but the study by Cheung et al. and our RTX-only study (Fig. 1)
were not in concordance. Other recent studies testing single antigen vaccines
composed of proteins expressed during biofilm or in response to iron starvation showed
that very few of these single antigen formulations were protective on their own

27,46.

Given that the aP antigens of either DTaP or Tdap (PT, FHA, PRN, and +/- FIM) do
provide some protection against disease, we hypothesize that new antigens to be
included in the aP should be tested not only alone, but also in combination with aP
antigens. Only one study has investigated ACT as an antigen in combination with the
aP in mice

21.

Cheung et al. reported that adding 12.5 or 25 µg to 1/8th aP, significantly

decreased bacterial burden in mice at 7 days post challenge with strain 18323

21.

PT

and FHA are formulated in the DTaP (INFANRIX®) at 25 µg each in 1 human dose.
Therefore, the use of 25 µg ACT is roughly equal to 1 human dose of antigen (assuming
no adjustment for molar mass of each antigen). We chose to test the utility of RTX
antigen with lower antigen doses in an effort to best model what would be scaled
towards a commercial vaccine dose. To do so, we identified a partially protective dose
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of aP, so synergistic effects of addition of the antigen to be tested. We titrated the aP
vaccine from 1/20th to 1/160th human dose. As decreasing aP doses were tested, we
saw an increase in innate immune responses to levels observed in naïve challenged
mice (Fig. 7). From the bacterial burden in the lung, we determined that 1/40th dose of
aP is protective, while 1/80th is only partially protective. However, it is important to note
that 1/40th aP immunization was non-protective in the nares at day 1, but at that dose,
B. pertussis was cleared by day 3 (Fig. 2EF). These data show that the protective
capacity of an aP dose in the mouse is dependent on the location in the airway and the
time elapsed since B. pertussis challenge. Using total clearance in all locations, 1/40th
aP immunization results in sterilizing immunity against our challenge dose as observed
at three days post challenge. Based on these data, we selected the 1/40th (minimal
effective dose) and the 1/80th (maximal non-effective dose) to supplement with AC
toxoid antigen (RTX).
We identified the 1/80th aP dose that would allow us to tease out RTX antigen effects
that would otherwise be masked by the use of a high mouse to human aP dose (e.g.
1/5th). With the 1/80th aP dose, it is clear that innate responses are occurring due to the
lack of protection provided by the immunization. We hypothesize that decrease in innate
responses would correlated with induction of antibody production that either: neutralizes
the effects of the pathogen (e.g. toxins: PT or ACT) or results in killing of the pathogen
(e.g. opsonization, phagocytosis, or complement killing). We were able to detect
antibodies that recognized RTX (Fig. 3AB) and we saw that adding RTX enhanced
production of anti-PT (Fig. 3A). When we supplemented the 1/80th aP dose with RTX,
we were able to observe positive effects on the response to B. pertussis challenge such
as decreased: bacterial burden (Fig 2B), IL-6 secretion (Fig. 4A), IFN-γ (Fig. 4E), IL-5
(Fig. S4), IL-2 (Fig. S4). We speculate that the neutralization of ACT in vivo leads to a
decrease in the innate immune responses at day 1 post challenge, but at day 3, the
levels of these pro-inflammatory cytokine were not affected by the inclusion of RTX (Fig.
4BF and S4). We observed that B. pertussis challenge increased neutrophil levels in the
nasal lavage and that these levels were not reduced to non-challenged levels during our
study (Fig. 5AB). Neutrophils in both the nares and lungs were overall decreased by day
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3 post challenge in the RTX supplemented groups. Adding RTX antigen to the 1/40th
and 1/80th vaccines decreased the total neutrophils in the lungs at day 1 and same
trend was observed for blood neutrophils (Fig. 5EF). Interestingly, we observed that
adding RTX to aP (1/40th nor 1/80th) did not affect nasal neutrophils amounts (Fig. 5AB).
We speculate that ACT may have specific effects in the lung and not in the nares of
mice, but more experiments are necessary test this hypothesis.
ACT can induce apoptosis in macrophages

59

and it is also known that IL-12 production

by macrophages plays a role in vaccine-mediated clearance of B. pertussis

60.

We

measured the number of macrophages in the lungs and nasal lavages of aP or RTX
supplemented aPs and saw less macrophages when RTX was added to the aP (Fig.
6ABCD). This data was somewhat counterintuitive but Skopova et al. have shown that
cAMP signaling and hemolysin activity synergize and provoke PMN and macrophage
influx into the lungs

12.

Our macrophage observations suggest anti-RTX may be

neutralizing ACT in vivo. There are also two more possibilities: 1) there may be less
macrophage recruitment because there are less bacteria or 2) if macrophages are less
impaired (due to ACT neutralization), they may be effectively migrating to the lymph
nodes to present antigens. At this point, we do not have sufficient data to fully
understand the relationships between the amount of macrophages in the airway and if
that is an indication of protection and/or an effect of ACT neutralization.
B. pertussis strains have evolved in response to aP immunization
longer expressed by circulating B. pertussis strains
was isolated and sequenced that lacked PT

63.

62

61.

Pertactin is no

and recently, a B. pertussis strain

B. parapertussis is not capable of

expressing PT 64 but causes as many as ~15% of whooping cough cases. B. holmesii is
an underappreciated pathogen that cause whooping cough-like illness and does not
express PT

65.

In addition, there are unpublished reports of strains sequenced by the

CDC that lack expression of filamentous hemagglutinin. Given the potential rise of triple
mutant strains that do not make pertactin, FHA, or PT, it is possible that the efficacy of
aP protection will further decline if strains arise that lack the main antigens that most aP
vaccines contain. Based on these possibilities, we propose that adding additional
antigens that are both immunogenic and important for bacterial virulence is necessary
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to slow the progression of B. pertussis evolution

66,

and the resistance to aP-mediated

immunity.
We aimed to investigate ACT as a vaccine antigen and we developed a new evaluation
approach involving analysis of multiple correlates of protection (Fig. 7). Our data
suggest that RTX antigen may enhance protection of aP vaccines, based on what we
observed in CD-1 mice. The different protection levels observed in each of the regions
of the airway (nares, trachea, and lungs) suggest that it may also be advantageous to
consider the development of mucosal B. pertussis vaccines. This would allow for the
pathogen to be neutralized rapidly in the upper airway before infection is fully
established when highly potent PT and ACT are impairing the innate and adaptive
immune responses. Higgs et al.

67

proposed that aP vaccines containing antigens that

direct a more diverse response, may be more effective. While we have focused on
adding RTX to a Th2 inducing aP, it would be very interesting to formulate and test RTX
containing vaccines with Th1 adjuvants. Neutralization of ACT along with a cellular
response would likely be an ideal protection profile and possibly address the waning
protection issue of the aP. Our study was focused on RTX but there are other
candidates that should be evaluated as well. Our study highlights the importance of
titrating the vaccine dose and we expect this will provide new methodologies for the
development of pertussis vaccines. Significant research is still necessary to formulate
and evaluate safe and more effective next generation pertussis vaccines, which could
include ACT as an antigen.
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Figures
Figure 1. RTX only immunization does not protect against B. pertussis challenge
in CD-1 mice nor does including RTX with 1/5th aP improve clearance kinetics but
ACT neutralizing antibodies are produced.

Fig
ure 1. RTX only immunization does not protect against B. pertussis challenge in
CD-1 mice nor does including RTX with 1/5th aP improve clearance kinetics but
ACT neutralizing antibodies are produced. (A) CD-1 mice were vaccinated with PBS
vehicle, 1/5th human dose of aP, RTX (5.6 µg) + MPLA (20 µg), RTX (5.6 µg) + Alum
(125 µg), or PBS as control vehicle (naïve)(n=4, with 4 technical replicates). Mice were
IN challenged with 2x107 Bp (UT25Sm1). At days 1 and 3 pc the bacterial burdens were
determined by culturing of homogenates of the lungs on BG agar. The dashed line
represents the lower limit of detection due to plating. Bacterial loads in mice vaccinated
with aP were significantly lower than the PBS control group at day 1 (p = <0.0001) and
day 3 (p = <0.0001) in the lung. (B) CD-1 mice were vaccinated with PBS control
vehicle, wP, aP, aP + ACT or aP + RTX and challenged intranasally with UT25Sm1
(n=4, with 4 technical replicates). Mice vaccinated with aP, aP+ACT, and aP+RTX had
a significantly lower bacteria burden than the PBS control group at day 1 (p <0.0003, p
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<0.0006, p <0.0013) in the lung. Bacterial loads in all immunized mice were significantly
lower than PBS group at day 3 and 8 (p <0.0001; all groups) in the lung. Data in each
group were compared to every other group at day 1, 3, or 8 pc using one-way ANOVA
with Tukey’s post hoc test. (C) Serum from vaccinated/challenged mice was used to
determine if ACT neutralizing antibodies were produced following RTX or ACT inclusion
in aP vaccine by adenylate cyclase toxin neutralization assay. J774A.1 macrophages
were cultured with active ACT, and serum from mice. Neutralization of ACT results in
increase of macrophage survival. Serum from vaccinated mice with aP+ACT and
aP+RTX resulted in neutralization of ACT, compared to unvaccinated, aP, and wP
groups. Results are shown as mean ± SEM, ****, p<0.0001 *** p< 0.001 by one-way
ANOVA.
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Figure 2. Respiratory tract bacterial burden of CD-1 mice immunized with aP
vaccines or aPs supplemented with RTX antigen.

Figure 2. Respiratory tract bacterial burden of CD-1 mice immunized with aP
vaccines or aPs supplemented with RTX antigen. Immunization with 1/20th, 1/40th,
1/80th, and 1/160th of human dose aP was used to titrate the minimal effective dose and
the maximum non-effective dose. RTX (5.6 µg) was included into 1/40th and 1/80th aP
doses. Vaccinated CD-1 mice were challenged with 2 x 107 Bp, and bacterial burden
was determined at days 1 and 3. CFU counts were determined from (AB) lung
homogenate, (CD) trachea homogenate, and nasal lavage (EF). Results are mean ±
SEM (n=4-8, with 4 technical replicates) from independent experiments, ****, p<0.0001
*** p< 0.001, **p<0.01, * p<0.05 determined by one-way ANOVA with Tukey post hoc
test compared to naïve mice (PBS control). The dashed line represents the lower limit of
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detection due to plating. The blue boxes indicate aP groups whereas aP+RTX are
indicated by gold triangles. Gray squares indicate mock vaccinated, and challenged
mice. In E and F there were no statistically significant comparisons between the aP
titration doses as determined by ANOVA.
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Figure 3: Serological responses from mice immunized with aP titrations or aPs
supplemented with RTX.

Figure 3: Serological responses from mice immunized with aP titrations or aPs
supplemented with RTX. (AB) ELISA was used to determine the anti-RTX IgG titers in
serum of immunized and challenged mice at 1 and 3 days pc. (CD) Anti-PT IgG titers in
serum of immunized and challenged mice at indicated time points. Titrations of aP were
compared by one-way ANOVA with Tukey’s post hoc test, shown below graphs and
compared to PBS group. Unpaired two-way T test was used to compare addition of RTX
to aP titrations, shown by brackets. Results plotted on graph are mean ± SEM, *** p<
0.001 **p<0.01, *p<0.05.
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Figure 4: Analysis of proinflammatory cytokines from lungs of mice immunized
with aP titrations or aPs supplemented with RTX.
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Figure 4: Analysis of proinflammatory cytokines from lungs of mice immunized
with aP titrations or aPs supplemented with RTX. Th1 associated cytokines from
supernatant of lung homogenates analyzed at days 1 and 3 pc. Cytokines (AB) IL-6,
(CD) IL-17, (EF) IFN-γ, and (GH) IL-1β. The blue boxes indicate aP groups whereas
aP+RTX are indicated by gold triangles. Gray squares indicate mock vaccinated, and
challenged mice, while white squares represent non-vaccinated and non-challenged
mice (NC). Results are mean ± SEM, **** p<0.0001, *** p< 0.001, *p<0.05 by one-way
ANOVA with Tukey post hoc test compared to PBS (naïve) but challenged mice.
Brackets between two points represent unpaired two-way T test. Dashed line indicates
upper limits of detection, and dotted line indicates lower limit of detection.
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Figure 5: Flow cytometric analysis of blood, pulmonary, and nasal lavage
neutrophils from mice immunized with aP titrations or aPs supplemented with
RTX.

Figure 5: Flow cytometric analysis of blood, pulmonary, and nasal lavage
neutrophils from mice immunized with aP titrations or aPs supplemented with
RTX. Quantification of the percentage of live, single cells that were classified as
neutrophils (GR-1hiCD-11b+) from (AB) nasal lavage, (CD) lung homogenate, or (EF)
blood. Results are mean ± SEM, *** p< 0.001 ,** p<0.01, *p<0.05 by one-way ANOVA
with Tukey post hoc test compared to PBS (naïve) but challenged mice. Brackets
between two points represent unpaired two-way T test.
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Figure 6: Flow cytometric analysis of macrophages from lung and nasal lavage of
mice immunized with aP titrations or aPs supplemented with RTX.

Figure 6: Flow cytometric analysis of macrophages from lung and nasal lavage of
mice immunized with aP titrations or aPs supplemented with RTX. Percentage of
macrophages (defined as CD-11b+F4/80+) from live, single cells from (AB) nasal lavage
and (CD) single cell suspension prepared from lung homogenate. Results shown are
mean ± SEM, *p<0.05 by one-way ANOVA with Tukey post hoc test compared to PBS
(naïve) but challenged mice. Brackets between two points represent unpaired two-way
T test.
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Tables
Table 1: Composition of vaccines for Fig. 1
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Table 2: Composition of vaccines used in the titration of aP and RTX
supplementation studies
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Supplemental Figures
Figure S1. RTX only nor RTX supplemented aP immunizations alter B. pertussis
clearance in CD1 mice.

Figure S1. RTX only nor RTX supplemented aP immunizations alter B. pertussis
clearance in CD1 mice. (A-B) CD1 mice were vaccinated with PBS vehicle, aP, RTX
adjuvanted with alum or MPLA and challenged intranasally with B. pertussis strain
UT25. At days 1 and 3 post challenge the bacterial burdens were determined by
culturing of nasal wash, homogenates of trachea on Bordet Gengou (BG) agar.
Experiments were performed with 4 mice per group with 4 technical replicates. The
dashed line represents the lower limit of detection. (CD) CD1 mice were vaccinated with
PBS control vehicle, wP, aP, aP + ACT or aP + RTX and challenged intranasally with
UT25. At days 1, 3, and 8 post challenge the bacterial burdens were determined.
Experiments were performed with 4 mice per group with 4 technical replicates.
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Figure S2. Mouse inflammatory cytokine array of lung homogenate supernatant.

Figure S2. Mouse inflammatory cytokine array of lung homogenate supernatant.
Lung homogenate supernatant from 4 mice in each group were pooled and used to
probe membranes labelled with antibodies for 40 inflammatory cytokines. Pseudocolor
image of day 3 cytokine production are shown in duplicate. The control group is not
challenged with B. pertussis.

125

Figure S3. Cytokine analysis of lung homogenates of CD1 mice immunized with
various aP doses and supplemented with RTX antigen.

Figure S3. Cytokine analysis of lung homogenates of CD1 mice immunized with
various aP doses and supplemented with RTX antigen. Lung homogenates were
collected from mice of each of the groups indicated and the concentration of each
cytokine indicated was determined. Minimal detection limits are indicated. Error bars
show standard error of the mean. The blue boxes indicate aP groups whereas aP+RTX
are indicated in gold.
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Figure S4. Cytokine analysis of lung homogenates of CD1 mice immunized with
various aP doses and supplemented with RTX antigen.

Figure S4. Cytokine analysis of lung homogenates of CD1 mice immunized with
various aP doses and supplemented with RTX antigen. Lung homogenates were
collected from mice of each of the groups indicated and the concentration of each
cytokine indicated was determined. Minimal detection limits are indicated. Error bars
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show standard error of the mean. The blue boxes indicate aP groups whereas aP+RTX
are indicated in gold.
Figure S5: Serological responses from mice immunized with aP titrations or aPs
supplemented with RTX.

Figure S5: Serological responses from mice immunized with aP titrations or aPs
supplemented with RTX. (AB) ELISA was used to determine the anti-RTX IgG levels
in serum of immunized and challenged mice at 1 and 3 days pc. (CD) Anti-PT IgG levels
in serum of immunized and challenged mice at indicated time points. Antibody
concentration (µg/ml) represented were determined using relative EC50. Serum
absorbance values were logarithmically plotted to known antibody standards using a
four-parameter logistic curve. Relative EC50 was then determined by fitting serum
concentration to dilutions of samples using a four-parameter logistic curve. Titrations of
aP were compared by one-way ANOVA with Tukey’s post hoc test, shown below
graphs. Unpaired two-way T test was used to compare addition of RTX to aP tritrations,
shown by brackets. Results plotted on graph are mean ± SEM, *** p< 0.001 **p<0.01,
*p<0.05.
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Figure S6

A

B

C
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Figure S6. Representative images and gating strategy for neutrophils from blood
of CD1 mice immunized with various aP doses and supplemented with RTX
antigen. (A) Cells were first gated on live, single cells. Then classified as either (B)
neutrophils (CD11b+Gr-1Hi) or (C) macrophages (CD11b+F4/80+). Quadrants
demonstrate positively labeled cells determined by single label controls marker flow
cytometry controls. Region of interest shows neutrophil population (Gr-1+CD11b+).
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Figure S7. Heat map modeling of the effects of base aP dose and
supplementation of RTX antigen on correlates of protection in mice.

Figure S7. Heat map modeling of the effects of base aP dose and
supplementation of RTX antigen on correlates of protection in mice. In order to
understand the key variables collected in this study, in relation to base aP dose and the
effects of adding RTX, we developed a heat map that shows the relative increase or
decrease of each variable. The color scale indicates relative changes in bacterial
burden, cytokines, or phagocytes whereas the black-grey-white scale indicates relative
toxin specific antibodies in the serum of each group.
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Abstract
Current acellular pertussis vaccines fall short of optimal protection against the human
respiratory pathogen Bordetella pertussis

resulting in increased incidence of a

previously controlled vaccine preventable disease. Natural infection is known to induce
a protective mucosal immunity. Therefore, in this study, we aimed to use acellular
pertussis vaccines to recapitulate these mucosal immune responses. We utilized a
murine immunization and challenge model to characterize the efficacy of intranasal
immunization (IN) with DTaP vaccine or DTaP vaccine supplemented with curdlan, a
known Th1/Th17 promoting adjuvant. Protection from IN delivered DTaP was compared
to protection mediated by intraperitoneal injection of DTaP and whole-cell pertussis
vaccines. We tracked fluorescently labeled DTaP after immunization and detected that
DTaP localized preferentially in the lungs while DTaP with curdlan was predominantly in
the nasal turbinates. IN immunization with DTaP, with or without curdlan adjuvant,
resulted in anti-B. pertussis and anti-pertussis toxin IgG titers at the same level as
intraperitoneally administered DTaP. IN immunization was able to protect against B.
pertussis challenge and we observed decreased pulmonary pro-inflammatory cytokines,
macrophage and neutrophil infiltrates in the lung, and bacterial burden in the upper and
lower respiratory tract at day 3 post challenge. Furthermore, IN immunization with DTaP
triggered mucosal immune responses such as production of B. pertussis-specific IgA,
and increased IL-17A. Together, the induction of a mucosal immune response and
humoral antibody-mediated protection associated with an IN administered DTaP and
curdlan adjuvant warrant further exploration as a pertussis vaccine candidate
formulation.
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Introduction
Pertussis is a human upper respiratory disease, primarily caused by the Gram-negative
pathogen Bordetella pertussis. The disease is most severe in unvaccinated infants,
where it manifests as fits of paroxysmal coughs followed by the classical whoop as air
re-enters the respiratory system, leading to the more commonly known name: whooping
cough.1 Additional complications include vomiting, increased mucus production, and
apneic episodes. In severe cases, these symptoms can lead to elevated leukocytosis,
pulmonary hypertension, hypoxia, and in some cases death.1–3 Furthermore there is
speculation that pertussis may enhance development of neurodegenerative diseases
later in life.4
In the pre-vaccine era, pertussis was responsible for 200,000 deaths annually in the
United States.5 Widespread use of diphtheria tetanus whole-cell pertussis (DTP; wP)
vaccines controlled the incidence of pertussis.6 However, adverse side effects
associated with wP immunization1 led to the development of an acellular pertussis
vaccine (DTaP; aP) that was introduced into the schedule in 1996. In the United States
the number of pertussis cases has been increasing since the 1990s, despite high
vaccine coverage.7 Additionally, increasing numbers of cases have been documented in
older children, adolescents and adults.8 The increase in incidence of pertussis cases
suggests that current aP vaccines do not offer complete protection from B. pertussis
infection. Multiple hypotheses have been proposed explaining the resurgence of
pertussis cases including: (1) waning of protective immunity from DTaP/tdap9–11, (2)
vaccine driven evolution of B. pertussis strains12, (3) increased carriage and
transmission through asymptomatic carriers13, and (4) increased surveillance and more
accurate diagnoses technology.
Vaccine-induced protection in aP immunized individuals has been associated with a
robust antigen-specific IgG response to the components of the aP vaccines.14–17
Likewise, wP immunization also resulted in antigen-specific IgG responses; with the
addition of a shift to a more diverse T cell response, inducing cell-mediated immunity.18
In the murine model, immunization through intramuscular (IM) and intraperitoneal (IP)
administration has been well characterized demonstrating a Th1/Th17 response from
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wP immunized mice, and a Th2 with weak Th17 mediated response in aP immunized
mice following B. pertussis challenge.19 However, these immunizations fail to induce the
mucosal immune responses elicited from natural infection. Recent studies have
revealed that protection correlates with tissue resident memory T (TRM) cells in the lung
and nasal cavity of convalescent mice, that produce interleukin-17 (IL-17) and
interferon-gamma (IFN-γ).20 TRM cells have been shown to persist in the respiratory
tissue and expand upon re-challenge of a convalescent mouse with B. pertussis, as well
as decrease bacterial burden upon adoptive transfer to naïve mouse.21 The study of this
population has renewed interest in the induction of a mucosal immune response
capable of decreasing bacterial burden at the site of infection.
The induction of a mucosal immune response to B. pertussis is associated with the
production of secretory IgA antibodies (sIgA) in the nasal cavity. In humans previously
infected with B. pertussis, IgA antibodies have been isolated from nasal secretions.22 B.
pertussis-specific IgA antibodies isolated from convalescent patients have been shown
to inhibit adherence of B. pertussis to respiratory epithelial cells in vitro23, suggesting a
protective role of IgA antibodies in mucosal immunity. Initial studies using IgA-deficient
mice did not show strong support for a critical role in bacterial clearance of the
respiratory tract.24 However, work with a live-attenuated IN pertussis vaccine (BPZE1)
recently demonstrated protective role of sIgA antibodies in the respiratory tract.25
DTaP vaccine does not contain a strong pro-inflammatory adjuvant such as endotoxin
of wP vaccine or BPZE1. We aimed to investigate IN DTaP immunization alone or with
an additional pro-inflammatory adjuvant. We formulated vaccines containing the
adjuvant curdlan, a 1,3 β-glucan, derived from Alcaligenes faecalis. This polysaccharide
has immunostimulatory properties and forms a “sticky” gel at a neutral pH. Importantly,
curdlan has been shown to bind to dendritic cells through the ligand Dectin-1, thereby
inducing expression of NF-κB26 leading to a Th1/Th17 mediated immune response as
well as production of antigen-specific respiratory IgA antibodies and serum IgG
antibodies.

26–29

Our objective was to determine whether IN DTaP immunization would

induce a protective immune response in a murine model. We observed that the gel
properties of curdlan facilitated DTaP localization in the upper respiratory tract. We
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measured serum and respiratory antibody responses that correlated with protection
from bacterial challenge. This study suggests mucosal vaccination with acellular
vaccine may be a strategy for decreasing incidence of pertussis.
Results
Acellular pertussis vaccine was retained in the upper and lower respiratory tract when
administered by intranasal administration.
Pertussis toxin facilitates infection by disrupting innate immune responses in the airway.
30

Therefore, we hypothesized that neutralization of pertussis toxin at the site of

infection is essential for protection against B. pertussis. We propose that intranasal
immunization would prime a protective mucosal immune response. Furthermore, the
gel-like properties of curdlan may have a beneficial role in increasing antigen uptake. To
determine if use of curdlan would increase vaccine retention in the respiratory system,
we IN vaccinated CD-1 mice with commercially available DTaP (IN-aP), DTaP with
curdlan (IN-caP), or PBS (mock vaccinated) and tracked the vaccine up to 48 h after
vaccination (Fig. 1a). Using in vivo animal imaging, we observed fluorescently labeled
DTaP particles in the nasal cavity at 6, 12 and 24 h post-vaccination (Fig. 1b). At 12 h
post-vaccination, we detected significantly higher levels of fluorescence in IN-caP
vaccinated mice compared to IN-aP mice (Fig. 1c), suggesting more DTaP particles
were retained in the nasal cavity. This method resulted in the quantification of total
particles in nasal cavity. To quantify DTaP particles that were bound to innate immune
cells we utilized flow cytometry. Single-cell suspensions were prepared from
homogenized lung tissue and antigen presenting cells (APCs) bound to DTaP were
quantified as live, single cells positive for CD11b+DTaP+ (Fig. 1d). We observed a
significant increase in CD11b+ cells that were bound to or contained DTaP particles in
IN-aP mice compared to IN-caP (Fig. 1e). Together, these data suggest a higher
deposition of DTaP in the lung with IN-aP when compared to IN-caP. Conversely, in the
nasal cavity we measured higher levels of DTaP when mice were vaccinated with INcaP, compared to IN-aP. These findings suggest that addition of curdlan to the DTaP
vaccine causes retention in the nasal cavity, but without it, the vaccine components are
more readily detected in the lung.
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To visualize the deposition of DTaP particles, sections from the lung and nasal cavity
were imaged using confocal microscopy. Vaccinated mice were euthanized after 6 h,
lung tissue was flash frozen and skulls were embedded in paraffin for sectioning.
Sections from the lung and nasal cavity were counterstained with NucBlue and
ActinGreen to visualize epithelial tissue and fluorescent DTaP particles (Fig. 2ac).
Vaccine particles were quantified by measuring the percentage of total image field
emitting DTaP fluorescence. We detected a significant increase of fluorescent particles
in the lungs of mice that were vaccinated with IN-aP compared to IN-caP (Fig. 2b).
Using microscopy, there was no significant difference in the number of particles
detected in the nares comparing IN-aP to IN-caP (Fig. 2d). Interestingly, we observed
that DTaP particles from the IN-aP vaccinated mice were localized in the lumen of the
nasal passages, while particles from IN-caP vaccinated mice were deposited into the
epithelial cells (Fig. 2c). Overall these data suggest curdlan impacts localization of
DTaP in the airway.
Intranasal immunization induces production of anti-PT and anti-FHA IgG in serum
To determine vaccine induced protection, we utilized an established vaccine and
challenge protocol.31 CD-1 mice were immunized IN with either IN-aP or IN-caP. These
groups were compared to pertussis immunizations that are known to be protective:
DTaP (IP-aP) and whole-cell pertussis (IP-wP) administered intraperitoneally (IP).
Additionally, we aimed to determine if the effects of curdlan were dependent by route,
thus we included mice immunized with IP delivered DTaP and curdlan (IP-caP). Lastly,
we compared the findings to mock vaccinated mice, with IN delivered PBS, or mice IN
immunized with curdlan only (IN-curdlan). All mice were immunized with 1/12th of the
antigen load contained in the human vaccine dose. Mice were vaccinated at day 0, then
received a booster vaccine at day 21. Mice were challenged on day 35 with B.
pertussis.
We first sought to determine if an IN delivered DTaP vaccine would induce a systemic
immune response. To answer this, we performed enzyme-linked immunosorbent assays
(ELISAs) with serum from vaccinated and challenged mice against B. pertussis antigens
found in the vaccine: pertussis toxin (PT) and filamentous hemagglutinin (FHA). We did
143

not detect a significant difference in serum IgG titers between collection timepoints at
days 1 and 3 post challenge (pc) (data not shown). Serum anti-PT IgG titers were
similar between mice immunized with IP-aP and those immunized through IN
administration, as no significant differences were determined between IP-aP, IN-aP or
IN-caP (Fig. 3a). Similarly, we observed a robust titer response to the bacterial adhesin
FHA in IN vaccinated mice; however, IN-aP serum anti-FHA titer was 7-fold higher than
IN-caP (Fig. 3b). We next determined if IN administration of DTaP (with or without
curdlan) would lead to an increased Th1 immune response resulting in a higher ratio of
IgG2a compared to IgG1 antibodies. Neither route nor adjuvant impacted the ratio of
IgG2a to IgG1.
Intranasal immunization induces production of anti-B. pertussis IgA in lung
In the murine model, recent data has pointed to the importance of IgA and a local
mucosal immune response in the lung and nasal cavity.32–36 We aimed to measure the
presence of IgA antibodies in the murine respiratory tissue due to IN immunization.
Using ELISAs we measured B. pertussis specific IgA titers in homogenized lung tissue
supernatant and nasal lavage fluid. Interestingly, we detected a robust IgA response in
the lung only when mice were immunized through the IN route (Fig. 4a). Antigenspecific IgA response was not observed in mice immunized with curdlan alone. We
observed detectable IgA B. pertussis-titer in the nasal lavage fluid from both IN-aP and
IN-caP vaccinated groups, although only IN-aP resulted in a significant increase
compared to baseline levels (Fig. 4b). The presence of B. pertussis binding IgA in the
lungs and nasal cavity suggests that IN DTaP is capable of priming a mucosal immune
response in the upper and lower murine respiratory systems.
Intranasal immunization decreased pulmonary pro-inflammatory environment
It has been well established that neutralization of PT and inhibition of bacterial adhesins
associated with DTaP protection leads to a markedly reduced pro-inflammatory
environment at the site of infection when compared to a natural infection.17 Conversely,
challenge in whole-cell protected animals resulted in a severe pro-inflammatory
response, similar to the natural infection of B. pertussis.

37

We hypothesized that the

immunostimulatory properties of curdlan would induce a more pro-inflammatory
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response following challenge with B. pertussis compared to IP-aP. Cytokine
concentrations were determined from supernatant of lung homogenate at day 3 pc. The
pro-inflammatory interleukin-6 (IL-6) has been shown to be increased following B.
pertussis infection of a naïve mouse, while DTaP induced protection drastically
decreases IL-6 production.31,38 Our results demonstrate a significant reduction of IL-6 in
the lungs of either IN-aP or IN-caP immunized mice when compared to mock
vaccinated or IN-curdlan control mice, and are comparable to levels observed in IP
immunized groups (Fig. 5a). We measured a similar reduction in the Th1 associated
cytokine IFN-γ in the IN administered groups, IN-aP and IN-caP; although, these levels
were higher in IN-caP immunized mice (Fig. 5b). We only observed a significant
increase in the Th2 associated interleukin-5 in IN-wP immunized mice compared to
mock vaccinated mice (Fig. 5c).
IN administration of curdlan, and moreover, vaccine administration through the IN route
regardless of adjuvant has been shown to induce an increased IL-17 response.27,28
Thus, we hypothesized that we would observe increased levels of IL-17 in mice
immunized with IN-caP compared to IN-aP or IP-aP. We quantified IL-17A in lung
supernatant and observed significant increases of IL-17A with the addition of curdlan in
IP-caP and IN-caP immunized mice supporting our hypothesis (Fig. 5d). Furthermore,
we observed that IN administration induced a significant increase in IL-17A compared to
IP immunization. This IL-17A response was lower than the robust IL-17A induced by IPwP (Fig. 5d).
Natural infection with B. pertussis is known to cause severe leukocytosis in the murine
model39, which can be measured by elevated neutrophils in the peripheral blood.
Following B. pertussis challenge, we observed that all vaccinated groups ameliorated
symptoms of leukocytosis; however, only the administration of DTaP either by IP or IN
administration significantly reduced CD11b+Gr-1hi neutrophils in the peripheral blood
(Fig. 6a). In the lungs, neutrophils were decreased in IN-aP, IN-caP, and IP-aP
immunized groups compared to mock vaccinated mice. We observed a similar finding
in pulmonary macrophages, although we only determined a significant decrease in mice
immunized with IN-caP compared to mock vaccinated mice (Fig. 6c). Taken together
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these data suggest that immunization with DTaP through the IN route reduces the proinflammatory environment of the murine lung during B. pertussis challenge.
Intranasal immunization reduced respiratory B. pertussis bacterial burden.
Lastly, we examined the clearance of B. pertussis from the respiratory tract following IN
immunization. At days 1 and 3 pc, viable bacterial burden was quantified by counting of
CFU in the lung, trachea, and nasal lavage fluid. We observed a significant reduction in
viable bacteria recovered from the lung in all immunized groups by day 3 pc; however,
these changes were not observed at day 1 pc (Fig. 7ab). IN-aP and IN-caP immunized
mice bacterial burdens were reduced by 99.4% and 99.7%, respectively, compared to
mock vaccinated mice. This reduction in viable bacterial burden was similar to that of
mice immunized by IP-aP, an immunization that is known to be effective (Fig. 7b).
Importantly, this reduction in bacterial burden was not observed following immunization
with curdlan alone, further suggesting an antigen-specific response. Similar trends were
observed in the trachea homogenate (Fig. 7cd), and nasal lavage fluid (Fig. 7ef), as all
immunized groups regardless of IP or IN delivery cleared B. pertussis to the limits of
detection. In summary, we observed similar clearance of B. pertussis from the
respiratory tract of mice immunized IN compared to mice immunized with vaccines
known to be protection delivered by the IP route.
Discussion
The natural immune response to B. pertussis is initiated by the colonization of the
respiratory tract, which leads to a cascade of inflammatory cytokines such as; IL-6, IFNγ, TNF-α, and IL-1β leading to increased inflammatory infiltrate consisting of: dendritic
cells, macrophages, neutrophils, and lymphocytes.31,40 Numerous studies suggest the
infection is cleared through opsonization of bacteria by the humoral immune response,
combined with a Th1/Th17 cell-mediated response.15,19,41,42 Additionally, factors
associated with a local immune responses have been observed in convalescent mice
following challenge with B. pertussis, such as antigen-specific IgA titers and TRM cells,
which were shown to decrease bacterial burden when adoptively transferred to naïve
mice.21
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The induction of a protective immune response also has been observed through
mucosal immunizations against B. pertussis. Oral vaccination with heat-killed B.
pertussis in newborn infants resulted in the production of B. pertussis specific serum
and mucosal antibodies; although, this protection was not long lived.43 In the mouse
model, a live-attenuated IN pertussis vaccine, BPZE1, has shown protection up to one
year after immunization44, and is in clinical trials.45 Furthermore, BPZE1 vaccine
produced antigen-specific IgA antibodies in the baboon model, indicative of elicitation of
mucosal immune response.46 The mucosal immune response was further explored in a
murine model where BPZE1 induced a protective secretory IgA immune response, and
the generation of long lasting IL-17 secreting TRM cells in the respiratory system.25
Similarly, this population of antigen-specific memory cells was found to be expanded by
an acellular pertussis vaccine (LP-GMP) consisting of a TLR2 agonist and intracellular
receptor stimulator of interferon genes (STING) agonist, which correlated with the IL-17
secreting TRM population.47 Promisingly, generation of the IL-17 secreting TRM cell
population was observed following whole-cell immunization through IP administration;
however, Tdap administration through the same route did not generate this population.20
In our study, we demonstrate that by altering the administration route of DTaP
immunization from IP to IN delivery, the vaccine still induced a protective immune
response. Using fluorescent labeled DTaP particles we visualized that IN-aP was
readily detectable (Fig. 1). In vivo imaging analysis demonstrated significantly more
labeled IN-caP present in the nasal cavity of mice. We detected a higher proportion of
IN-caP particles compared to IN-aP particles that embedded in the epithelium of the
nasal turbinates (Fig. 2). These particles had a smaller diameter, which may suggest
that when the curdlan adjuvant was included DTaP particles were more readily
phagocytosed by APCs compared to IN-aP particles. Further work examining the lymph
nodes responsible for antigen priming would be beneficial to determine the role of nasal
associated lymphoid tissue compared to vaccination of the lung, and trafficking to
mediastinal lymph nodes. The location of antigen priming following IN immunization
may play a critical role in the optimization of future human IN vaccines. Determining if
antigen uptake in the nasal cavity is essential to induce a protective immune response
would play a key role in the development of a human IN pertussis vaccines.
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We determined that while IN-caP vaccinated mice had significantly lower detection of
DTaP in the lungs compared to IN-aP immunized mice that the bacterial clearance was
similar between the two groups (Fig. 7), suggesting that antigen priming still occurred.
This was further demonstrated through seroconversion as robust antigen-specific serum
IgG antibody titers were detected from the two IN immunized groups (Fig. 3). The IgG
subclass data (Fig. 3) suggest that immunization with IN-aP most likely induces a Th2
response. Other studies with BPZE1 or LP-GMP adjuvants have observed shifts to Th1
response using IN route. 20,25
A key finding of our current study was the production of antigen-specific IgA in the
respiratory system only in mice that were administered DTaP through IN administration:
IN-aP and IN-caP (Fig. 4). Another difference between the IN-aP and IN-caP groups
was the level of IL-17A present in the lung homogenate (Fig. 5). We found that inclusion
of curdlan in DTaP resulted in higher levels of IL-17A whether administered through IN
or IP route although IL-17A was highest in IN-caP. These findings correlate with results
from others suggesting a role of curdlan and IN administration in IL-17 production.27,28
Together these data demonstrate induction of mucosal immune response specific to B.
pertussis in the respiratory system.
In our model, addition of curdlan to DTaP increased IL-17 responses but did not
improve clearance (Fig. 7). A caveat of the current work is role of aluminum hydroxide
was not addressed. All IN immunizations consisted of DTaP, which contains alum,
observations from IN-caP may be affected by the presence of alum. Understanding the
role of aluminum hydroxide, along with other potential adjuvants in the mucosal immune
response needs to be further studied. Our work does not address long-term protection
mediated by IN administration of DTaP or the inclusion of curdlan adjuvant. Future
studies will focus on the longevity of IN immunity.
In conclusion, we observed that by altering the route of administration from IP to IN a
protective response was reproduced, resulting in clearance of the pathogen to limits of
detection. Furthermore, we determined that IN delivery of DTaP was sufficient to prime
a local mucosal immune response at site of infection. The inclusion of the adjuvant
curdlan in DTaP immunization did increase IL-17 production in the lung; however, we
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did not observe a shift in the type of immune response compared to DTaP alone. In
humans, DTaP and tdap do not provide perfect protection against pertussis; however,
there is no clear path forward to the next generation vaccine. It is clear that developing
a new vaccine will take considerable efforts. Here in our study we observed a surprising
result, that IN DTaP vaccine could protect mice against B. pertussis. These data cause
us to wonder if a change in the route of DTaP immunization would be a promising
booster vaccine strategy.
Materials and Methods
Composition and administration of vaccines used in study
The vaccines administered in the study were prepared no longer than 1 h before
administration. INFANRIX (GSK) human vaccine (DTaP), and the National Institute for
Biological Standards and Control WHO whole-cell pertussis vaccine (NIBSC code
94/532) were used in the study. Vaccines were diluted with PBS to 1/12th of the human
dose (based on total antigen content). Curdlan (Invivogen, tlrl-curd) was prepared by
dissolving 50 mg in 2.5 ml sterile purified water. Curdlan preparation was brought into
solution by adding 100 µl 1N NaOH and vortexing. The curdlan suspension (20 mg/ml)
was then sonicated for 10 mins and placed in 37°C water bath until administration.
Curdlan adjuvant was administered at 200 µg per mouse. These experiments were
conducted in accordance with the National Institutes of Health Guide for the care and
use of laboratory animals. The protocols used were approved by West Virginia
University Institutional Animal Care and Use Committees (WVU-ACUC protocol
1602000797).
Vaccination of mice for vaccine particle tracking
CD-1 (outbred; strain code 022) mice aged four weeks were obtained from Charles
River Laboratories. At five weeks mice were anesthetized with 77 mg/kg ketamine and
7.7 mg/kg xylazine. Mice were administered 50 µl of vaccine or control, with 25 µl into
each nostril (IN).
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Tracking of DTaP in respiratory system
DTaP vaccine particles were labeled using the Alexa Fluor 660 Protein Labeling Kit
(Molecular Probes). Briefly, 0.5 ml of DTaP vaccine was added to 50 µl of 1 M sodium
bicarbonate, then added to Alexa Fluor 660 dye stock. The mixture was incubated for 1
h at room temperature with agitation. The solution was concentrated by dialysis in
phosphate-buffered saline overnight to remove unlabeled dye. Labeled vaccine was
used to immunize mice. At 0, 6, 12 and 24 h post vaccination fluorescent signal was
measured using an IVIS Spectrum (Xenogen). Mice were anesthetized using 3%
isoflurane, mixed with oxygen prior to and throughout imaging. The following
parameters were used: 1) A binning setting of 4 was kept constant for all images, 2)
each image was quantified using the automatic image setting, 3) fluorescence photons
were measured using total radiant efficiency of a common region of interest placed on
the nasal cavity, and 4) measurements were normalized using Living Image (Xenogen
ver. 2.5). Use of this quantification method accounted for variations in exposure
between images.
At 6, 12, 24, and 48 h post vaccination, animals were euthanized to quantify DTaP in
lungs by flow cytometry analysis. Lungs were removed, and homogenized using
gentleMACS C tubes (Miltenyi Biotec) with enzymatic lung dissociation kit (Miltenyi
Biotec, 130-095-927). All samples were blocked using Fc Block (BD), then labelled with
Alexa Fluor 700 – conjugated CD11b (Biolegend, 101222), DTaP particles were
detected with Cy5 channel. Following a 1 h dark incubation labeled samples were
washed, then fixed using 0.4% w/v paraformaldehyde overnight. Samples were
resuspended in PBS and analyzed on a LSR Fortessa flow cytometer (BD). DTaP
containing myeloid cells were classified as CD11b+DTaP+ single, live cells.
Detection of DTaP particles in lung and nasal cavity
Detection of DTaP particles in the lung and nasal cavity were confirmed using confocal
imaging. Mock vaccinated and challenged mice were euthanized at 6 h post
vaccination. Prior to homogenization, the post-caval lobe of the mouse lung was
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removed. The post-caval lobe was flash frozen in OCT medium (Tissue Plus, Fisher
Healthcare), using liquid nitrogen. The samples were stored at -80°C until sectioning.
Sectioned samples (6 µm) were fixed in acetone, then stained with ActinGreen Ready
Probes (Invitrogen) and NucBlue Ready Probes (Invitrogen), using manufacturer
protocols.
Skulls were removed from mouse, and the lower jawbone discarded. The skulls were
fixed in formalin for 12 h at 4°C, then de-calcified at room temperature for 24 h, before
samples were embedded in paraffin. Sectioned samples were de-paraffinized and
rehydrated using xylene, and washes with decreasing ethanol concentrations (100 to
70%). An antigen retrieval step was performed using citrate buffer, where samples were
heated to 98°C for 20 mins. Samples were then stained as mentioned above. Samples
were analyzed for DTaP particles in tissue and airway mucus using a Nikon A1R
confocal microscope. DTaP particles were quantified using ImageJ (version 1.52a).
Briefly, the threshold tool was used to select only the fluorescent particles above
background levels. Then, the threshold adjusted area was quantified using the analyze
particles tool. Thus, the data is represented as the percentage of fluorescent particles
per area of the total image field. Three image fields per sample were quantified and
averaged per mouse.
B. pertussis strains and growth conditions
B. pertussis strain UT25Sm148 was used for murine challenge in all experiments.
UT25Sm1 was cultured as described previously.31 Briefly, UT25Sm1 was cultured on
Bordet Gengou agar plus 15% defibrinated sheep’s blood (Remel) with streptomycin
100 mg/ml. B. pertussis was incubated at 36°C for 48h, then transferred to modified
Stainer-Scholte liquid medium49, without the cyclodextrin, heptakis. Liquid cultures were
incubated for 24 h at 36°C, with shaking until reaching an OD600 of ~0.6, at which time
cultures were diluted for challenge dose.
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Vaccination and B. pertussis challenge
IN immunized mice received 50 µl of vaccine as described above. IP immunized mice
received 200 µl of vaccine injected into the peritoneal cavity. IN and IP immunized mice
received the same antigen dose of 1/12th. Mice received a boost of the vaccines with
the same concentrations twenty-one days after initial immunization. At thirty-five days
post initial vaccination, mice were challenged with 2x107 CFU B. pertussis administered
in 20 µl through nostrils. At days 1 and 3 pc mice were euthanized, blood and
respiratory tissue were isolated as previously described.31
Serological analysis of B. pertussis specific antibodies
Serological responses specific to B. pertussis antigens were quantified by ELISA. Highbinding microtiter plates were coated with PT (50ng/well)(LIST Biologicals) and FHA
(50ng/well)(Enzo Life Sciences), as described in Boehm et al.31 Serological responses
against UT25Sm1 were cultured to an OD600 of 0.24 and microtiter plates coated with
50µl of bacteria per well. Bound antibodies were detected using goat anti-mouse IgG,
IgA, IgG2a, and IgG1 antibody conjugated to alkaline phosphatase (Southern Biotech).
Positive antibody titers were determined using a baseline set at two times the average
of blanks.
Quantification of pulmonary and blood APCs
To determine cell types infiltrating the lung and leukocytes present in peripheral blood,
single cell suspensions from the tissues mentioned above were prepared, as described
previously.31 Briefly, lung tissue was homogenized by Dounce homogenizers, filtered
with a 100 µm filter, and red blood cells were lysed for 2 min at 37°C (Pharmlyse). Cell
populations were determined using antibodies to cell surface markers: PE-conjugated
GR-1 (BD, 553128), Alexa Fluor 700-conjugated CD11b (Biolegend, 101222),
PerCP/Cy5.5-conjugated F4/80 (Biolegend, 123128). Neutrophils and macrophages
were classified as CD11b+Gr-1hi single, live cells or CD11b+F4/80+ single, live cells,
respectively.
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Lung homogenate cytokine analysis
To quantify inflammatory cytokines at the site of infection, lung homogenate supernatant
was prepared and stored at -80°C, as described in prior work.31 Quantitative analysis of
cytokines was performed using Meso Scale Discovery cytokine kits: V-PLEX proinflammatory panel (K15048D) and IL-17A V-PLEX (K152RFD), per the manufacturer’s
instructions.
Statistical Analysis
Experiments in the study were performed with 3 to 8 biological replicates. Data were
analyzed using GraphPad Prism 7. Comparisons between groups were performed using
one-way analysis of variance (ANOVA) with Dunnett’s and Tukey’s post hoc tests.
Comparisons between groups with or without curdlan were analyzed by two-tailed
unpaired t-test, when applicable multiple T-tests with Holm-Sidak post hoc test were
applied to curdlan inclusion groups.
Data Availability
Data for all figures are available upon reasonable request to the corresponding author.
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Figures
Figure 1: Localization of acellular pertussis vaccine in the upper and lower
respiratory system after IN vaccination.

Figure 1: Localization of acellular pertussis vaccine in the upper and lower
respiratory system after IN vaccination. (a) Schematic of vaccine tracking protocol.
CD-1 mice were intranasally vaccinated with either fluorescent DTaP alone (IN-aP) or
fluorescent DTaP with curdlan (IN-caP). Vaccine particle deposition in the lungs and
nasal cavity was measured at 0, 6, 12, 24, and 48 h after immunization. (b)
Representative images of nasal cavity fluorescence at 6, 12, and 24 h. The region of
interest used for fluorescence quantification is shown in blue. (c) Fluorescence
measurements normalized to PBS control at 6, 12, and 24 h. Results shown as mean ±
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SEM of total radiant efficiency, *P < 0.05. P values were determined by multiple T-tests
with Holm-Sidak post hoc test between IN-aP and IN-caP vaccinated mice. (d)
Representative plots showing live, single cells that are CD11b+DTaP+. (e) Flow
cytometric analysis of CD11b+ cells from the lung that contain or are bound to DTaP
particles at 6, 12, 24, and 48 h post immunization. Results shown as mean ± SEM, *P <
0.05, *** P < 0.001, ****P < 0.0001. P values were determined by one-way ANOVA with
Dunnett’s post hoc test comparing IN-aP immunized mice to control mock vaccinated
mice.
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Figure 2: Acellular pertussis vaccine particle localization altered by curdlan
adjuvant.

Figure 2: Acellular pertussis vaccine particle localization altered by curdlan
adjuvant. (a) Representative images of flash frozen lung sections 6 h after
immunization with IN-aP or IN-caP. Fluorescent particles were detected using a 660
laser, samples were counter-stained with NucBlue (blue) and ActinGreen (green). (b)
Fluorescent DTaP particles were quantified by determining the percentage area of
particles per field of view. (n=3-4, with averages of 3 images per lung). Results are
shown as mean ± SEM, *P < 0.05. (c) Representative images of paraffin embedded
nasal cavity sections 6 h after immunization with IN-aP or IN-caP. (d) Fluorescent DTaP
particles quantified by determining the percentage area of particles per field of view.
(n=3-4, with averages of 3 images per lung). P values were determined by one-way
ANOVA with Tukey’s post hoc test.
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Figure 3: Intranasal immunization induces production of anti-PT and anti-FHA IgG
in serum.

Figure 3: Intranasal immunization induces production of anti-PT and anti-FHA IgG
in serum. ELISAs were used to compare serological responses from mice immunized
through IN or IP routes to mock vaccinated mice. Total IgG serum antibody titers from
immunized and challenged mice were quantified against (a) PT and (b) FHA at day 3
pc. Serum (c) IgG1 and (d) IgG2 antibody titers against B. pertussis were compared to
mock vaccinated mice at day 3. Results shown as mean ± SEM, **P < 0.01, *** P <
0.001, ****P < 0.0001. P values were determined by one-way ANOVA with Dunnett’s
post hoc test compared to mock vaccinated mice.
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Figure 4: Intranasal immunization induces production of anti-B. pertussis IgA in
respiratory system.

Figure 4: Intranasal immunization induces production of anti-B. pertussis IgA in
respiratory system. ELISAs were performed using (a) lung homogenate supernatant
and (b) nasal lavage fluid from vaccinated and challenged mice at day 3 pc. IgA titers
were determined against whole-cell B. pertussis. Results are shown as averages of two
independent experiments, represented on a log10 scale for lung and linear scale of
nasal lavage with mean ± SEM (n = 4-8). ****P < 0.0001. P values were determined by
one-way ANOVA with Dunnett’s post hoc test compared to mock vaccinated mice.
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Figure 5: Intranasal immunization decreased pulmonary pro-inflammatory
cytokines during challenge.

Figure 5: Intranasal immunization decreased pulmonary pro-inflammatory
cytokines during challenge. Analysis of cytokines from supernatant of lung
homogenate at day 3 pc. Cytokines (a) IL-6, (b) IFN-γ, (c) IL-5, (d) IL-17A were
quantified by electrochemiluminescence assay. Results shown as mean ± SEM, *P <
0.05, **P < 0.01, *** P < 0.001, ****P < 0.0001. P values were determined by one-way
ANOVA with Dunnett’s post hoc test compared to mock vaccinated mice. Bars
connecting groups indicate values determined by two-tailed un-paired t-test. Upper and
lower limits of detection shown as dash or dotted lines, respectively if data points
reached these limits.
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Figure 6: Intranasal immunization reduced neutrophil and macrophage
accumulation in the lung and circulating neutrophils after B. pertussis challenge.

Figure 6: Intranasal immunization reduced neutrophil and macrophage
accumulation in the lung and circulating neutrophils after B. pertussis challenge.
(a) The percentage of live, CD11b+Gr-1hi neutrophils from a single cell suspension of
the peripheral blood. Percentages of (b) CD11b+Gr-1hi neutrophils and (c)
CD11b+F4/80+ macrophages in single cell lung homogenates. Results shown as
means ± SEM, *P < 0.05 **P < 0.01, *** P < 0.001, ****P < 0.0001. P values were
determined by one-way ANOVA with Dunnett’s post hoc test compared to mock
vaccinated mice.
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Figure 7: Intranasal immunization reduced respiratory B. pertussis bacterial
burden

Figure 7: Intranasal immunization reduced respiratory B. pertussis bacterial
burden. Analysis of bacterial burden was determined at days 1 and 3 pc. Bacteria were
quantified by counting of serially diluted CFUs following immunization and challenge.
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CFU counts were determined from lung homogenate (A and B), trachea homogenate (C
and D), and nasal lavage fluid (E and F). Results are mean ± SEM (n = 4 – 8, with 4
averaged technical replicates) from two independent experiments. *P < 0.05, ** P <
0.01, *** P < 0.001, ****P < 0.0001. P values were determined by one-way ANOVA with
Tukey’s post hoc test compared to mock vaccinated mice, or between connected
columns. The dashed line represents the lower limits of detection due to plating.
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Chapter 5 - Discussion
Pertussis is a bacterial disease that only exists in the human population. Thousands of
years of evolution have optimized B. pertussis to the microenvironment of the human
respiratory system. This is understandably so, Homo sapiens are a species that fit the
niche of B. pertussis. We are a social species that live in close quarters thereby
permitting the dissemination of bacteria that spreads through respiratory droplets.
Human offspring are born without fully developed immune symptoms, leaving them
more susceptible compared to their adult counterparts. When one individual becomes
sick others congregate to care for that person, more so in the case of an infant. Thus,
giving rise for bacteria to spread to a new host and continue the infectious cycle.
However, the same forces of evolution that lead to the specialized niche of B. pertussis
in the human respiratory system, confined the bacteria to life in only one host reservoir.
As, scientists this is a flaw we can exploit, and have done so in the past. When Edward
Jenner developed the smallpox vaccine, he initiated a mechanism of eradication of the
disease by protecting the only species capable of spreading the smallpox virus. In 1980,
natural occurring smallpox was declared eradicated through years of widespread wholecell vaccination 1. It may now be surprising to some that pertussis, now classified as a
re-emerging infectious disease by the CDC in the United States, was once a proposed
target for eradication in the 1970s

2,3.

Like smallpox, pertussis incidence was well-

controlled though widespread immunization with a wP vaccine 4. The resurgence of
pertussis began to occur in the US in the mid-1980s, and cases have remained well
above that level since. This increase in cases coincides with the switch to aP in
developed countries. One of the hypotheses on why this increase is occurring is that aP
immunization inhibits the toxin-mediated symptoms the disease, but not colonization of
the bacteria. This realization has renewed interest in the development of a vaccine that
can inhibit colonization of B. pertussis, with the ultimate goal of reducing the number of
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cases to levels seen in the wP era, thereby re-opening the door the possible eradication
of pertussis.
A major long-term goal of this work was to make progress on developing a vaccine that
improved upon the shortcomings of current acellular pertussis vaccines covered in
chapter 1. In this work we demonstrate the protective effects of neutralizing ACT, a key
virulence factor of B. pertussis, through an IP administered vaccine. We then explored
another route of administration, finding that IN administration of DTaP induced a
systemic protective response and a mucosal immune response in the respiratory tissue.
This work demonstrates that the neutralization of toxins achieved through parenteral
vaccination can be reciprocated by vaccinating the nasal cavity directly, thereby
inhibiting PT before it disseminates beyond the respiratory system. This work suggests
that the mechanisms of protection in either of the vaccine strategies should be further
elucidated and incorporated into future pertussis vaccines.
Lessons learned from Ne Cre luc mouse model
The mouse model has been used for vaccine optimization since the development of wP
vaccines5. Naturally, along the way, improvements to the mouse model have enabled a
better understanding of vaccine-induced protection. In setting out to improve the current
vaccines, we aimed to design experiments that were capable of showing this
improvement. In a landmark study, Guiso et al. developed the intranasal pertussis
challenge murine model 6. In that study, the authors found similar protection from a
dose of 1/4th and 1/10th of the human antigen concentration compared to a group
receiving the full human dose 6. We based our initial experiments on these vaccine
concentrations.
One of the aims of chapter 2, was to use the NeCre luc, neutrophil reporter mouse
model to trace the real-time kinetics of the neutrophil response between DTaP and wP
immunized mice. In these experiments, we immunized the reporter mice with 1/5th the
human dose of DTaP and wP. At this high vaccine dose, we observed an aggressive
pro-inflammatory response following B. pertussis challenge of wP immunized compared
to DTaP immunized mice (Chap. 2, Figure 4,5). Transcriptional analysis of the lung
during early and late phases of an acute infection revealed the highest pro-inflammatory
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associated gene changes in the wP-primed mice. Strikingly, we observed the highest
levels of neutrophil recruitment occurred after the bacterial burden was cleared to limits
of detection, while in comparison to the DTaP-primed group the percentage of
neutrophils in the lung had returned to baseline levels following clearance of the
infection (Chap. 2, Figure 3,7). The intensity of the neutrophil response may have
overwhelmed this group, as we observed severe morbidity in wP-primed mice at day 6,
which required euthanasia. The clearance of the pathogen prior to the recruitment of
neutrophils suggests that morbidity was due to the immune response elicited. The
NeCre luc model provided a novel method of visualizing the spatiotemporal localization
of neutrophils in immunized mice. In these studies, we compared the quantification of
neutrophils using the luminescence of the luciferase-induced reporter to the
quantification of neutrophils through flow cytometry. We determined that using flow
cytometry we could accurately depict the neutrophil response over time, with the benefit
of using a more standard mouse strain. The NeCre luc reporter mouse may be the most
beneficial to those study the neutrophils recruited to a concentrated site, such as those
studying the role of innate immune cells in the tumor microenvironment, or acute topical
infections. In completing this aim of the study, we concluded that a wP vaccine
concentration of 1/5th the human dose may be too high to properly characterize the
response of neutrophils overtime.
A second aim of the NeCre luc study was to determine the protective role of a purified
toxoid of ACT, RTX, as a single antigen vaccine administered with aluminum hydroxide.
We hypothesized that antibodies generated against the antigen would neutralize the
toxin activity of ACT, thereby inhibiting the ACT mediated suppression of neutrophils
discussed in chapter 1. RTX immunization generated a strong IgG antibody response
specific to the RTX antigen; however, RTX as a single antigen vaccine alone was not
protective because we did not observe a reduction of bacterial burden in these
experimental conditions. Immunization with only RTX would not address PT, thus in
these experiments, PT would still be active. Thereby, inhibiting neutrophil and
macrophage chemotaxis to the site of infection. We reasoned that while RTX as a single
antigen did not induce protection the benefits of neutralizing ACT may be more evident
when PT is neutralized as well. In this scenario when macrophages and neutrophils
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were recruited to the lung, their bactericidal activity would not be inhibited. This
realization caused us to re-craft our approach to a vaccine where we could study the
synergistic effects of neutralizing ACT, along with the protective activity of DTaP
vaccines.
Optimization of the mouse model
In chapter 3, we built upon our observations learned in the NeCre luc immunization and
challenge model. In these experiments we aimed to determine the protective effects of
incorporated RTX in a DTaP vaccine. In initial experiments, we included the RTX toxoid
discussed in chapter 2, into a 1/5th human dose of DTaP. In these results, we measured
an antigen-specific immune response but did not observe an increase in protection
compared to DTaP immunized mice. It occurred to us, that the use of such a high dose
of vaccine in the mouse model is not relevant to the dose that is administered to
humans. This reflection led us to the idea that to establish a relevant model, we needed
to determine the lowest vaccine dose that induced protection. We proposed performing
a vaccine dose titration to find this dose in mice. This would lead to a vaccine dose that
would: 1) more accurately depict the vaccine concentration administered to humans,
and 2) establish a sub-protective dose to incorporate future vaccine antigens, such as
RTX to determine protection. In chapter 3, we determined that 1/40th of the human dose
of DTaP vaccine protected mice while, the 1/80th dose did not. We were then able to
add RTX to 1/80th human dose DTaP vaccine. This finding does correlate with others
suggesting that 1/50th the human dose of DTaP was protective in mice, as we identified
1/40th the human dose to be the lowest-protective dose by our 2-fold titration

7,8.

Defining this sub-optimal dose is crucial in re-thinking the design of DTaP/TdaP
immunizations. DTaP/TdaP are safe vaccines which protect individuals from classical
pertussis. Therefore, if a potential vaccine is to replace either of these standards, the
candidate vaccine would need to perform better, in addition to protecting an individual
through a different mechanism. Defining a sub-optimal vaccine dose from which,
synergistic effects of potential vaccine antigens can be observed, gives researchers a
mechanism to demonstrate increased vaccine potency.
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Incorporation of RTX with DTaP
In chapter 1, we discussed the immunomodulatory activity of ACT. ACT increases
intracellular cAMP of macrophages and neutrophils recruited to the site of infection. The
levels of cAMP suppress the bactericidal activity of the macrophages and neutrophils
including phagocytosis, oxidative burst and NET formation in neutrophils 9–11. We, along
with others hypothesized that neutralizing ACT through vaccination would increase
vaccine efficacy of current acellular vaccines

12,13.

In chapter 3, we discussed the

protective effects of including RTX into a DTaP vaccine. In these studies, we immunized
mice using the outbred CD-1 mouse line. Incorporation of RTX into the DTaP vaccine
resulted in the production of anti-ACT binding antibodies, that were capable of
neutralizing ACT activity against murine macrophages (Chap. 3, Fig. 1,3). These in vitro
observations translated to in vivo vaccine-mediated protection, as we observed
decreased bacterial burden and pro-inflammatory responses with the inclusion of RTX
compared to DTaP alone (Chap. 3, Fig. 2). Defining the sub-optimal vaccine dose was
critical to this experiment. We observed synergic effects of RTX at 1/80th human vaccine
dose; while those effects were masked at the higher doses of DTaP (Chap. 3, Fig. 1).
We observed that the inclusion of RTX into the DTaP vaccine increased vaccineinduced protection when compared to DTaP alone. We did not observe an increase in
Th1 associated cytokines, suggesting that DTaP with RTX did not alter the vaccineinduced immune response from the Th2 promoting DTaP. Overall, the immune
response to B. pertussis was similar to DTaP induced protection. We observed strong
IgG responses to the B. pertussis toxins, and a reduction in the pro-inflammatory
response evident by a reduction in pro-inflammatory cytokines, macrophages, and
neutrophils in the lung when RTX was included in DTaP compared to DTaP alone. The
data suggests that the enhanced protection was due to the production of anti-ACT
neutralizing antibodies. However, due to the nature of the Th2 response observed from
DTaP with RTX, it seems unlikely that the inclusion of an additional antigen alone would
increase the duration of protection compared to DTaP. We hypothesized that to alter the
T-helper cell response and increase the duration of protection, we needed to continue
investigating ways to promote a cell-mediated immune response.
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The work performed in this dissertation was completed in the mouse model of pertussis.
The use of animal models has vastly contributed to the understanding of the
pathogenesis and the immune response elicited against B. pertussis and other
Bordetella species. Mice and humans generate similar pro-inflammatory T-cell
responses and antibody profiles upon infection with B. pertussis

14.

In chapters 3 and 4,

we utilized only female CD-1 outbred mice, compared to inbred mouse strains. The use
of inbred mouse strains increases the reproducibility of experiments compared to
experiments using outbred mice strains. Outbred strains were used in our experiments
specifically to increase the genetic variability, to model the genetic variability seen in the
human population. As a result, we observed increased variation in experiments
performed using CD-1 mouse lines compared to inbred strains such as BALB/c (data
not shown). In addition to genetic variability between mouse strains, future experiments
should utilize both male and female sexes. Epidemiology pertussis studies have found a
higher proportion of pertussis in female patients compared to male counterparts15.
Classically, females are more susceptible to upper respiratory infection compared to
males16 . However, females are known to induce greater innate immune cell activation
and stronger humoral responses than males in both human and mice

17.

It is possible

that male mice may not reciprocate the strength of the immune response observed
following immunization and challenge of female mice. In future experiments the
incorporation of both male and female mice can address this concern.
Importance of a Mucosal Response against B. pertussis
In our studies, we found it interesting that bacteria were cleared earliest in the lungs
compared to nares and trachea (Chap 3., Fig. 2). We began to investigate the possibility
of a mucosal pertussis vaccine that could prime the respiratory tract directly. We
hypothesized that by administering the vaccine intranasally, the primed local immune
response could neutralize the pathogen before the impairment of the innate immune
response by toxins of B. pertussis.
Mucosal-vaccine induced immunity poses the benefit of preventing the establishment of
an infection prior to PT entering the circulatory system. Conversely, parenteral pertussis
vaccine-induced immunity requires circulating PT to encounter memory T and B cells
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present in the draining lymph nodes, then mount a secondary immune response to the
infection. It is well documented that natural infection of a human patient confers longterm protection. While the human mucosal immune response is yet to be characterized,
B. pertussis-specific IgA antibodies suggest a role for mucosal protection

18

. Evidence

in support of a role of a mucosal immune response against B. pertussis from the
baboon model find that convalescent baboons and mice clear the infection significantly
earlier than any parental vaccine, wP or aP

19,20.

The natural response to pertussis was

discussed in chapter 1, but is known that natural infection with B. pertussis induces a
strong mucosal response, which correlates to sterilizing immunity

21,22.

Wendelboe et

al., reviewed published data comparing the duration of protection from acellular and wP
pertussis vaccines to convalescent protected individuals 23. The authors determined that
humans who were previously infected with B. pertussis were protected up to 20 years,
compared to up to 12 years following wP immunization, and 4 years from those
immunized with various DTaP vaccines

23.

We posed the question, “If we can mimic an

infection with an acellular vaccine, could we induce a protective response?” Now, there
are clear differences between an infection with pathogenic bacteria and a vaccine
composed of purified protein. For one, not only does the pathogen express thousands
of potential PAMPS, but the colonization of the respiratory tract produces additional
damage-associated molecular patterns (DAMPS) that would be not produced following
intramuscular acellular immunization. PAMPS/DAMPS associated with the natural
infection recruit cells of the innate immune system to the infection, leading to
phagocytosis of the bacteria, and ultimately antigen presentation of the many potential
antigens to naïve T cells

24,25.

This is unlikely to occur with a parenterally administered

subunit vaccine, where a humoral response is generated against the specific antigens
contained in the vaccine.
As discussed previously, there has been promising pre-clinical success with a liveattenuated B. pertussis intranasal vaccine, BPZE1

26–29.

BPZE1 is a highly attenuated

strain, lacking production of three functional virulence factors of B. pertussis: PT,
dermonecrotic toxin, and tracheal cytotoxin 29. The strain is not pathogenic but is able to
colonize the respiratory tract, before eventually cleared. The vaccine strain is protective
in mice and baboons, and in mice has been shown to induce a Th1 mediated response
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26,29,30.

Recently, it has shown that immunization with this strain resulted in production of

IL-17, IgA antibodies, and the TRM population in the nares of mice, each of these factors
was shown to play a role in protection

28.

The work performed by Solans et al. further

demonstrates the importance of a local mucosal immune response in reducing
colonization of the respiratory tract, and of generating a pro-inflammatory cell-mediated
response in long-term protection against B. pertussis.
Intranasal DTaP induced a protective immune response
In chapter 4, we changed the route of vaccine administration from an intraperitoneally
administered vaccine to an intranasally administered vaccine. In doing so, going from a
vaccine response that was well characterized to the relativity unexplored vaccine route:
mucosal vaccination

8,22,31–33.

One of the challenges we were faced with was the

number of potential antigens that encounter the nasal-associated lymphoid tissue
(NALT) on a daily basis

34.

Data from orally administered vaccines demonstrates that

gut-associated lymphoid tissue promotes tolerance over immunogenicity

35.

We

reasoned that because the alum adjuvant is not optimal for mucosal vaccination, that IN
administered DTaP may not induce enough inflammation to induce a protective immune
response

36.

It may be that in order to induce a systemic response, the vaccine would

have to stimulate a pro-inflammatory response upon vacation, as was the case in the
BPZE1 vaccine discussed above. To increase the pro-inflammatory properties of DTaP,
we supplemented DTaP with the β-glucan curdlan. Curdlan was an attractive candidate
as it had been previously tested as an intranasal adjuvant, and has been shown to
promote a Th1/Th17 immune response in vitro and in vivo

37–40.

Specifically, curdlan

binds to the fungal receptor dectin-1 expressed on the surface of DCs, found at high
concentrations in the NALT, along with macrophages

41,42.

Also, lining the mucosal

surface are microfold (M) cells, which specialize in phagocytosis of macromolecules,
viruses, and bacteria. On the basal surface of the M cells are intraepithelial pockets,
which can contain DCs, T and B cells 34,41. APCs from the mucosal tissue can then track
to the draining lymph nodes, where they activate B cells, ideally inducing a systemic
and mucosal immune response 34.
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Mucosal immunizations provide a unique vaccination strategy because antigen priming
can occur in multiple lymphoid organs and tissues. Furthermore, the appropriate tissue
may change based on the type of vaccine and/or depending on the pathogen. In the
case of pertussis, the appropriate tissue for vaccination is yet to be determined and all
human vaccines are provided by IM injection. Since we aimed to vaccinate the airway,
we thought it was necessary to track where the vaccine is going during IN immunization.
In chapter 4, we accomplished this by fluorescently labeling the DTaP vaccine particles.
In Chap. 4, Fig 1,2, we observed that the majority of DTaP alone (IN-aP) was deposited
in the lung while DTaP with curdlan (IN-caP) was found mostly in the nares. Ultimately,
we did not determine a difference in B. pertussis-specific IgG antibody titers present in
the serum or IgA antibodies in the lung supernatant. Suggesting that whether antigen
uptake occurred in the lungs or the nasal cavity, IN immunization elicited a systemic
response not
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Figure 1: Proposed model of IN-caP induced protection.
The fungal polysaccharide curdlan is administered as a semi-gel state at a neutral pH. The
immunostimulant properties of the β-glucan elicit a Th1/Th17 response. Curdlan binds to DCs through
the dectin-1 receptor. The dectin-1 signaling pathway induces the non-canonical expression of NF-κB,
promoting a Th1/Th17 immune response. Curdlan as an adjuvant induced antigen-specific serum IgG
antibodies, and IgA antibodies in the lungs of vaccinated mice.
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significantly different than IP. Furthermore, the inclusion did not further reduce the
bacterial burden of the respiratory system (Chap. 4, Fig. 7). In these experiments we
demonstrated that the IN administration of DTaP could induce the production of IgA
antibodies. It is then possible that antibodies found in the lung homogenate and nasal
lavage fluid could be neutralizing PT at the site of infection. Thus, leading the lower
levels of pro-inflammatory cytokines found in the lung homogenate. These data suggest
that IN-aP immunization alone is capable of generating a systemic and mucosal
immune response.
Role of curdlan in a mucosal immune response
Curdlan has been shown to induce Th17 responses when administered through the
intranasal route

37.

In this study, we determined the highest amount of IL-17A in the

lungs of groups that were IN immunized, with the DTaP with curdlan inducing the
highest levels (Chap. 4. Fig. 5d). However, while significant, this response is not as
strong as was observed following wP-induced IL-17A response as we demonstrated in
this and other studies. What is interesting is that when we measured DTaP vaccine
particles in the nares of the mice, more appeared to be embedded in the nasal cavity
epithelium with IN-caP than compared to more particles in the lumen with IN-aP (Chap.
4, Fig. 2c). Furthermore, the particles from IN-caP had a smaller, more, particulate
appearance. It may be that curdlan played a role in antigen uptake in the nasal cavity. In
this study, we only observe a correlation between the smaller particles in the mucosal
tissue and the increased IL-17A production found in DTaP with curdlan. Future
experiments will be needed to further elucidate this mechanism. One of the caveats of
this experiment is that we did not identify the cell types that contained or bound vaccine
particles in microscopy imaging. It is possible that when DTaP was administered with
curdlan, the vaccine particles were more likely to be phagocytosed by M cells of the
mucosa, which are known to endocytose particulate antigens

43.

Thereby, it may be

possible that antigen uptake is more efficient through this mechanism.

178

Future directions in pertussis vaccine development
In this work, we demonstrated the induction of a protective response from an
intranasally administered vaccine. This work suggests that mucosal immunization with
the current DTaP vaccine alone produces a systemic immune response and the
production of IgA antibodies and IL-17A in the respiratory tract. The next question to
answer is, what is the mechanism of protection elicited from DTaP and DTaP with
curdlan? In order to develop effective mucosal pertussis vaccines, a better
understanding of the mucosal immune response to B. pertussis is needed.
Identification of target vaccine tissue
The use of fluorescent vaccine particles gave us the ability to track the vaccine in the
nasal cavity of mice. Presumably, antigen uptake and presentation could be explored
using a similar experimental design that could identify M cells and continued tracking of
the vaccine particles. An experiment of this nature would also help to answer the
question of appropriate tissue targeting. In our experiments, a volume of 50 µl of the
vaccine was administered intranasally. This volume is known to reach the lungs in the
mice, while the use of lower volumes results in the majority of detection of bacteria or
labeled protein accumulating in the upper respiratory system

44,45.

Thus, in the mouse

model, this administration route has the potential of antigen priming occurring in the
upper and lower respiratory system, as the dose is exposed to the two tissues. In
performing the experiment mentioned above, one could elucidate whether either of the
tissues plays a role in establishing the mucosal immune response. Additionally, upon
antigen presentation either to TRM in the respiratory tissue or draining lymph node one
would expect to measure a spike in pro-inflammatory cytokines following the
immunization. Using a B. pertussis outer membrane vesicle vaccine (OMV) Raeven et
al., measured the induction of a moderate pro-inflammatory response compared to wP
immunization

46.

This response was measured in serum 4 hours post-boost

immunization, resulting in significant increases of G-CSF, KC, CXCL10, IL-6, IL-1β, IL5, MCP-1. Similarly, Warfel et al., measured increases of IL-6, IL-1β, IL-23, G-CSF,
MCP-1, and MIP-1x from nasopharyngeal washes from baboons following challenge
with B. pertussis

47.

As early as 48 hours after challenge levels of IL-6 and G-CSF were
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significantly increased compared to negative control baboons. It may be beneficial to
study the production of cytokines and chemokines produced early in the immune
response to B. pertussis infection in the context of immunizations. The rationale being,
that the production of cytokines associated with antigen presentation measured in NALT
tissue or the draining lymph nodes could further elucidate the generation of the B.
pertussis-specific immune response. In the mouse model it may not seem to be of
consequence, but in human applications targeting of the appropriate tissue depends on
the delivery method used in vaccination. In humans, nasal droppers, nasal sprays,
nebulizers, and dry powders have been used for delivery of vaccines to the upper
respiratory tract

34,48.

Vaccination of the lower respiratory system requires the use of a

nebulizer-generated small-particle liquid or powder vaccines that are capable of
reaching the lungs

34,49.

Understanding the differences in the immune response elicited

between antigen priming occurring in either tissue will be crucial for the translation to
non-human primate and ultimately clinical trials.
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Figure 3: Summary of proposed mucosal immune response to B. pertussis.

During the primary infection with B. pertussis innate immune cells are recruited nasal cavity. Bacteria
and potential antigens can be phagocytosed by DC cells embedded in the epithelium layers, once
activated DCs migrate to the draining lymph nodes where they present antigen to the naïve T cells.
Specialized lymphoid tissue in the nasal cavity, NALT, line the nasal cavity. These NALT tissues contain M
cells that endocytosis bacteria or particulate antigen and translocate the organism or macromolecule to
DCs, B and T cells present on the basal surface of the cells. Antigen priming of naïve T cells differentiate
to Th1, and Th17 effector cells in the draining lymph nodes or NALT tissue. TFH cells activate B cells which
promote B. pertussis antigen specific IgG and IgA antibodies. Effector Th1 and Th17 migrate to
respiratory tract, a subset of CD4 memory effector cells are retained in the tissue as TRM. Effector
Th1/Th17 cells recruit macrophages and neutrophils phagocytose the now opsonized bacteria. Upon
secondary infection by B. pertussis TRM recognized the pathogen proliferating to effector Th1 and Th17 T
cells, secreting IL-17 and IFN-γ. IL-17-secreting T cells have also been shown to play a critical role in the
secretion of SIgA antibodies. The activation of the mucosal memory response immediately recruits
macrophages and neutrophils to the infection, which with help from SIgA antibodies can efficiently
phagocytosis B. pertussis. Thus, limiting the extent of the secondary infection. Figure adapted from Wilk
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et al.50 Solans and Locht51 and Neutra and Kozlowski41. PMN-polymorphonuclear neutrophils, Mφmacrophage, B- Naïve B cells, T-Naïve T cell, NALT-Nasal associated lymphoid tissue, Th17-Th17 T helper
cell, Th1-Th1 T helper cell, DC-Dendritic cell, TFH -T follicular helper cell, TRM TH17- Tissue resident
memory Th17 cell, TRM TH1- Tissue resident memory Th1 cell, Mem B- Antigen-specific Memory B cell

Importance of nasal cavity specific analysis
The findings presented in chapter 4 suggest that intranasal immunization is a viable
strategy that needs to be further investigated. We and other groups are studying
intranasal immunization against B. pertussis

28,52.

It is clear that to continue down this

avenue of research, the correlates of protection of the local mucosal immune response
need to be fully characterized. Until recently, the majority of pertussis research has
focused on characterizing the immune response in the lower respiratory tract in the
mouse model; however, except in rare cases, B. pertussis infects the upper respiratory
system

53.

Wilk et al., have begun to focus on the immune response and bacterial

clearance of the nasal cavity, specifically 8. This approach involves the intricate process
of removal of the epithelial lining for analysis by flow cytometry and bacterial burden.
Through this method, they have identified the role of IL-17 in promoting nasal cavity
SIgA and IL-17-secreting TRM cells in vaccine-induced protection8,28. The role of TRM in
protection against B. pertussis is yet to be fully understood. Data exists that correlates
the presence of the TRM cell population in the nasal cavity to long term protection,
specifically in the nasal cavity of mice 52. Currently, it is suggested that the production of
IFN-γ and IL-17 are essential to clearance in the nasal cavity, and data have shown the
production of IFN-γ and IL-17 from TRM and γδ T cells in the nares

8,28,54.

However, the

mechanism of clearance remains to be discovered.
A closer examination of the nasal cavity, the bacterial burden in the nares can be more
accurately depicted. The nasal cavity clearance data included in this dissertation, along
with the work of others, quantify bacteria burden present in nasal lavage fluid

14.

This

method quantifies bacteria that were removed from the upper respiratory system by the
lavage; however, it is apparent that a significant portion of the bacteria remain

52.

In

moving forward, techniques to more accurately quantify the bacterial burden in the
nares will be necessary to establish true sterilizing immunity. The importance of
clearance in the nares is emphasized by our findings that the infection in the lung was
cleared, but not nasal cavity. The different anatomy and microenvironments of the lung
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and of the upper respiratory tract may play a role in bacterial adherence and
colonization

55.

Findings by Conover et al. suggest that B. pertussis can potentially form

biofilms in the mouse nose, while they did not in the mouse lungs; however, this is yet to
be shown by other groups

56.

The authors found that the BPS polysaccharide of B.

pertussis was responsible for colonization and promoted biofilm formation in the nasal
cavity; but not in the lungs. Additionally, FHA has also been shown to promote biofilm
formation and is critical for biofilm formation in the mouse nose and trachea

57.

Understanding of differences between the lower and upper respiratory system will be
essential in determining why B. pertussis infection persists in the nasal cavity compared
to the lower respiratory system. To observe these differences, experiments capable of
addressing the mechanisms behind the immune responses between the tissues are
needed.
In wP immunized and naïve mice we have measured robust recruitment of
macrophages and neutrophils to the lungs (Chap. 2, Fig. 4, Chap. 3, Fig. 5,6, Chap. 4,
Fig. 6). In these experiments, we determined the numbers of cells recruited to the
infection; we did not address their functionality. It is possible that due to the Th1
response induced in convalescent or wP vaccine-induced protection APCs may more
efficiently phagocytose bacteria. The experiments performed by Wilk et al. and Solans
et al. have shown that IL-17 is critical for B. pertussis clearance from the nasal cavity.
The mechanism; however, is yet to be determined. It would make the most sense to
start with the roles of neutrophils in the nasal cavity, as IL-17 is known to induce
recruitment of neutrophils.
Neutrophils in the nasal cavity, the unsung hero?
The question we are faced with is what changes between neutrophils in the mucosal
response of an immune individual and that of a naïve individual? We have already
discussed the first answer, that neutrophils have only been found to play a role in the
clearance when bacteria are opsonized. We now know that IgA secreted through the
mucosa can opsonize B. pertussis, presumingly leading to increased phagocytosis

28.

Another reason may be the timing of the neutrophil response. In a primary infection,
there is a slight increase in neutrophils at day 1; however, the neutrophil response does
183

not peak until days 5 and 7 post-infection

58–61.

It could be hypothesized that the IL-17

produced by TRM and γδ T cells present in the nasal cavity, would recruit neutrophils to
the nasal cavity earlier. Thus, decreasing the ability of B. pertussis toxins to inhibit
phagocytosis of the bacteria. A third reason could be the neutralization of the toxins
themselves. Secreted IgA and IgG present in the mucosa of a protected host could be
inhibiting dysregulation of the innate immune response. The neutralization of PT alone
has been shown in numerous studies to provide protection

62,63.

Neutralizing PT in the

mucosa would increase neutrophil and macrophage recruitment to the site of infection,
PT inhibits both macrophage and neutrophil recruitment to the infection

64,65.

Lastly, it

was previously mentioned that B. pertussis biofilm formation could occur in the
nasopharynx and trachea of a mouse 66. Neutrophils produce NETS that trap bacteria in
a “web” of DNA and proteins, destroying them through released enzymatic granules and
proteases

11.

Recently Thanabalasuriar et al., demonstrating that NETS were able to

confine P. aeruginosa biofilms in the ocular biofilms and prevent dissemination

67.

These mechanisms provide potential roles of neutrophil-mediated clearance in the
mucosal response to B. pertussis; however, as mentioned above, experiments need to
be performed on neutrophils of the nasal cavity.
Neutralizing ACT in the nasal cavity
In chapter 3, we demonstrated the neutralization of ACT from serum of aP+RTX
immunized mice (Chap. 3, Fig. 1). ACT can inhibit many of the bactericidal actions of
macrophages and neutrophils, as discussed in Chapter 1. Determining the effects of
neutralizing ACT directly in the respiratory tract, could lead to a more complete inhibition
of the “one-two punch” toxin activity of PT and ACT, thus increasing clearance of B.
pertussis in the nasal cavity64. In chapter 3, found that the inclusion of RTX into DTaP
administered through IP injection reduced IL-6 production in the lung. (Chap 3, Fig. 4).
IL-6 is a pleiotropic pro-inflammatory cytokine known to be increased upon B. pertussis
infection, as we and others have observed a large increase in IL-6 following challenge
of a naïve or wP protected mouse

31,68.

In our interpretation, a reduction of IL-6

correlates with DTaP-mediated protection. Interestingly, in chapter 4, we observed the
lowest levels of IL-6 in the lung when mice were immunized intranasally compared to
intraperitoneally with IN-aP or IN-caP (Chap. 4, Fig 5.). Suggesting that priming the site
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of infection, rather than inducing priming in a distal lymph node and generating a
systemic response induces a stronger response in the respiratory tract.
It would then appear that by administering RTX in an intranasal DTaP vaccine, one
could combine the additive effects of neutralizing RTX, with the enhanced local
response generated from an intranasal vaccine. One would suspect that these
protective effects would be the most evident in the bactericidal activity of macrophages
and neutrophils in the respiratory tract where the cells would encounter active ACT. In
particular, we would hypothesize enhanced phagocytosis and bacterial killing in
neutrophils and macrophages due to neutralizing ACT mediated inhibition of oxidative
burst. Additionally, it is known that ACT can inhibit NET formation due to cAMP levels 11.
It would be interesting to measure NET production and bacteria mediated killing in the
lungs and nasal cavity, although these fragile structures will require fine-tuning of
protocols. Furthermore, there is potential for NET formation to reduce biofilm formation
in the upper respiratory system. Again, these experiments will need to focus on the
upper respiratory system, but the results could be pivotal in the generation of future
pertussis vaccines.
Potential future adjuvants
Our work with curdlan adjuvant demonstrated a modest increase in IL-17A in the lungs
of mice immunized with DTaP and curdlan compared to mice immunized with DTaP
alone (Chap. 3, Fig. 5). However, we did not observe an increase in macrophages or
neutrophils recruited to the lungs. This may be due to the fact that all DTaP groups still
contain aluminum hydroxide, promoting a Th2 response that is masking the effects of
curdlan. Experiments to further elucidate the effects of β-glucans without aluminum
hydroxide are ongoing and have yielded positive initial results. Still, it may be that
optimal adjuvant is still yet to be found. Studies examining TLR 2 and 9 agonists from
the Kingston Mills group have had success in the mouse model inducing Th1/Th17
responses and increasing IgG2a antibodies

14,69.

The same group has combined a

TLR2 agonist with c-di-GMP, an agonist for the intracellular receptor stimulator of
interferon genes (STING). This parenteral vaccine has been shown to promote
Th1/Th17 responses, and particularly a B. pertussis-specific TRM response in the lungs.
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Importantly, this protective response was measured up to 10 months after
immunization. Work isolating outer membrane vesicles (OMV) from B. pertussis has
proven to be successful. B. pertussis OMVs and DT toxoids were shown to induce
Th1/Th17 immune responses and increase the IgG2a/IgA ratio compared to a DTaP
vaccine

70.

OMV vaccines are promising because they provide an increased pro-

inflammatory response compared to DTaP; but, less reactogenicity than wP
immunizations

46,71.

Particulate adjuvants are an interesting area of research as the

particles may increase phagocytosis in the upper respiratory system, as discussed
above. The combination of DTaP, CpG, and microparticles intranasally administered
was shown to protect mice similar to levels observed in mice immunized with parenteral
administered DTaP

72.

It is possible that the conjugation of toxoids to the particles could

increase vaccine effectiveness in future vaccines. Defining an optimal adjuvant is crucial
to the success of a mucosal pertussis vaccine. The problem arises that boosting the
immune response with a powerful adjuvant could have adverse effects and ultimately
might also prevent licensure due to safety concerns.
Mucosal pertussis booster
It is because of this balancing act that the commercial producers of pertussis vaccines
are at an impasse. DTaP/Tdap do prevent a large number of potential cases of
whooping cough but these vaccines are not as effective as the wP vaccines in regard to
the durability of protection. The use of the DTaP/Tdap vaccine strategy does protect the
majority of those who receive the vaccine from clinical pertussis. It is clear that
shortcomings exist with DTaP/Tdap vaccines, but the question remains, what is the
alternative? DTaP/Tdap vaccines were originally designed to be safer vaccines capable
of inducing similar protection to that of their wP predecessors, and they have. After
completing the 5th dose DTaP protection ranges from 80-90% effectiveness 2. Data from
adolescents suggest that the problem exists in years following the completion of DTaP
73.

According to ClinicalTrials.gov, there are currently 318 clinical trials either ongoing,

recently completed or upcoming studying pertussis, of those 62 are focused on booster
immunizations. However, most of these focus on safety and formulation of currently
available immunizations. It seems that the vaccine industry is reluctant to replace
current vaccines due to effectiveness in preventing disease and their safety. However,
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there is potential for replacement of Tdap with a booster vaccine capable of inducing a
Th1/Th17 response. The problem, as eluded to in chapter 1, is that vaccine imprinting of
the Th1 primary response induced from wP in humans promotes the same response
even after DTaP booster immunizations 74. This dilemma provides the strongest support
for the development of an intranasal vaccine. The hypothesis being that parenteral
booster immunizations are recognized by the memory T and B cells generated from the
parenteral priming immunization. In altering the route of administration to the intranasal
route, and with a different mucosal adjuvant the vaccine will stimulate the differentiation
of naive B and T cells and induce a local mucosal immune response.
The work completed in this dissertation highlights the need to re-evaluate a system
when the current strategies cannot address the problem. The development of the next
generation of B. pertussis vaccines must improve upon waning immunity of DTaP/Tdap
immunizations. It is the consensus of current literature that the most applicable way to
do so is through mimicking the natural infection. To accomplish this goal researchers
will need to continue to optimize systems that have reached their potential. To do so will
require innovative methods, that are outside the realm of previous strategies. In this
work, we demonstrate the optimization of the mouse model of pertussis to implement
testing of future B. pertussis antigens and demonstrate the incorporation of a protective
ACT toxoid into an acellular pertussis vaccine. We then altered the route of
administration of the DTaP vaccine to a mucosal delivered vaccine and demonstrated
the additive effects of generating a local mucosal immune response, capable of
neutralizing B. pertussis toxins at the site of infection. This work establishes a
foundation

for

future

vaccine

development,

demonstrating

the

potential

for

improvements of DTaP/Tdap vaccines through the inclusion of RTX and intranasal
delivery of pertussis vaccines.
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